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Abstract 
Both migraine and depression rank amongst the most common disabling chronic diseases 
worldwide, with great burdens on populations and general communities. The comorbidity 
between migraine and depression has been well-established. Epidemiological studies 
consistently reveal a bidirectional association between two diseases, with one disease 
increasing the risk for the other, and vice versa. Twin and family studies further suggest that 
this bidirectional association can be explained, at least partly, by their shared genetic factors. 
However, the mechanisms underlying this comorbidity are still not clear. The aim of this 
thesis was to investigate the association between migraine and depression by analysis of 
phenotype and genotype data, in order to have a better understanding of their mechanisms. 
In this thesis, we first reported a comprehensive review on genetic epidemiology of migraine 
and depression and discussed their potential biological mechanisms from past relevant 
genetic studies. Overall, seven candidate genes seemed to be involved in the susceptibility of 
comorbid migraine and depression, suggesting the potential shared genetic risk factors were 
likely implicated in serotonin and dopamine dysfunction, folate metabolism, GABAergic 
system and growth factor activity. On the other hand, no specific genetic risk locus was 
identified to be associated with their co-occurrence at genome-wide significance level 
(p<5×10-8). 
In the following phenotypic studies, a total of 5319 population-based Australian twin pairs 
were utilised and analysed, each diagnosed with self-reported clinically-accepted status of 
migraine and depression. As a result, both migraine and depression showed a strong familial 
aggregation. Importantly, we observed a bidirectional association between migraine and 
depression, with an increased risk for depression in relatives of probands reporting migraine, 
and vice versa. Additionally, the observed risk for migraine in relatives of probands reporting 
depression was considerably higher than the reverse, indicating that patients with comorbid 
migraine and depression are genetically more similar to patients with only depression than 
patients with only migraine. 
Subsequent twin analyses estimated additive genetic factors account for 56% of the variance 
in migraine (i.e., heritability of 56%) and 42% of the variance in depression, respectively. For 
cross-trait analysis, a significant genetic correlation at 0.36 and a bivariate heritability at 
ii 
 
5.5% (i.e., 5.5% of the variance in migraine and depression was due to shared genetics) were 
observed between migraine and depression, which provided strong evidence for the shared 
genetically determined mechanisms underlying two diseases. As expected, when analysing 
the strict status of the International Headache Society (IHS) based migraine and major 
depressive disorder (MDD), both their heritabilities and shared genetic components had a 
substantial increase. 
The genetic studies concentrated on joint analyses of three large population-based genome-
wide association studies (GWAS) summary statistics for migraine and MDD. Firstly, we 
performed a meta-analysis of MDD GWAS and observed two possible MDD-related risk loci 
(rs16924945 and rs7647854) nearly reached the genome-wide significance level. Afterwards, 
we utilised linkage disequilibrium (LD) score regression to evaluate the heritability of 
migraine and MDD, and their genetic correlation, at molecular genetic level. As a summary, 
the heritability was estimated at approximately 14% of European population-based migraine, 
25% of European population-based MDD, and 47% of Han Chinese population-based MDD, 
respectively. The European population-based migraine also showed a significant genetic 
correlation at 0.18 with the European population-based MDD, but was not significantly 
correlated with the Han Chinese population-based MDD. 
In conclusion, this thesis greatly develops our current knowledge on comorbid migraine and 
depression. The association between migraine and depression is likely bidirectional and can 
be explained almost entirely by their shared genetic factors. It remains to be seen whether 
these shared genetic factors are related to serotonin and dopamine dysfunction, folate 
metabolism, GABAergic system and growth factor activity. 
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Chapter 1: Introduction
 
1.1 Background 
1.1.1 The challenge of studying complex disease 
In the wake of the Human Genome Project (HGP) and International haplotype map 
(HapMap) Project, human genetic studies have carried forward to a new era. By facilitating 
research at the DNA sequence level, a number of genetic risk variants have been associated 
with susceptibility to diseases or traits of interest. These achievements greatly enrich our 
knowledge of biological pathophysiology for many diseases, and provide avenues for 
pharmaceutical research and development. Although the identification of associated genetic 
variants provides hints to explore pathophysiology, it is not straightforward to identify the 
causal variant(s) at implicated loci (due to the correlation between neighbouring variants) and 
elucidate their underlying biological mechanisms. 
In contrast to simple or Mendelian disease, that is induced by a single genetic mutation, 
complex diseases, such as migraine and depression, are caused by multiple genetic risk 
factors and environmental (trigger) factors that often interact. The study of complex disease is 
further complicated by the observation that common diseases often co-occur (i.e., are 
comorbid) within the same individual. Hence, determining the aetiologies underlying 
common complex diseases such as migraine and depression as well as their co-occurrence, is 
currently one of the most challenging puzzles faced by scientists. 
 
1.1.2 Overview of migraine and depression 
Both migraine and depression are common complex diseases with complicated inheritance 
patterns, episodic manifestations and great burdens on general populations (1). Migraine is a 
chronic neurological headache disorder accompanied with some autonomic nervous 
symptoms such as nausea, vomiting, photophobia (sensitivity to light) and phonophobia 
(sensitivity to sound). Depending on the absence and presence of aura symptoms, migraine 
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can be divided into two primary subtypes––migraine without aura (MO) and migraine with 
aura (MA). The International Classification of Headache Disorders (ICHD) published by the 
International Headache Society (IHS) (2) is used as the most reliable and acceptable 
diagnostic criteria for migraine. According to the IHS criteria, previous studies consistently 
showed a lifetime prevalence of migraine at 10–20% (3-6) and a moderate influence from 
genetic factors (i.e., heritability) at about 33–53% in migraine susceptibility (7). Females 
seem to have higher lifetime prevalence and heritability of migraine compared to males. 
Genetics of migraine were investigated by a number of linkage studies and association 
studies. Overall, three candidate genes, namely CACNA1A, ATP1A2 and SCN1A, were found 
to be related to the susceptibility of familial hemiplegic migraine (FHM) (8-14), a subtype of 
MA particularly with motor weakness; and ten genome-wide significant single nucleotide 
polymorphism (SNP) loci (in PRDM16, in MEF2D, in TRPM8, near TGFBR2, in PHACTR1, 
in ASTN2, in LRP1, in FHL5, in TSPAN2 and in C7orf10) were frequently identified to be 
associated with migraine from seven previous migraine genome-wide association studies 
(GWAS) (15-21). In spite of these positive findings, the pathophysiology of migraine is still 
not clear. Most scientists believe that migraine is probably triggered by either cerebral 
vasodilation (22), the cortical spreading depression (CSD) (23, 24), or the activation and 
sensitization of trigeminovascular complex (25). 
Depression is one of the most common psychiatric disorders characterised by a substantial 
decline in mood (e.g., diminish interest in almost everything, feel depressed or down) and 
behaviour (e.g., psychomotor retardation or agitation, feel fatigue or loss of energy). 
Generally, depression is referring to as unipolar depressive disorder that only has episodes of 
depression compared to bipolar disorder that has episodes of both depression and mania. This 
thesis specifically focused on studying the unipolar depressive disorder, which mainly 
consists of major depressive disorder (MDD) and minor depressive disorder (MiDD) 
differentiated by the extent of severity and chronicity. Two authoritative criteria are usually 
used to diagnose depression: one is the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) published by the American Psychiatric Association (26), and the other is 
the International Classification of Diseases and Related Health Problems (ICD) published by 
World Health Organization (WHO) (27). Based on these two diagnostic criteria, the lifetime 
prevalence of MDD is estimated at approximately 20–30% (28-31), with a heritability of 37–
48% (32, 33). MDD is also more common and heritable among females than males. Unlike 
migraine, until now, only limited achievements were obtained in the genetics of depression. 
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Some candidate genes such as SLC6A4 (34, 35) and MTHFR (36-38) were reported to be 
associated with depression, but most linkage studies and GWAS failed to robustly identify or 
replicate genetic risk loci. Recently, an encouraging MDD GWAS (39) was performed by the 
consortium of China Oxford and Virginia Commonwealth University Experimental Research 
on Genetic Epidemiology (CONVERGE). The authors reported two genome-wide significant 
SNPs—rs12415800 (p=2×10-8, near SIRT1) and rs35936514 (p=1×10-8, mapped in an intron 
of LHPP)—in Han Chinese females with severe and recurrent MDD, but further studies are 
still required to replicate and confirm. During examination of this Thesis, a new GWAS (40) 
recruited more than 300,000 participants of European ancestry from 23andMe and robustly 
identified 15 genome-wide significant loci covering 17 independent SNPs with MDD risk. 
Although these latest studies identified the first genetic risk factors for depression, the 
pathophysiology of depression is still far from understood. Currently, the most accepted 
hypothesis on the mechanisms of depression relates to the dysfunction of brain monoamine 
neurotransmitters (i.e., serotonin, dopamine, and norepinephrine) (41). 
 
1.1.3 Overview of comorbid migraine and depression 
Comorbidity is described as an association in medicine when at least one disease or condition 
co-occurs with the primary disease in an individual at a specific time, and such co-occurrence 
is found at a frequency greater than chance (42). The comorbidity between migraine and 
depression is well-established, supported by previous population and community-based cross-
sectional studies (43-54) and longitudinal studies (55-60). Most longitudinal studies reveal a 
bidirectional association between two diseases, with migraine or severe headache increasing 
up to a roughly 1 to 6-fold higher population risk for suffering depression, and vice versa. 
Such association is also expected to be stronger with the increased severity of two diseases. 
For instance, Wang et al., (48) observed that MDD seemed to be stronger associated with MA 
(odds ratio [OR]=13.9, 95% confidence interval [CI]: 2.6–73.1) compared to MO (OR=4.2, 
95% CI: 1.1–16.3), from a community-based student sample. Another case-control study in 
the UK (49) revealed that the OR for MA, MO and probable migraine associated with 
depression were estimated at 5.6 (95% CI: 3.5–9.0), 3.7 (95% CI: 2.2–6.1) and 3.6 (95% CI: 
2.7–5.0), respectively, by a logistic regression. 
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Since both migraine and depression show significant familial aggregation and considerable 
genetic basis, the comorbidity between two diseases is believed to be, at least partly, caused 
by shared underlying genetically determined mechanisms. Indeed, three previous twin and 
family studies consistently reported the shared genetic components between two diseases (61-
64). For instance, Schur et al., (63) used a bivariate structural equation modelling (SEM) in a 
US sample of 758 monozygotic (MZ) and 306 dizygotic (DZ) female twin pairs to estimate a 
trait-specific heritability of 52% (95% CI: 11–66%) for self-reported doctor’s diagnosis of 
depression and 44% (95% CI: 18–55%) for self-reported doctor’s diagnosis of migraine 
headache, and the authors also estimated that 20% of the variance in depression and migraine 
is due to shared genetics (i.e., bivariate heritability of 20%) and 4% of the unique 
environmental component is shared. Another twin study using 223 MZ male, 100 DZ male, 
602 MZ female, 286 DZ female, and 280 DZ opposite sex Dutch twin pairs (61) estimated a 
heritability of 45% for latent class analysis (LCA)-derived migrainous headache and 55% for 
anxious depression—a measure consisting of a factor score based on several measures of 
anxiety, depression, and neuroticism—and estimated a genetic correlation (rG) between 
migrainous headache and anxious depression of 0.30 (95% CI: 0.18–0.43). Additionally, a 
family-based study in a large Dutch genetic isolate utilised IHS diagnostic criteria and 
reported significant heritability estimates for MO (h2=0.77, 95% CI: 0.38–1.00), MA 
(h2=0.96, 95% CI: 0.51–1.00), and all migraine (h2=0.56, 95% CI: 0.26–0.86), which all 
decreased (albeit non-significantly) after adjustment for symptoms of depression or use of 
antidepressant medication (62). Interestingly, a comparison of the heritability scores for 
depression between patients with migraine and controls found evidence for shared genetic 
factors only between MA and depression. 
In spite of the strong evidence from twin and family studies supporting the shared genetic 
components between migraine and depression, currently no conclusive findings have been 
reported from genetic studies of comorbid migraine and depression. Except for some 
common candidate genes identified by candidate gene association studies (CGAS) (65), no 
risk loci were identified to be related to comorbid migraine and depression at genome-wide 
significance level, principally due to the failures of depression GWAS. As such, the 
underlying mechanisms of this comorbidity are poorly understood (66). Most longitudinal 
studies (55-60) support the hypothesis that shared genetic and environmental factors cause 
the co-occurrence of migraine and depression possibly through common physical conditions 
and brain patterns. Although, some pharmaceutic experiments and physiological observations 
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(67-69), suggest a causal relationship between the two diseases is also possible, that is, one 
disease fully causes the other through its chronic negative symptoms. Additionally, some 
studies (64, 70) also suggest that comorbid migraine and depression may be a different 
genetic entity compared to “pure” migraine and “pure” depression. 
 
1.2 Significance and aims 
Migraine and depression are two of the most disabling diseases worldwide (1), with a large 
burden on individual patients, their relatives, and society (71, 72). The complexity of 
migraine and depression mainly express in their recurrent episodic phenomena, diversified 
neurological manifestations, and complicated heredity. Currently, the mechanisms underlying 
two diseases are still not clear and so far there is no effective treatment to cure this 
comorbidity (66, 67). Hence, a better understanding of co-occurring migraine and depression 
will enhance the accuracy of diagnosis of migraine and depression and enrich our knowledge 
on their shared biological pathophysiology, ultimately leading to a reduction in occurrence 
and disability experienced by patients, and improved therapeutic approaches. 
Therefore, this thesis focuses on investigating the association between migraine and 
depression through these seven specific area aims: 
1. Comprehensively review the current knowledge on the genetic epidemiology of 
migraine and depression, summarising the potential candidate risk genes associated 
with co-occurring migraine and depression, and describing possible biological 
mechanisms underlying their comorbidity; 
2. Examine the familial aggregation of migraine, depression and their co-occurrence in a 
large population-based Australian twin sample; 
3. Investigate the genetic contribution in susceptibility to migraine and depression and 
the existence of shared genetic variance between two traits, by comparing relative 
risks (RR) estimated in MZ twin pairs to those estimated in DZ twin pairs; 
4. Elucidate the role of gene (the trait-specific heritability) and environment in 
susceptibility to migraine and depression; 
5. Estimate the shared genetic and environmental variance between migraine and 
depression via twin modelling, and investigate whether the shared genetic 
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components are due to the same genetic factors or due to one disorder causing the 
other; 
6. Identify genetic variants associated with MDD susceptibility by meta-analysis of 
MDD GWAS summary statistics; 
7. Evaluate the SNP-based heritability of migraine and MDD and their genetic 
correlation by joint analysis of GWAS summary statistics. 
 
1.3 Thesis outline 
The thesis outline is illustrated in Figure 1-1. In Chapter 2, a general literature review is 
provided to survey the basic background and genetics of migraine, depression and their 
comorbidity. Four subsequent chapters comprise the main text of the thesis employing 
different research strategies and study designs. Chapter 3 provides a summary on the genetic 
epidemiology of migraine and depression from previous studies. To investigate the 
association between migraine and depression, Chapter 4 and 5 describe analyses in a large 
Australian population-based twin sample, while Chapter 6 utilises molecular genetic data 
(GWAS summary statistics) for migraine and MDD. Finally, general conclusions and 
discussion are provided in Chapter 7. The four projects performed in this thesis are briefly 
described below. 
 
Project 1 (Aim 1) 
Genetic epidemiology of migraine and depression (Chapter 3) 
URL: http://www.ncbi.nlm.nih.gov/pubmed/27302564 
This Chapter (published review article) firstly summarised all published twin and family 
studies of co-occurring migraine and depression, to summarise supports for the presence of 
shared genetic components between the two diseases. Subsequently, after reviewing the 
CGAS and GWAS for migraine and depression, overlapping candidate genes and SNP loci 
were summarised. Based on the overlapping genes and SNP loci, the hypothesised biological 
mechanisms underlying migraine and depression were discussed. Finally, the article 
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highlighted that no overlapping genes were robustly identified between CGAS and GWAS, 
and the possible reasons for this result were discussed. 
 
Project 2 (Aim 2 & 3) 
Familial aggregation of migraine and depression: insight from a large 
Australian twin sample (Chapter 4) 
URL: http://www.ncbi.nlm.nih.gov/pubmed/27263615 
In Chapter 4 (published research article), a research study in a large Australian population-
based twin sample was conducted to investigate the familial aggregation of migraine, 
depression and their co-occurrence. Migraine was diagnosed by either self-report, the ID 
migraineTM Screener (73), or IHS criteria (2). Depression was defined by fulfilling either 
MDD or MiDD based on the DSM criteria (26). Familial aggregation of migraine and 
depression was tested by evaluating the RRs for migraine and depression in co-twins of twin 
probands reporting the same disease; and the association between migraine and depression 
was assessed by calculating the RRs for migraine and depression in co-twins of probands 
reporting the other disease. A considerable genetic contribution of migraine and depression 
and the existence of their shared genetic components were further determined by checking 
whether higher RRs could be observed within MZ twin pairs compared to DZ twin pairs (i.e., 
excluding environmental factors). 
 
Project 3 (Aim 4 & 5) 
Shared genetic factors underlie migraine and depression (Chapter 5) 
URL: http://www.ncbi.nlm.nih.gov/pubmed/27302564 
Followed by the works performed in Chapter 4, the study in Chapter 5 (published research 
article) utilised the same twin sample to estimate the contributions from genetic factors (trait-
specific heritability) and environmental factors for susceptibilities to migraine, depression, 
and their co-occurrence. The univariate twin modelling was applied to calculate the 
heritability of migraine and depression; and the bivariate Cholesky twin modelling (74) was 
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applied to evaluate the shared genetic components (i.e., bivariate heritability and genetic 
correlation) underlying two diseases. Both univariate and bivariate models were constructed 
via R package OpenMx (75), with liability thresholds adjusted by age and sex. Furthermore, 
different sex-limitation models (76) (including the non-scalar sex-limitation model with and 
without specific genetic component for males, and the restricted scalar effects sex-limitation 
model) were built to explore the potential influence from sex-specific effects on migraine and 
depression risks. Regarding the identified significant genetic correlation between two 
diseases, further approaches were used to test whether this genetic correlation is due to the 
shared aetiology or the potential causation between two diseases, by checking the 
significance of environmental correlation and the presence of causal environmental factors. 
 
Project 4 (Aim 6 & 7) 
Migraine and major depressive disorder: heritability and genetic 
correlation captured by SNPs (Chapter 6) 
The study in Chapter 6 consists of two analyses. In the first section, a meta-analysis of two 
MDD GWAS statistics based on European and Han Chinese populations was conducted by 
using METAL (URL: http://genome.sph.umich.edu/wiki/METAL_Program) fixed-effect 
models (77) and METASOFT (URL: http://genetics.cs.ucla.edu/meta/) Han and Eskin’s 
random-effects model (78), to identify the possible genome-wide significant loci associated 
with MDD susceptibility. The second section was a comparison study of the twin modelling 
in Chapter 5. To calculate the trait-specific heritability of migraine and MDD, as well as the 
presence of genetic correlation between two diseases at molecular genetic level (i.e., based on 
SNP data), a linkage disequilibrium (LD) score regression (79) was built via the LDSC 
package (https://github.com/bulik/ldsc) based on three GWAS summary statistics for 
migraine and MDD. Furthermore, the study also checked the genetic basis for 
PGC+CONVERGE MDD GWAS sample by meta-analysis and its genetic correlation with 
migraine. 
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 Figure 1-1 Ph.D. thesis structure 
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Chapter 2: Literature review 
 
2.1 Introduction 
This chapter reviews the general literature on (i) the human genome and (ii) migraine, 
depression, and their association. In the first part, a brief background of the human genome is 
provided; including historical perspectives, basic knowledge of genetics, and an introduction 
to four widely used genetic analysis approaches to study human genetics. The second part 
presents an up-to-date overview for migraine and depression, covering topics of global 
burden, clinical feature, diagnostic criteria, classification, epidemiology, pathophysiology, 
and genetic architecture (e.g., heritability and genetic risk loci). The evidence for the 
association between migraine and depression are summarised, with emphasis on phenotypic 
studies. In addition, the potential mechanisms underlying comorbid migraine and depression 
are also discussed at the end of this chapter. 
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2.2 Overview of Human Genome 
“The problem with genetic research is, we’re just starting down this path, feeling our way in 
the dark. We have a small lantern in the form of a gene, but the lantern doesn’t penetrate 
more than a couple of hundred feet. We don’t know whether we’re going to encounter 
chasms, rock walls or mountain ranges along the way. We don’t know how long the path is.” 
(80) This is the quotation given by Dr Francis S. Collins, which points out the arduous 
development of genetics. 
 
2.2.1 Historical background of genetics 
Humans never stop exploring the profound mystery of inheritance and transmission of traits 
from generation to generation. As early as 10000 years ago, ancient Egyptians had already 
known how to domesticate and selectively breed animals with special traits tailored to 
various life demands. A stone carving from ancient Assyria in 800 BC also shows a process 
of artificial fertilisation of date palms, indicating that the ancient Assyrians and Babylonians 
had grasped some skills on animal fertility based on their historical experiences. 
By the middle of the nineteenth century, after long-term observations and research on 
numerous different organisms, Charles Darwin published his well-known theory of natural 
selection that supposed the variations and evolutions of species were driven by natural 
selection and survival competition over long periods. Following Darwin’s works, Gregor 
Mendel, an Augustinian monk, put forward the basic idea of inheritance pattern from his 
experiments and observations of pea plant hybridisation. He summarised that traits of 
descendants were transmitted through two discrete pieces of inherit factors (i.e., genes) from 
each parent (i.e., egg and sperm). This theory now is known as Mendelian inheritance and 
regarded as the foundation of genetics. Since the middle of the twentieth century, after James 
Watson and Francis Crick detailed the double helix structure of DNA, the field of genetics 
rapidly progressed into the molecular level. 
A new era of genetics arose when in 2004 the Human Genome Project (HGP) produced the 
first complete sequence of a human genome. The International HapMap Project was then 
established in order to illustrate a haplotype map of the human genome based on different 
global population samples (e.g., CEU: Utah Residents with Northern and Western European 
11 
 
Ancestry, representing a Caucasian population; CHB: Han Chinese in Beijing; YRI: Yoruba 
in Ibadan, Nigeria). HapMap data has now been applied in multiple fields of genetic studies 
such as predicting proportions of genetic and environmental factors to the susceptibility to a 
specific phenotype, identifying genetic variants associated with target diseases, and 
investigating gene expressions to the target diseases. 
 
2.2.2 General knowledge of genetics 
Humans usually contain 22 pairs of autosomal chromosomes and 1 pair of sex chromosomes 
(a total of 46 chromosomes). Deoxyribonucleic acid (DNA) is a large molecule contained in 
each chromosome, made up of sugar, phosphate and four nucleotides according to their 
different nitrogenous bases, including pyrimidines adenine (A), thymine (T), guanine (G) and 
purines cytosine (C). DNA has a double helix structure where a single strand of DNA is 
forced by the phosphodiester bonds and two strands of DNA are stably linked by hydrogen 
bonds between nucleotides depending on the principle of complementary base pairing (i.e., 
A–T and C–G) (81). The crucial role of DNA in heredity has long been confirmed. Generally, 
haploid cells or gametes (i.e., the egg and the sperm) with genetic information are produced 
from parents during meiosis (a special cell division). A zygote is then formed by a union of 
an egg and a sperm. Therefore, both parents each pass on approximately 50% of their genetic 
information to their offspring. 
A DNA fragment with inheritance information of phenotypic traits is known as a gene. A 
haplotype, or haploid genotype, is a combination of genes, which can be inherited together 
from a single parent. Genes transmit traits from generation to generation through encoding 
specific protein products. This process is termed gene expression that comprised of two main 
steps: transcription and translation. Transcription is a process of generating messenger RNA 
(mRNA) from a gene by the RNA polymerase. During transcription, two strands of DNA 
separates, and the matched nitrogenous bases are added in its complimentary bases of a single 
strand of DNA to form a mRNA strand, and finally the mRNA are synthesised after breakage 
of hydrogen bonds linked DNA-RNA helix. Translation is the process of synthesising protein 
from mRNA obtained in transcription. During translation, mRNA firstly assembles with a 
ribosome that serves as a workbench, and the transfer RNA (tRNA) carrying a particular 
amino acid is then attached to the ribosome corresponding to the mRNA codon––a sequence 
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of three nucleotides involved in a specific amino acid. This procedure begins with a start 
codon, continuously moves forward to the following mRNA to create amino acid chain 
known as a polypeptide, and terminates with the stop codon. Afterwards, proteins with 
various functions are made up of these polypeptides. 
A genetic locus is a specific physical position in a genome. One alternative form of a gene or 
genetic locus is an allele. Individuals inherit a pair of alleles from their parents, with the same 
alleles known as homozygous (e.g., AA, aa) and the different alleles known as heterozygous 
(e.g., Aa). The core concept of Mendelian inheritance is the role of alleles in one gene: an 
allele is described as dominant if it has effects on phenotype when the individual has at least 
one copy of this allele, and an allele is recessive if it has effects on phenotype when the 
individual has two copies of this allele from both parents. In other words, the allele A is 
dominant if individuals with AA and Aa have the same phenotype; and allele a is recessive if 
individuals with aa show different phenotype compared with individuals with AA or Aa. 
Linkage disequilibrium (LD) commonly exists in human genome, representing a 
phenomenon of non-random co-occurrence of two alleles at different loci on the same 
haplotype. The strength of LD can be illustrated using statistical measures including the LD 
coefficient D, D’, and r2. The LD coefficient D is calculated as the difference between the 
observed haplotype frequency pAB and the expected haplotype frequency pApB when alleles A 
and B are independent or linkage equilibrium (LE, completely comply with the Hardy-
Weinberg equilibrium [HWE], describing that the allele and genotype frequencies will not 
change during inheritance without evolutionary influences. Mathematically, given two alleles 
A with frequency p, and a with frequency q, the expected genotype frequencies for AA, Aa, 
and aa under HWE are p2, 2pq, and q2, respectively): 
𝐷𝐷 = 𝑝𝑝𝐴𝐴𝐴𝐴 − 𝑝𝑝𝐴𝐴𝑝𝑝𝐴𝐴. 
Because LD is also constrained by allele frequencies, two alternative LD measures derived 
from D are considered to be more appropriate (82). One measurement D’ normalises D by 
dividing its maximum possible absolute value: 
𝐷𝐷′ = 𝐷𝐷
𝐷𝐷𝑚𝑚𝑚𝑚𝑚𝑚
, 
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where 𝐷𝐷𝑚𝑚𝑚𝑚𝑚𝑚 = �𝑚𝑚𝑚𝑚𝑚𝑚{𝑝𝑝𝐴𝐴𝑝𝑝𝐴𝐴, (1 − 𝑝𝑝𝐴𝐴)(1 − 𝑝𝑝𝐴𝐴)}       𝑤𝑤ℎ𝑒𝑒𝑚𝑚 𝐷𝐷 < 0𝑚𝑚𝑚𝑚𝑚𝑚{𝑝𝑝𝐴𝐴(1 − 𝑝𝑝𝐴𝐴),𝑝𝑝𝐴𝐴(1− 𝑝𝑝𝐴𝐴)}       𝑤𝑤ℎ𝑒𝑒𝑚𝑚 𝐷𝐷 > 0. Another commonly used 
measurement is the correlation r2 between pairs of loci, calculated as: 
𝑟𝑟2 = 𝐷𝐷2
𝑝𝑝𝐴𝐴(1−𝑝𝑝𝐴𝐴)𝑝𝑝𝐵𝐵(1−𝑝𝑝𝐵𝐵) (83). 
All these measurements are estimated between 0 and 1, representing the strength from LE to 
LD. 
The nucleotide sequence in a genome is changeable. During human reproduction, genetic 
variations occasionally take place in the nucleotide sequence that ensures the genetic 
uniqueness of each individual and the evolution of species. Mutations are defined as a 
permanent change in nucleotide sequence triggered by multiple causes such as damages from 
chemicals and radiations. Mutations can be classified into small-scale, if alternations occur in 
one or few nucleotides; and large-scale, if alternations happen in the chromosomal structure. 
Some common patterns of mutation are described here: replacement of a single nucleotide or 
multiple nucleotides (e.g., change in a single nucleotide such as changing “C” to “T” that 
may cause the substitution of one amino acid in a protein); insertion or deletion of a single 
nucleotide or multiple nucleotides (e.g., add extra nucleotides or subtract nucleotides such as 
changing “ATTCCG” to “ATTAGCCG” [insertion of “AG”] or “ACCG” [deletion of “TT”] 
that cause a frameshift or truncation of the polypeptide); duplication of a segment of 
nucleotides (e.g., a one or more duplication times of a piece of nucleotides such as changing 
“ATTCCG” to “ATTAGAGAGAGCCG” that probably alter the following amino acid 
composition of the polypeptide); and other mutations such as insertion of an extra 
chromosome and relocation of a section of nucleotides. In spite of lower incidence rate, 
mutations can substantially cause either negative or positive variations. As an example, sickle 
cell anaemia (84) is a well-known disease that is triggered by a mutation of a single 
nucleotide from A to T in the β-globin gene. This mutation changes the β-globin gene-
encoded amino acid from glutamic acid to valine and thus leads to the alteration of 
haemoglobin (with two β-globin subunits) from normal Haemoglobin A (HbA) to 
Haemoglobin S (HbS). When both β-globin subunits are replaced by HbS, it will cause 
human’s red blood cells into a sickle shape that fail to carry oxygen to human tissues, thereby 
causing severe anaemia. However, when there is only one abnormal β-globin subunit, 
although individuals will still experience a mild anaemia which can be remitted by decreasing 
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numbers of HbS, they can also obtain resistance to the malaria parasite benefited from these 
sickle cells. 
The most common genetic variations in the human genome are single nucleotide 
polymorphisms (SNPs). SNPs are variations of a single base pair and make up 90% of human 
genetic variations. For instance, some individuals carry A–T base pair at a given position but 
some others may have a substitution of C–G base pair at that position. A SNP with a minor 
allele frequency (MAF) larger than 5% is often termed a ‘common variant’, whereas a SNP 
with an MAF less than 0.5% is termed a ‘rare variant’. A SNP with MAF between 0.5% and 
5% is best described as a ‘less common variant’. There are over 15 million SNPs with a MAF 
greater than 1% in human genome. Most of them occur in the non-coding regions (e.g., 
introns, pseudogenes) and are typically thought to have no effects on phenotype 
developments; while some other SNPs occur within or near (<15 kb from) genes and may 
play an important role in human genetics. For instance, the E4 variant in the apolipoprotein E 
(APOE) gene is associated with susceptibility to Alzheimer disease possibly through 
increased number of toxic amyloid plaques (a sticky buildup which accumulates outside 
nerve cells [neurons] in the brain) (85); and the polymorphism in the ADAM 
Metallopeptidase Domain 33 (ADAM33) gene is consistently observed to be related to asthma 
possibly via restricting bronchial hyperresponsiveness and decreasing lung function (86). 
Other SNPs may have more subtle effects on phenotypes. Details of identified SNPs are 
catalogued in the Single Nucleotide Polymorphism Database (dbSNP; URL: 
http://www.ncbi.nlm.nih.gov/SNP/). 
 
2.2.3 Analytic methods of studying the genetics of human diseases 
Human genetic diseases can be classified into simple or Mendelian diseases if the diseases 
are caused by a single genetic mutation such as sickle cell anaemia, and complex diseases if 
the diseases are caused by multiple genetic factors such as migraine and most psychiatric 
disorders (e.g., depression, anxiety). Generally, complex disease is more common than 
simple or Mendelian disease, and is often diagnosed by the patient report of symptoms since 
there are no obvious relevant biomarkers or laboratory-based tests. 
Complex disease is also more difficult to study compared to simple or Mendelian disease. 
Firstly, the diagnosed phenotypes of complex disease may be highly heterogeneous due to 
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different sample sources and diagnostic measurements. Secondly, susceptibilities of complex 
diseases are frequently related to numerous genetic factors of small effect, which often 
interact and show a wide variation of effect size. As such, very large samples with sufficient 
power are required to identify genetic risk variants contributing small effects. Thirdly, as 
indicated from the consistent observations that most complex diseases are estimated with a 
moderate heritability, the environmental (trigger) factors likely play an important role in 
developments of complex diseases. Fourthly, although the assumption of quantitative genetic 
approaches is typically centred on additive genetic variance, non-additive gene-gene 
(epistasis) and/or allelic (dominance) interaction is known to exist for many complex traits 
and present as dominance and epistatic variance, respectively. And although common 
complex diseases such as migraine and depression are expected to be the result of the 
combined effect of genes, environmental factors, and their interactions (87), it is difficult to 
detect such non-additive genetic effects (88, 89). These reasons, together with the fact that 
common diseases are often comorbid within the same individual, increase the challenge of 
studying complex diseases. Several commonly used approaches of studying genetics of 
human complex disease are summarised in this section. 
 
2.2.3.1 Twin studies 
Twin studies have been widely used and designed to examine genetic traits (90). Twin studies 
can be used to estimate the relative genetic and environmental contributions to a target 
phenotype. Assuming total phenotypic variance is composed of the variance from additive 
genetic factors (A), non-additive (dominance) genetic factors (D), non-unique (shared) 
environmental factors (C) and unique environmental factors (E), MZ twin pairs share 100% 
of their A, D, and C, while DZ twin pairs share 50% of A, 25% of D, and 100% of C on 
average (91). According to this principle, the proportions of genetic and environmental 
contributions can be estimated by comparing concordance between MZ and DZ twin pairs. 
The proportion of the phenotypic variance due to genetic differences is termed the heritability 
(92), including two types: the narrow-sense heritability (h2, percentage of additive genetic 
variance in total phenotypic variance) and the broad-sense heritability (H2, percentage of 
additive and non-additive genetic variance in total phenotypic variance) (93). 
The Falconer’s formula provides the simplest way to estimating the heritability of a disease: 
h2=2×(rMZ - rDZ), where rMZ and rDZ represent the resemblance or concordance rates of MZ 
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and DZ twin pairs. However, the Falconer’s formula does not account for other 
circumstances such as sex and age, and also not easily generalise with missing data (94). 
Alternatively, structural equation modelling (SEM), a multivariate statistical analysis 
technique, is more commonly used to compare the difference between the observed and 
expected variance-covariance metrics of disease for MZ and DZ twin pairs via full 
information maximum likelihood or other statistical methods (90). Furthermore, SEM can 
also be extended to analyse multiple diseases co-occurring together. Three multivariate 
models are often used: the Cholesky model (74), the independent pathways (IP) model and 
the common pathways (CP) model (95). The path diagrams of univariate and multivariate 
SEM are shown in Figure 2-1 (90) and Figure 2-2 (96). 
 
Figure 2-1 The path diagram of MZ and DZ twin pairs measured on a single trait. The square frame stands for 
the observed variable and the circle frame stands for the latent variable. The relationship between these two 
variables is linked by the single-way arrow, which shows the causal path. The double-way arrow describes the 
correlation path between two latent variables. The additive genetic variance is correlated 1 between MZ twins 
and 0.5 between DZ twins and the non-additive genetic variance (epistatic, dominance component) correlated 1 
between MZ twins and 0.25 between DZ twins. 
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2.2.3.2 Linkage studies 
After confirming genetic effects for a target disease by twin and family study, scientists are 
then interested in identifying genetic risk loci associated with susceptibility of the disease. 
Linkage studies are based on the observation that genes and genetic markers located proximal 
to each other on the same chromosome have a tendency to be inherited together during 
meiosis. When a chromosomal location is found to transmit with a specific disease across 
generations, the risk gene is likely involved in this chromosomal location. To identify the 
linkage of a disease locus (T) associated with a target disease and explain its inheritance in 
pedigrees, linkage studies use a transmission model by adding a genetic marker (M) with a 
fixed location in the genome. If the disease locus (T) is not associated with M, alleles will 
segregate independently during meiosis; while if T is associated with M, the specific allele 
from T will tend to segregate jointly with a certain allele from M (97). The LOD score (the 
base 10 logarithm of odds) is utilised to measure the distance of the marker inherited 
together. A high LOD score indicates a high chance that the marker locus co-segregates with 
the disease. However, linkage studies have several limitations. For instance, assuming the 
wrong transmission model may miss a true linkage; linkage studies often require a large 
number of family samples with multigenerational cases, which are difficult to collect when 
analysing a disease with a high mortality and/or late onset; linkage studies are less useful 
when analysing complex diseases with polygenetic inheritance patterns, since this approach 
thoughts to have less statistical power to detect genes with tiny effects; and the implicated 
(linked) region typically spans a large distance (10-20 Mb) meaning considerable work 
remains to identify the specific causal genetic variant(s). 
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 Figure 2-2 The path diagram for multivariable model measured for one twin only. Interpretations of symbols 
are same as Figure 2-1. (A) The Cholesky model only shows A and E, assuming there are n latent variables of A 
and E corresponding with n observed phenotypes. For each latent variable, n causal paths of first latent variable 
load on the all phenotypes, and n-1 causal paths of second latent variable load on the phenotypes (except the 
causal path linked to the first phenotype) and so on, until 1 causal path of last latent variable load on only the 
last phenotype. (B) The IP model separates the latent variables into the common latent variable (i.e., AC, CC, EC) 
and the single latent variable (i.e., A, C, E). The common latent variables load on all the phenotypes and the 
single latent variables only have effects on the specific phenotype. (C) The CP model is an extension of the IP 
model, which assumes that all the common latent variables firstly contribute to an intermediate latent variable, 
and the intermediate latent variable then loads on all the phenotypes. 
 
2.2.3.3 Candidate gene association studies (CGAS) 
CGAS is another early approach utilised to implicate genetic risk variants in a putative 
candidate gene (i.e., selected gene) that is hypothesised to play an etiological role in 
susceptibility to a target disease according to prior knowledge. In the design of CGAS, 
genetic variants are implicated by comparing their occurrence in individuals with the disease 
(cases) to their occurrence in individuals without the disease (controls) (98). CGAS were 
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historically the primary approach to investigate the role of genes in the pathogeneses of 
complex diseases because of its simple study design and low costs. However, CGAS also 
have several disadvantages. Firstly, CGAS often investigate the known plausible genes rather 
than unknown novel genes. Secondly, findings of CGAS are typically performed in small 
sample sizes and proved difficult to replicate, thereby increasing the likelihood of false-
positive and false-negative findings. Lastly, publication bias is another potential source of 
false-positive findings in CGAS, caused by the fact that studies with positive or significant 
results are more likely to be published compared to those with negative or non-significant 
results. 
 
2.2.3.4 Genome-wide association studies (GWAS) 
Due to the limitations of linkage studies and CGAS, GWAS are regarded as a more powerful 
approach for complex diseases. GWAS are based on a non-random inheritance pattern that 
the SNPs with causal variants are more likely to transmit across generations because of the 
presence of LD. In contrast to CGAS, which only test specific loci, GWAS study common 
genetic variations across the entire human genome for genetic association with a phenotype 
(Figure 2-3). GWAS have greatly improved our understanding of the genetic basis of many 
complex diseases and traits (99, 100). Typically, GWAS have four main steps: i) selection of 
cases and controls corresponding to the target disease of interest; ii) genotyping quality 
control and SNP filtering; iii) association test between the selected SNPs with the disease; 
and iv) replication study from another independent sample (101). A Manhattan plot is used to 
summarise GWAS results, with genomic coordinates on the x-axis and negative logarithm of 
estimated p-value on the y-axis. GWAS are advantageous compared to other study designs 
because of the relative easily collected samples and the ability to detect associated alleles 
even if their effect is small (102). However, GWAS primarily analyse SNPs with a MAF 
larger than 1-5% and hence do not detect rare variants and other (e.g. structural) variants. In 
addition, GWAS require large study samples and cannot provide information on gene 
function (99). 
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 Figure 2-3 General approach of GWAS: comparing SNP differences between thousands of cases and controls. 
(URL: https://www.mpg.de/10680/Modern_psychiatry) 
Misclassification of cases and controls in GWAS may bias or even mislead the results, 
especially for complex diseases with high phenotypic heterogeneity. For example, subgroups 
of case individuals may differ in their diagnoses due to differences in their collection, cases 
may also appear phenotypically similar but have differing genetic aetiologies; and 
undiagnosed individuals may be present in the control group. Population stratification has the 
most potential to confound GWAS, which arises from the presence of multiple subgroups 
(populations) with a systematic difference in allele frequencies (103). Several methods have 
been developed to handle population stratification (104). Primarily, population structure can 
be accessed via a quantile-quantile plot (Q-Q plot). A Q-Q plot ranks the calculated p-values 
for association of each SNP from smallest to largest and plots them against the expected 
distribution (e.g., χ2, student t statistics). Population stratification can also be indicated by an 
excessive genomic inflation factor (λGC), which is calculated as the observed median χ2 
divided by the expected median χ2 (105). However, deviant Q-Q plots and λGC>1 may reflect 
true polygenic effects; the study power needs to be taken into account to interpret whether 
there is an excessive type I error rate that is most likely due to population stratification. Other 
approaches include utilising principal components analysis (PCA, which is widely used to 
quantify patterns of population [i.e., ancestry] structure in GWA studies. Briefly, SNPs are 
treated as features; genotyped individuals are projected into a subspace spanned by the top 
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principal components [PCs]. These top PCs reflect variation due to population structure in the 
sample, where individuals from the same population form a cluster in this subspace.) (106, 
107) and structured or family-based association tests (108), to increase genetic homogeneity 
of study subjects. 
Furthermore, as GWAS perform multiple testing for hundreds of thousands of SNPs, using a 
nominal statistical significance threshold of a p-value less than 0.05 would obviously result in 
many false-positive discoveries. Therefore, to account for testing an estimated 1 million 
independent common SNPs, a genome-wide significance level (p<5×10-8) is specified (109). 
The Bonferroni correction evaluates p-value threshold as the nominal p-value over the 
number of statistical tests conducted (e.g., Bonferroni corrected p=5×10-8=0.05/106, where 
106 is the number of independent common SNPs estimated from HapMap data). Two other 
alternative approaches are also commonly used: permutation testing (perform the test under 
the same null hypothesis by random reassignment of phenotypes) and evaluating the false 
discovery rate (FDR, a statistic represents the proportion of false-positive results from the 
significant results) (110). 
GWAS summary statistics can be further analysed by some advanced statistical approaches. 
Three cutting-edge statistical approaches are introduced here. The genetic risk score (GRS), 
also known as polygenic risk score, is an approach that estimates an individual’s genetic risk 
by calculating a weighted count of SNP risk alleles, to quantify the amount of genetic 
variance of a given disease and identify the common genetic variance among diseases (111). 
GRS can be calculated by summing statistics of the SNP effects from a GWAS based specific 
p-value thresholds (e.g. p<0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0). A 
significant association between a GRS and a phenotype in an independent GWAS sample 
implies a common genetic signal shared between the GWAS phenotypes. Another analytic 
approach, the genome-wide complex trait analysis (GCTA) (112), is based on utilising linear 
mixed model (LMM), to estimate the proportion of phenotypic variance that can be described 
by the genome-wide SNPs, especially for complex diseases. GCTA evaluates the genetic 
architecture of a target disease by modelling random effects of genome-wide SNPs from 
genetically independent individuals (i.e., individuals with higher genetic relationships than a 
cut-off value [e.g., 0.01, 0.025] are excluded to prevent the estimated genetic variation from 
being driven by the phenotypic correlations). The approach also can be extended to many 
other advanced analyses, such as estimating genetic correlation between two diseases, and 
test the variance explained by the sex chromosome. The LD score regression (79, 113) is the 
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method recently proposed to assess the SNP-based heritability of a target disease and SNP-
based genetic correlation between diseases. LD score is a statistic quantified by an additive 
sum of LD measurements r2 of one tagging allelic variant in LD with neighbouring variants 
(114). Generally, for each SNP variant, a higher LD score corresponds to a higher GWAS test 
statistics (e.g., Z-score, β). According to this principle, the index variant will more likely to 
be a causal variant if it tags more genetic variation, and issues like population stratification 
caused by genetic drift will not influence LD. LD score regression is constructed using LD 
score against with a GWAS test statistics, with the estimated slope corresponding to the 
heritability for single disease and genetic covariance for cross-diseases, respectively. The 
genetic correlation between two diseases can then be evaluated by the covariance normalised 
by the disease-specific heritabilities. 
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2.3 Migraine 
Migraine is a recurrent disabling headache accompanied with complicated heredity and 
neurological manifestations like nausea, vomiting, photophobia and phonophobia. The Global 
Burden of Disease Study 2010 ranked migraine as one of the most disabling diseases in the 
world (1). Data (1) showed that approximately 14.7% (1 billion) of people worldwide 
suffered from migraine, and in sum, migraine accounted for nearly 22.4 million years lived 
with disability (YLDs), 2.9% of total global YLDs. Burdens of migraine not only reflect in 
disability such as severe headache pain and mental stress, but also express in the decreased 
quality of life, especially for the social life such as impaired family and employment 
relationship, and financial costs. For instance, in North America, the total costs were 
estimated at $1036 in the US and $471 in Canada over a three-month period for patients with 
chronic migraine, and at $383 in the US and $172 in Canada over a three-month period for 
patients with episodic migraine (115). In Europe, the economic costs of migraine were also 
substantial: the annual costs of chronic migraine ranged from €1495 in Germany to €3718 in 
the UK, and the annual costs of episodic migraine varied from €486 in France to €1092 in 
Spain (116). The main costs of migraine include direct clinical services such as 
hospitalisation, primary care and medications, and indirect economic loss from decreased 
working efficiency. Thus, more attentions are still urgently required for migraine researches. 
 
2.3.1 Diagnosis 
Before the publication of ICHD, clinicians usually diagnosed migraine based on sending a 
self-reported questionnaire or a face-to-face interview. In 1988, the IHS published the first 
version of ICHD to standardise headache diagnoses based on systematically summarising 
signs and symptoms of different headaches. According to the latest ICHD-3 (2), migraine 
lists as a primary headache that is caused by headache conditions themselves rather than other 
inducements. Table 2-1 illustrates the classification of migraine, comprised of six main 
forms: MO, MA, chronic migraine, complications of migraine, probable migraine and 
episodic syndromes that may be associated with migraine. Depending on the presence and 
absence of aura, migraine can be divided into two main subtypes: MA and MO. 
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Table 2-2 presents the diagnostic criteria for MO and MA. Generally, MO can be regarded as 
a recurrent headache lasting 4 to 72 hours, characterised by some specific manifestations. 
While MA is considered as a more severe and complex migraine subtype compared to MO: 
MA patients often experience some neurological deficits (aura symptoms) occurring before 
or after a headache attack. Most patients (>90%) will experience the visual disturbances 
(117), which are usually described as a scintillating scotoma appearing near the centre of 
vision and then spreads to a zigzag figure with a scintillating edge like a fortification 
spectrum. In addition, sensory aura is the second common type of aura that presents as an 
increasingly sense of pins-and-needles starting from one-side part of body slowly to the other 
areas on the same side. Other aura symptoms occur less frequently. In particular, motor aura 
is an indication of hemiplegic migraine, of which FHM is the most well understood subtype. 
Individuals with FHM should meet the diagnostic criteria of MA particularly with motor 
weakness and have at least one first- or second-degree relative who reported the same attack. 
FHM consists of at least three subtypes (i.e., FHM1, FHM2 and FHM3) according to the 
three identified causative genetic mutations (i.e., CACNA1A, ATP1A2 and SCN1A). 
 
Table 2-1 The classification of migraine according to ICHD-3 
1. Migraine without aura (MO) 
2. Migraine with aura (MA) 
2.1 Migraine with typical aura 
(Typical aura with headache; 
Typical aura without headache) 
2.2 Migraine with brainstem 
aura 
2.3 Hemiplegic migraine 
(Familial hemiplegic migraine; 
Sporadic hemiplegic migraine) 
2.4 Retinal migraine 
3. Chronic migraine 
4. Complications of migraine 
4.1 Status migraine 4.2 Persistent aura without 
infarction 
4.3 Migrainous infarction 4.4 Migraine aura-triggered 
seizure 
5. Probable migraine 
5.1 Probable migraine without aura 5.2 Probable migraine with aura 
6. Episodic syndromes that may be associated with migraine 
ICHD-3: the International Classification of Headache Disorders, 3rd edition. 
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Table 2-2 ICHD-3 based Diagnostic criteria for MO and MA 
MO MA 
A. At least five attacks fulfilling criteria B-D. 
B. Headache attacks lasting 4-72 hours (untreated or 
unsuccessfully treated). 
C. Headache has at least two of the following four 
characteristics: 
1. Unilateral location; 
2. Pulsating quality; 
3. Moderate or severe pain intensity; 
4. Aggravation by or causing avoidance of routine 
physical activity (e.g., walking or climbing stairs). 
D. During headache at least one of the following: 
1. Nausea and vomiting; 
2. Photophobia and phonophobia. 
E. Not better accounted for by another ICHD-3 diagnosis. 
A. At least two attacks fulfilling criteria B and C. 
B. One or more of the following fully reversible aura 
symptoms: 
1. Visual; 
2. Sensory; 
3. Speech and/or language; 
4. Motor; 
5. Brainstem; 
6. Retinal. 
C. At least two of the following four characteristics: 
1. At least one aura symptom spreads gradually over 
≥5 minutes, and/or two or more symptoms occur in 
succession; 
2. Each individual aura symptom lasts 5-60 minutes; 
3. At least one aura symptom is unilateral; 
4. The aura is accompanied, or followed within 60 
minutes, by headache. 
D. Not better accounted for by another ICHD-3 diagnosis, 
and transient ischemic attack has been excluded. 
ICHD-3: the International Classification of Headache Disorders, 3rd edition. 
 
2.3.2 Clinical features 
A migraine attack can be divided into four or five phases that lead on from each other: 
prodrome phase, aura phase, headache phase, resolution phase and recovery phase. Patients 
may suffer a combination of these five phases that may change from attack to attack. Figure 
2-4 shows the main symptoms of five phases in a migraine attack. 
Prodrome phase often lasts several hours or sometimes even several days before aura and 
headache phase, accompanied with several symptoms including psychologic (e.g., 
depression, fatigue), neurologic (e.g. photophobia, phonopobia), constitutional (e.g., thirst, 
anorexia) and autonomic (e.g., nausea, vomiting) signs. It is also known as “premonitory 
phase” or “preheadache phase” and occurs in about one-third of migraineurs (118). The aura 
phase only presents in MA patients generally lasting 5 to 60 minutes before headache phase. 
The migraine aura refers to gradually developing neurological symptoms such as visual, 
sensory and speech disturbances (e.g., trouble speaking or writing, confusion). The disabling 
headache phase typically involves severe, sometimes unbearable throbbing (describe 85% of 
patients) and pulsating head pain. This stage usually attacks only one side of the head (small 
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number of patients report both sides) or shifts from one side to the other, and lasts for about 4 
to 72 hours. In resolution and recovery phase, patients will have some postdromal symptoms 
such as exhausted, sadness, excessive sleep and impaired concentration, which often lasts 
hours or several days (119). 
 
Figure 2-4 The main symptoms and process of five phases in a migraine attack. (URL: http://aeirc-edu.com/wp-
content/uploads/migraine-booklet....pdf) 
 
2.3.3 Epidemiology 
2.3.3.1 Prevalence 
Prevalence is defined as a percentage of a population who report experiencing a specific trait 
or disease during a specific time period. Both lifetime prevalence and one-year prevalence are 
commonly used in epidemiology. 
Table 2-3 summarises the lifetime prevalence of migraine according to all the studies 
published by the end of March 2016 based on the IHS criteria (3-6, 117, 120-137). Overall, 
the lifetime prevalence of migraine varies widely from 3.3% in Benin (136) to 31.5% in 
Sweden (124), due to the analysis of different migraine subtypes, study populations, and 
diagnostic approaches. Previous studies reported a lifetime prevalence of migraine ranging 
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from 8.0% to 31.5% for Caucasian populations, with 2-3 times more prevalent in females 
than males. Although migraine is a common disease worldwide, fewer studies are performed 
for Asian and African populations, which consistently provided a lower lifetime prevalence 
of migraine (with a point estimate less than 12%), compared to Causation population-based 
studies. For instance, the lifetime prevalence of migraine was evaluated at 6.8% in Taiwan 
(123) and 6.4% in Nigeria (137). 
The lifetime prevalence of migraine subtypes is also variable. An early study performed by 
Rasmussen et al., (117) revealed a higher lifetime prevalence of MO compared to MA. This 
finding has been repeatedly observed in other studies (4, 127, 128, 131, 132), with lifetime 
prevalence estimates at 5.3–12.7% for MO and 2.7–7.3% for MA. However, one study 
reported an opposite result: a Mexico study (5) found that the lifetime prevalence for females 
was estimated at 14.1% for MA and 4.9% for MO. Though, further studies are required to 
replicate and confirm the findings from the Mexico populations. 
Also, according to the IHS criteria, the one-year prevalence of migraine based on the selected 
studies published before March 2016 are summarised in Table 2-4 (3, 71, 117, 122, 124, 126, 
138-177). Generally, the one-year prevalence of migraine is similar but slightly lower than 
the lifetime prevalence. The Caucasian population-based studies provide a one-year 
prevalence of migraine from 3.6% to 26.0%. The one-year prevalence of migraine in 
Caucasian populations seems higher compared to other populations, with estimated 
prevalence from 5.3% to 20.4% for Latin American populations, from 4.8% to 14.8% for 
Asian populations, and from 4.3% to 13.5% for African populations, respectively. Females 
are still about 2-3 times more likely to suffer migraine than males. Additionally, MO still 
shows higher one-year prevalence (5.6–15.2%) than MA (2.3–6.6%) for at least Asian (145) 
and Caucasian populations (126, 139, 151, 175). While a Tanzania study (153) showed a one-
year prevalence of 2.6% for MA and 1.4% for MO. Moreover, several studies evaluated one-
year prevalence of probable migraine, with an estimate at 4.2–14.6% of Caucasian 
populations (71, 154, 159, 164, 168, 170, 175) and 6.8% of Latin American populations 
(167). 
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Table 2-3 Lifetime prevalence of migraine according to the IHS criteria 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size Migraine type Lifetime prevalence 
(95% CI) 
Rasmussen, B.K (1992) Clinical IHS-based 
interview 
Denmark Population-based 740 MO 8.0% (6.0–10.0%) 
MA 5.0% (4.0–7.0%) 
Gobel, H (1994) Self-report IHS 
questionnaire 
Germany Population-based 5000 Migraine 27.5% 
O’Brien, B (1994) Self-report IHS 
questionnaire 
Canada Population-based 2922 Migraine 17.0% 
[24.9% of females, 7.8% of males] 
Russell, M.B (1995) IHS-based 
interview 
Denmark Population-based 4000 Migraine 17.7% (16.2–19.2%) 
[23.7% of females, 11.7% of males] 
MO 11.8% (10.5–13.1%) 
15.9% of females, 7.6% of males 
MA 5.5% (4.6–6.4%) 
7.5% of females, 3.6% of males 
Mitchell, P (1998) Self-report IHS 
questionnaire 
Australia Community-based 3654 Migraine 17.0% 
[22.0% of females, 10.0% of males] 
Launer, L.J (1999) Self-report IHS 
questionnaire 
Netherland Population-based 6491 Migraine 33.0% of females, 13.3% of males 
Lu, S.R (2000) Self-report IHS 
questionnaire 
Taiwan Population-based 
adolescent 
4064 Migraine 6.8% (6.0–7.6%) 
[7.8% of girls, 5.7% of boys] 
Mattsson, P (2000) Clinical IHS-based 
interview 
Sweden Population-based 
female 
728 Migraine 31.5% (28.0–34.8%) 
Deleu, D (2001) Clinical IHS-based 
interview 
Oman Community-based 
student 
403 Migraine 12.2% 
[15.5% of females, 6.6% of males] 
Zivadinov, R (2001) IHS-based 
interview 
Croatia Population-based 3794 Migraine 19.0% (17.6–20.5%) 
[22.9% of females, 14.8% of males] 
Kececi, H (2002) Clinical IHS-based 
interview 
Turkey Community-based 1320 Migraine 13.1% 
[17.1% of females, 7.9% of males] 
MO 10.6% 
[13.8% of females, 6.5% of males] 
MA 2.5% 
[3.3% of females, 1.4% of males] 
Russell, M.B (2002) Self-report IHS 
questionnaire 
Denmark Population-based 
twin 
5360 twins MO 19.0% of females, 7.0% of males 
MA 8.0% of females, 7.0% of males 
Svensson, D.A (2002) IHS-based 
interview 
Sweden Population-based 
twin 
1284 twins Migraine 10.3% 
[14.1% of females, 5.8% of males] 
Ho, K.H (2003) IHS-based 
interview 
Singapore Community-based 2096 MO 3.1% 
[3.6% of females, 2.4% of males] 
Carson, A.P (2004) Clinical IHS-based 
interview 
US Community-based 12750 MO 5.3% 
[4.2% of females, 1.0% of males] 
MA 2.7% 
[2.3% of females, 0.4% of males] 
Celik, Y (2005) Self-report IHS 
questionnaire 
Turkey Population-based 386 Migraine 19.9% (18.3–21.5%) 
[29.3% of females, 9.3% of males] 
MO 12.7% (11.5–14.0%) 
MA 7.3% (6.5–7.9%) 
Adeney, K.L (2006) IHS-based 
interview 
Peru Community-based 
female 
154 Migraine 9.1% (4.6–13.6%) 
Adoukonou, T (2009) Self-report IHS 
questionnaire 
Benin Community-based 
university student 
336 Migraine 11.3% (8.2–15.3%) 
[18.3% of females, 6.8% of males] 
Wahab, K.W (2009) Self-report IHS 
questionnaire 
Nigeria Community-based 
undergraduates 
1513 MO 9.6% (8.1–11.1%) 
[10.3% of females, 8.9% of males] 
Houinato, D (2009) IHS-based 
interview 
Benin Community-based 1113 Migraine 3.3% (2.4–4.6%) 
[4.0% of females, 2.2% of males] 
Arroyo-Quiroz, C (2014) Self-report ICHD-
II questionnaire 
Mexico Population-based 
female 
13489 Migraine 19.0% 
MO 4.9% 
MA 14.1% 
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Table 2-3 Lifetime prevalence of migraine according to the IHS criteria 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size Migraine type Lifetime prevalence 
(95% CI) 
Ezeala-Adikaibe, B.A (2014) Self-report ICHD-
II questionnaire 
Nigeria Community-based 1410 Migraine 6.4% (5.1–7.7%) 
[7.5% of females, 5.0% of males] 
Frederick, I.O (2014) Self-report ICHD-
II questionnaire 
US Population-based 
pregnancy female 
500 Migraine 20.0% (16.6–23.8%) 
IHS: International Headache Society; ICHD: the International Classification of Headache Disorders; MO: 
migraine without aura; MA: migraine with aura; PM: probable migraine. 
 
Table 2-4 One-year prevalence of migraine according to the IHS criteria 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size Migraine type One-year prevalence 
(95% CI) 
Rasmussen, B.K (1992) Clinical IHS-based 
interview 
Denmark Population-based 740 Migraine 10.0% (8.0–13.0%) 
[15.0% of females, 6.0% of males] 
Winnem, J (1992) Self-report IHS 
questionnaire 
Norway Community-based 230 Migraine 11.7% 
[13.8% of females, 5.4% of males] 
Abu-Arefeh, I (1994) Self-report IHS 
questionnaire 
UK Community-based 
children 
2165 Migraine 10.6% (9.1–12.3%) 
MO 7.8% (6.5–9.3%) 
MA 2.8% (2.0–3.8%) 
Ensink, F.B (1994) Self-report IHS 
questionnaire 
Germany Population-based 2000 Migraine 3.6% 
[5.3% of females, 1.7% of males] 
O’Brien, B (1994) Self-report IHS 
questionnaire 
Canada Population-based 2922 Migraine 15.2% 
[21.9% of females, 7.4% of males] 
Barea, L.M (1996) Clinical IHS-based 
interview 
Brazil Community-based 
student 
538 Migraine 9.9% 
[10.3% of girls, 9.6% of boys] 
Jaillard, A.S (1997) Self-report IHS 
questionnaire 
Peru Population-based 3246 Migraine 5.3% (4.9–5.8%) 
[7.8% of females, 2.3% of males] 
Lavados, P.M (1997) Self-report IHS 
questionnaire 
Chile Community-based 1540 Migraine 7.3% (5.9–8.6%) 
[11.9% of females, 2.0% of males] 
Montiel, I (1997) Self-report IHS 
questionnaire 
Spain Population-based 140 Migraine 24.3% (16.3–32.3%) 
[34.2% of females, 11.5% of males] 
Sakai, F (1997) IHS-based 
diagnostic pipeline 
Japan Population-based 4029 Migraine 8.4% 
[12.9% of females, 3.6% of males] 
MO 5.8% 
[9.3% of females, 2.1% of males] 
MA 2.6% 
[3.6% of females, 1.4% of males] 
Launer, L.J (1999) Self-report IHS 
questionnaire 
Netherland Population-based 6491 Migraine 25.0% of females, 7.5% of males 
Cheung, R.T (2000) IHS-based 
telephone 
interview 
Hong Kong Community-based 1436 Migraine 12.5% (10.8–14.3%) 
Hagen, K (2000) Self-report IHS 
questionnaire 
Norway Population-based 51383 Migraine 11.6% 
[15.6% of females, 7.5% of males] 
Mattsson, P (2000) Clinical IHS-based 
interview 
Sweden Population-based 
Female 
728 Migraine 18.0% (15.2–20.8%) 
Wang, S.J (2000) Self-report IHS 
questionnaire 
Taiwan Population-based 3377 MO 9.1% 
[14.4% of females, 4.5% of males] 
Dahlof, C (2001) Self-report IHS 
questionnaire 
Sweden Population-based 1668 Migraine 13.2% (11.3–15.1%) 
[16.7% of females, 9.5% of males] 
Zivadinov, R (2001) IHS-based 
interview 
Croatia Population-based 720 Migraine 16.7% (15.6–17.7%) 
[20.2& of females, 13% of males] 
MO 9.2% (8.3–10.2%) 
[11.3% of females, 7.3% of males] 
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Table 2-4 One-year prevalence of migraine according to the IHS criteria 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size Migraine type One-year prevalence 
(95% CI) 
MA 5.9% (5.1–6.8%) 
[8.6% of females, 3% of males] 
Henry, P (2002) Self-report IHS 
questionnaire 
France Population-based 10585 Migraine 7.9% 
[11.2% of females, 4.0% of males] 
Lampl, C (2003) IHS-based 
interview 
Austria Population-based 997 MO 5.6% (4.2–7.0%) 
[7.5% of females, 3.5% of males] 
MA 2.3% (1.4–3.2%) 
[3.6% of females, 0.6% of males] 
PM 8.5% (6.8–10.2%) 
[13.8% of females, 6.1% of males] 
Steiner, T.J (2003) IHS-based 
telephone 
interview 
UK Population-based 4007 Migraine 14.3% 
[18.3% of females, 7.6% of males] 
MA 5.8% 
[7.7% of females, 2.6% of males] 
Dent, W (2004) Self-report IHS 
questionnaire 
Tanzania Community-based 3351 Migraine 5.0% 
[7.0% of females, 2.6% of males] 
MO 1.4% 
[1.8% of females, 0.9% of males] 
MA 3.6% 
[5.2% of females, 1.6% of males] 
Patel, N.V (2004) IHS-based 
telephone 
interview 
US Population-based 8579 Migraine 14.7% 
[19.2% of females, 6.6% of males] 
PM 14.6% 
[15.9% of females, 12.6% of males] 
Zwart, J.A (2004) Self-report IHS 
questionnaire 
Norway Population-based 
adolescent 
8984 Migraine 7.0% 
[9.1% of girls, 4.8% of boys] 
Morillo, L.E (2005) IHS-based 
interview 
Argentina Community-based 1540 Migraine 4.7% 
[6.1% of females, 3.8% of males] 
Brazil 1386 13.3% 
[17.4% of females, 7.8% of males] 
Colombia 1591 10.2% 
[13.8% of females, 4.85 of males] 
Ecuador 1225 8.8% 
[13.5% of females, 2.9% of males] 
Mexico 1380 8.8% 
[12.1% of females, 3.9% of males] 
Venezuela 1496 9.8% 
[12.2% of females, 4.7% of males] 
Pahim, L.S (2006) Self-report IHS 
questionnaire 
Brazil Population-based 2715 Migraine 10.7% (9.4–12.1%) 
Ando, N (2007) Self-report ICHD-
II questionnaire 
Japan Community-based 
student 
6472 Migraine 4.8% 
[6.5% of female, 3.3% of male] 
Siberstein, S (2007) Self-report ICHD-
II questionnaire 
US Population-based 162576 PM 4.5% 
[5.1% of females, 3.9% of males] 
Visudtibhan, A (2007) Clinical IHS-based 
interview 
Thailand Community-based 
student 
1789 Migraine 13.8% 
[16.2% of females, 11.7% of males] 
Radtke, A (2009) IHS-based 
telephone 
interview 
Germany Population-based 7341 Migraine 10.6% 
[15.6% of females, 5.3% of males] 
Cooke, L.J (2010) IHS-based 
telephone 
interview 
Canada Population-based 
female 
1210 Migraine 26.0% 
Ofovwe, G.E (2010) Self-report ICHD-
II questionnaire 
Nigeria Community-based 
student 
1679 Migraine 13.5% 
[18.2% of girls, 9.2% of boys] 
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Table 2-4 One-year prevalence of migraine according to the IHS criteria 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size Migraine type One-year prevalence 
(95% CI) 
Vukovic, C (2010) Self-report ICHD-
II questionnaire 
Croatia Population-based 1542 Migraine 6.2% 
[8.3% of females, 4.0% of males] 
PM 8.8% 
[12.3% of females, 5.0% of males] 
Winkler, A.S (2010) IHS-based 
interview 
Tanzania Community-based 7412 Migraine 4.3% (3.8–4.7%) 
[6.4% of females, 2.2% of males] 
Fallahzadeh,H (2011) Self-report IHS 
questionnaire 
Iran Community-based 
student 
930 Migraine 12.3% (10.2–14.4%) 
Lucchetti, G (2011) ICHD-II based 
interview 
Brazil Population-based 383 Migraine 20.4% (16.6–24.9%) 
[23.5% of females, 11.2% of males] 
PM 6.8% (4.6–9.9%) 
[6.7% of females, 7.1% of males] 
CM 8.9% (6.1–12.0%) 
[10.9% of females, 3.1% of males] 
Matias-Guiu, J (2011) IHS-based 
telephone 
interview 
Spain Population-based 5668 Migraine 8.4% (7.7–9.1%) 
PM 4.2% (3.7–4.7%) 
Ertas, M (2012) ICHD-II based 
interview 
Turkey Community-based 5323 Migraine 16.4% 
[24.6% of females, 8.5% of males] 
PM 12.4% 
[13.4% of females, 11.5% of males] 
MA 3.5% 
[5.2% of females, 1.9% of males] 
CM 0.4% 
[0.7% of females, 0.2% of males] 
Ferrante, T (2012) Self-report ICHD-
II questionnaire 
Italy Community-based 904 Migraine 21.7% (19.0–24.4%) 
[29.7% of females, 11.4% of males] 
PM 4.2% (2.9–5.5%) 
[4.5% of females, 3.8% of males] 
Buse, D.C (2013) Self-report ICHD-
II questionnaire 
US Population-based 162756 Migraine 11.8% 
[17.3% of females, 5.7% of males] 
PM 4.6% 
[5.3% of females, 3.9% of males] 
Chu, M.K (2013) Self-report ICHD-
II questionnaire 
Korea Population-based 1507 Migraine 6.0% (4.8–7.2%) 
[8.7% of females, 3.2% of males] 
Kobor, J (2013) Self-report ICHD-
II questionnaire 
Hungary Community-based 
student 
7361 Migraine 12.5% 
[15.4% of girls, 9.2% of boys] 
Ozdemir, G (2014) Self-report IHS 
questionnaire 
Turkey Population-based 1462 Migraine 16.8% 
[23.1% of females, 10.3% of males] 
Vetvik, K.G (2014) Diagnostic 
pipeline based on 
ICHD-III beta 
Norway Population-based 3514 Menstrual 
migraine 
7.6% (6.8–8.5%) 
Krogh, A.B (2015) Self-report ICHD-
III questionnaire 
Norway Community-based 
adolescent 
488 MO 15.2% (12.0–18.4%) 
[18.8% of girls, 10.4% of boys] 
MA 6.6% (4.4–8.8%) 
[8.0% of girls, 4.7% of boys] 
PM 13.1% (10.1–16.1%) 
[13.8% of girls, 12.3% of boys] 
Poyrazoglu, H.G (2015) Self-report ICHD-
II questionnaire 
Turkey Community-based 
student 
10584 Migraine 7.2% 
[8.9% of females, 5.2% of males] 
Wang, Y (2015) Self-report ICHD-
III-beta 
questionnaire 
China Community-based 
nursing staff 
1102 Migraine 14.8% (9.2–20.4%) 
IHS: International Headache Society; ICHD: the International Classification of Headache Disorders; MO: 
migraine without aura; MA: migraine with aura; PM: probable migraine; CM: chronic migraine. 
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2.3.3.2 Pathophysiology of migraine 
Until now, the pathophysiology of migraine is still unknown. Based on the knowledge of the 
anatomy and physiology of headache pain, two theories are widely accepted and discussed––
the vascular theory and the neurovascular theory. 
The vascular theory supposes that migraine is induced by cerebral vasodilation (an increase 
in blood vessel diameter), supported by the two important observations: i) Ray and Wolff 
(178) found the sensitive region of headache pain are located at vessels, arteries, veins and 
venous sinuses; and ii) the most effective treatment on pain remission, such as ergotamine, is 
a vasoconstrictor. According to the vascular theory (22), intracranial vasospasm of cerebral 
arteries is the main cause of migraine aura and the migraine headache is triggered by the 
following extracranial and intracranial vasodilation, together with the induced sterile 
inflammation. The vascular theory also proposes that MO and MA are the same disorder: the 
aura symptoms are caused by different extents of vascular spasm, and the vasoconstriction 
will lead to the spreading oligemia (a condition of deficiency in blood volume) that is related 
to migraine aura. Visual aura is more frequency because visual cortex neurons are more 
sensitive to ischemia, and other aura symptoms will then appear with increased numbers of 
dysfunctional neurons. Some experimental studies provided evidence on vascular theory. For 
instance, Schytz et al., (179) found that infusion of vasodilatory substances (pituitary 
adenylate cyclase activating peptide-38) may induce headache or migraine attacks. A recent 
meta-analysis showed that the RRs of ischemic stroke were increased to 1.73 (95% CI: 1.31–
2.29) in individuals with migraine; 2.16 (95% CI: 1.53–3.03) in individuals with MA and 
1.23 (95% CI: 0.90–1.69) in individuals with MO, compared to the individuals without 
migraine (180). The similar association was found by other studies (181-183). 
Supported by more researchers, the neurovascular theory supposes that the vascular variance 
of migraine is a subsequence of neuronal phenomena. The cortical spreading depression 
(CSD), first proposed by Leao et al., (184), is described as a slowly (usually 3–5 mm/min) 
depolarization wave (i.e., electroencephalogram activity) spreading across the brain cortex 
and followed by a long-lasting suppression of neural activity, which is associated with 
dramatic deviations in ion homeostasis (185). Based on neurovascular theory, CSD is 
assumed to be related to migraine aura (186). As evidence, the scintillating scotoma often 
starts near the centre of vision and spreads to a zigzag figure within 10–15 mins under a 
speed at approximately 3 mm/min, which is observed to be evoked by an electrophysiological 
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issue at a similar rate as CSD (187, 188). Migraine pain is thought to be associated with this 
passing wave and the followed spreading oligemia (23): the depression wave is involved in 
the cortical neuronal hyperexcitability that causes the brain into an abnormal state through 
neurogenic sterile inflammation and central sensitization (24); and the following spreading 
oligemia, which is a reduced wave of cerebral blood flow, propagates across the brain and 
thus induces migraine. Particularly, MO is deemed as a special case where CSD occurs in a 
silent field of the cerebral cortex (189, 190). This theory is also supported by some 
observations (187, 191). For instance, the variance of blood oxygenation level-dependent 
signal was identified in migraine patients (187) and the hypothalamic activation is identified 
during migraine attacks (191). 
Another branch of neurovascular theory is based on activation and sensitization of the 
trigeminovascular complex—the system in which neurons from the trigeminal nerve, 
innervate cerebral blood vessels (25). The trigeminocervical complex is the main component 
of the trigeminovascular complex, which is associated with conveying sensory information 
and receiving nociceptive information from brain. This theory assumes that the dysfunction 
of trigeminovascular system is the foundation of basic neurovascular theory (192): the 
dysfunction of trigeminovascular system causes the release of substance P and calcitonin 
gene-related peptide; these neuropeptides work on cerebral vasodilation, and thus induce 
headache. 
 
2.3.4 Genetics of migraine 
2.3.4.1 Heritability of migraine 
Strong familial aggregation of migraine has been reported by multiple family studies (193-
199), with significantly increased RR (i.e., RR>1) of migraine in first-degree relatives of 
probands reporting migraine compared to the health controls, indicating the presence of 
familial genetic and/or environmental factors in migraine susceptibility. Twin studies can 
further evaluate the heritability (h2) of migraine by comparing concordance of MZ and DZ 
twin pairs. 
As summarised in Table 2-5 (7, 200-207), currently the heritability of migraine has only been 
assessed in Caucasian populations. From most studies, the heritability of migraine was 
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estimated at about 33–53%. Only additive genetic variance and unique environmental 
variance had contributions on migraine susceptibility and no influence came from non-
additive (dominance) genetic variance or non-unique (shared) environmental variance. 
Females seem to have a slightly higher heritability compared to males. Interestingly, only 
Sweden studies described a best fitting model with significant effects from non-additive 
genetic variance, suggesting a different inheritance pattern in the Swedish population. Only 
one Denmark study (203) provided information on a higher heritability of MA at 65% (70% 
for males and 60% for females) compared to common migraine. 
 
2.3.4.2 Genetic risk loci predisposing to migraine 
Both linkage studies and associated studies are effective approaches to identifying genetic 
risk loci of migraine. In terms of linkage studies, one of the earliest genome-wide linkage 
scan in Finnish family sample conducted by Wessman et al., (208) reported a risk locus on 
4q24 linkage to MA. A large Australian genome-scan study provided evidence for a risk 
locus on 18p11 linkage to a “severe migraine” phenotype based on the classification of latent 
class analysis (LCA) (209) and 5q21 linkage to a general “LCA-migraine” (210). 
Importantly, linkage analysis on FHM (with monogenetic basis) had achieved great success: 
three candidate genes were consistently identified by multiple studies (8-14), namely 
CACNA1A (calcium voltage-gated channel subunit alpha1 A, located at 19q13), ATP1A2 
(ATPase NA+/K+ transporting subunit alpha 2, located at 1q23) and SCN1A (sodium voltage-
gated channel alpha subunit 1, located at 2q24). The mutation of CACNA1A is related to 
shifting Ca2+ channel activation to lower voltages and increasing Ca2+ influx through single 
recombinant human Ca2+ channels, thereby raising FHM risk (12, 211). The mutation of 
ATP1A2 provides instructions for changing single amino acids in the Na+/K+ ATPase protein. 
Hence, it will take more time for neurotransmitters to flow between neurons, which is 
supposed to trigger the headache and neurological symptoms (14). The mutation of SCN1A is 
assumed to be involved in controlling one part of sodium channel called NaV1.1, which used 
to increase the sodium ions flow and release more neurotransmitters, and thus induces the 
headache (13). 
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Table 2-5 Heritability of migraine based on twin study 
Author (year) Diagnostic criteria Country Sample source Sample size 
(N of twins) 
Heritability (95% CI)  
[best fitting model] 
Larsson, B (1995) Self-report Sweden STR (younger cohort) 12884 Female: 49% [AE] 
Male: 39% [AE] 
STR (older cohort) 6448 Female: 58% [DE] 
Male: 44% [AE] 
Ziegler, D.K (1998) IHS-based interview US Kansas and Minnesota 
twin registries 
197 50% (26–69%) [AE] 
Svensson, D.A (1999) IHS-based questionnaire Sweden Swedish adolescent twins 1480 77% (0–94%) [AE] 
Ulrich, V* (1999) IHS-based telephone 
interview 
Denmark DTR 211 65% (49–78%) [AE] 
Female: 60% (37–78%) [AE] 
Male: 70% (47–86%) [AE] 
Mulder, E.J (2003) IHS-based questionnaire Australia ATR 2718 33% (23–43%) [AE] 
Self-report Denmark DTR 1882 53% (42–63%) [AE] 
Self-report of physician 
diagnosis 
Finland Finnish Twin Cohort 
(younger cohort) 
1912 37% (21–51%) [AE] 
Self-report Finland Finnish Twin Cohort 
(older cohort) 
8187 49% (41–57%) [AE] 
Self-report Netherland NTR (younger cohort) 1139 52% (39–63%) [AE] 
Self-report Netherland NTR (older cohort) 330 52% (32–69%) [AE] 
IHS-based telephone 
interview 
Sweden STR 12121 44% (36–51%) [ADE] 
IHS-based questionnaire UK St Thomas’ UK Adult 
Twin Registry 
1428 41% (29–51%) [AE] 
Svensson, D.A (2003) Self-report Sweden STR 6149 Female: 48% (27–65%) [AE] 
Male: 38% (0–73%) [AE] 
Nyholt, D.R (2004) IHS-based questionnaire Australia ATR 6265 36% (22–42%) [AE] 
Svensson, D.A (2004) IHS-based telephone 
interview 
Sweden STR 12095 44% (36–52%) [ADE] 
Ligthart, L (2006) IHS-based questionnaire Netherland Dutch female twins 928 49% (19–57%) [AE] 
Chen, C.C (2009) IHS-based questionnaire Australia ATR 6115 37% (34–40%) [AE] 
IHS: the International Headache Society; N: sample size; ATR: Australian Twin Registry; NTR: the 
Netherlands Twin and Family Registry; STR: Swedish Twin Registry; DTR: Danish Twin registry; A: additive 
genetic factors; D: non-additive genetic factors; E: non-unique environmental factors; CI: confidence interval. 
*study focused on migraine with aura (MA). 
Because of substantial limitations of linkage studies, association studies using the case-
control design are more commonly applied to study migraine genetics. Several candidate 
genes were identified to be associated with migraine susceptibility by using CGAS (212-
219). The methylenetetrahydrofolate reductase enzyme encoded gene MTHFR and the 
serotonin transporter gene SLC6A4 (or 5-HTT, SERT) are two of the most vital risk genes, 
which were consistently reported by numbers of CGAS. The former is possibly associated 
with migraine via hyperhomocysteinemia (an increased homocysteine level in the blood) 
through modulating level of folate, a co-substrate for the synthesis of methionine from 
homocysteine (220); and the latter is related to regulating neuronal expression of serotonin 
transporter to decrease serotonin level that may be involved with CSD variance (221). Other 
candidate genes related to migraine risk include the tryptophan hydroxylase 2 (TPH2), the 
dopaminergic neurotransmission related genes (e.g. the dopamine beta-hydroxylase gene 
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[DBH], the dopamine D2 receptor gene [DRD2]), the Gamma Aminobutyric Acid (GABA) A 
receptor gene (GABRQ) and the brain-derived neurotrophic factor (BDNF). More information 
is summarised in Chapter three. 
Currently, seven GWAS have been conducted for migraine (summarised in Table 2-6) (15-
21). Most of these GWAS have successfully identified potential genetic risk loci associated 
with migraine susceptibility at genome-wide significance level, except the studies performed 
by Ligthart et al., (21) and Cox et al., (18), primarily owing to their small study power. The 
first migraine GWAS (15) in 2010 identified a SNP locus rs1835740 (p<2×10-11, located 
between the MTDH and PGCP genes on chromosome 8q22) associated with MA, from 2731 
cases and 10747 controls of European ancestry. The pathophysiology of MTDH and PGCP in 
MA susceptibility seems to be related to glutamate metabolism: MTDH can decrease the 
neuronal excitability threshold through storing extracellular glutamate activating the N-
methyI-D-aspartate (NMDA) receptors via an indirectly encoded glutamate transporter 
protein (222); and PGCP can reduce threshold of CSD by an encoded glutamate 
carboxypeptidase (a zinc enzyme related to the release of C-terminal glutamate), thereby 
inducing migraine aura (15). However, this risk locus still needs further study to confirm 
since two recent CGAS (223, 224) failed to replicate such finding. Another large migraine 
GWAS completed by the International Headache Genetics Consortium (IHGC) (16) 
identified 12 genome-wide significant SNPs with migraine susceptibility by recruiting 23285 
migraine cases and 95425 health controls based on European populations. Recently, the 
largest published migraine GWAS (20) (utilising 59674 migraine cases and 316078 health 
controls) robustly identified 38 genome-wide significant loci harbouring 44-45 independent 
SNPs associated with migraine risk and confirmed ten previously implicated SNP loci (in 
PRDM16, in MEF2D, in TRPM8, near TGFBR2, in PHACTR1, in ASTN2, in LRP1, in FHL5, 
in TSPAN2 and in C7orf10). The biological pathways involved in migraine of these 10 
replicated risk genes are illustrated in Figure 2-5. Generally, these risk genes increase 
migraine susceptibility mainly through neuronal, vascular, metalloproteinase and pain 
pathways (225). 
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Table 2-6 Summary of recent GWAS on migraine 
Author (year) Migraine type Sample size 
(discovery phase) 
Genome-wide significant SNPs  
(chromosome, reported genes, and p-value) 
Anttila, V (2010) MA 2731 European ancestry cases;  
10747 European ancestry controls 
rs1835740 (8; MTDH, PGCP; p=2×10-11) 
Chasman, D.I (2011) Migraine 5122 European ancestry cases;  
18108 European ancestry controls 
rs10166942 (2; TRPM8; p=6×10-12) 
rs2651899 (1; PRDM16; p=4×10-9) 
rs11172113 (12; LRP1; p=4×10-9) 
Ligthart, L (2011) Migraine 2116 European ancestry cases;  
7318 European ancestry controls 
no genome-wide significant SNPs 
Cox, H.C (2012) Migraine 76 Norfolk Island founder cases; 
209 Norfolk Island founder controls 
no genome-wide significant SNPs 
Freilinger, T (2012) Migraine 2326 European ancestry cases;  
4580 European ancestry controls 
rs3790455 (1; MEF2D; p=7×10-11) 
rs7640543 (3; TGFBR2; p=1×10-9) 
rs9349379 (6; PHACTR1; p=3×10-8) 
rs6478241 (9; ASTN2; p=4×10-8) 
rs10166942 (2; TRPM8; p=1×10-12) 
rs11172113 (12; LRP1; p=3×10-8) 
Anttila, V (2013) Migraine 23285 European ancestry cases;  
95425 European ancestry controls 
rs2651899 (1; PRDM16; p=4×10-14) 
rs12134493 (1; TSPAN2; p=5×10-14) 
rs2274316 (1; MEF2D; p=1×10-8) 
rs6741751 (2; TRPM8; p=9×10-14) 
rs9349379 (6; PHACTR1; p=5×10-8) 
rs11759769 (6; FHL5; p=1×10-11) 
rs4379368 (7; c7orf10; p=1×10-9) 
rs11172113 (12; LRP1; p=4×10-19) 
MO 7107 European ancestry cases;  
69427 European ancestry controls 
rs12134493 (1; TSPAN2; p=5×10-8) 
rs6741751 (2; TRPM8; p=9×10-11) 
rs9349379 (6; PHACTR1; p=3×10-10) 
rs11759769 (6; FHL5; p=2×10-12) 
rs10504861 (8; MMP16; p=1×10-8) 
rs11172113 (12; LRP1; p=1×10-10) 
MA 5118 European ancestry cases;  
74239 European ancestry controls 
no genome-wide significant SNPs 
Clinical migraine 5175 European ancestry cases;  
13972 European ancestry controls 
rs10915437 (1; AJAP1; p=3×10-8) 
rs6741751 (2; TRPM8; p=1×10-8) 
rs6790925 (3; TGFBR2; p=2×10-8) 
rs6478241 (9; ASTN2; p=1×10-9) 
Gormley, G (2016) Migraine 59674 European ancestry cases;  
316078 European ancestry controls 
rs11172113 (12; LRP1; p=6×10-49) 
rs10218452 (1; PRDM16; p=5×10-38) 
rs67338227 (6; FHL5; p=2×10-27) 
rs10166942 (2; TRPM8; p=2×10-27) 
rs2078371 (1; TSPAN2; p=4×10-24) 
rs9349379 (6; PHACTR1; p=6×10-22) 
rs1925950 (1; MEF2D; p=9×10-22) 
rs4814864 (20; SLC24A3; p=2×10-19) 
rs1024905 (12; FGF6; p=2×10-17) 
rs186166891 (7; C7orf10; p=1×10-15) 
rs10786156 (10; PLCE1; p=2×10-14) 
rs4910165 (11; MRVI1; p=4×10-14) 
rs10456100 (6; KCNK5; p=7×10-13) 
rs6478241 (9; ASTN2; p=1×10-12) 
rs12260159 (10; HPSE2; p=3×10-10) 
rs77505915 (16; CFDP1; p=3×10-10) 
rs17857135 (17; RNF213; p=5×10-10) 
rs2506142 (10; NRP1; p=2×10-10) 
rs13078967 (3; GPR149; p=2×10-9) 
rs111404218(20; JAG1; p=2×10-9) 
rs7684253 (4; REST; p=3×10-9) 
rs1268083 (6; HEY2; p=5×10-9) 
rs75213074 (17; WSCD1; p=7×10-9) 
rs28455731 (6; GJA1; p=7×10-9) 
rs6791480 (3; TGFBR2; p=8×10-9) 
rs11624776 (14; ITPK1; p=8×10-9) 
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Table 2-6 Summary of recent GWAS on migraine 
Author (year) Migraine type Sample size 
(discovery phase) 
Genome-wide significant SNPs  
(chromosome, reported genes, and p-value) 
rs6693567 (1; ADAMTSL4; p=1×10-8) 
rs10895275 (11; YAP1; p=2×10-8) 
rs12845494 (X; MED14; p=2×10-8) 
rs10155855 (7; DOCK4; p=2×10-8) 
rs138556413 (2; CARF; p=2×10-8) 
rs4081947 (16; ZCCHC14; p=3×10-8) 
rs2223089 (10; ARMS2; p=3×10-8) 
rs561561 (11; IGSF9B; p=3×10-8) 
rs11031122 (11; MPPED2; p=4×10-8) 
rs140002913 (6; NOTCH4; p=4×10-8) 
rs144017103 (20; CCM2L; p=4×10-8) 
 MO 8348 European ancestry cases;  
139622 European ancestry controls 
rs11172113 (12; LRP1; p=4×10-16) 
rs7775721 (6; FHL5; p=1×10-12) 
rs6724624 (2; TRPM8; p=1×10-9) 
rs2078371 (1; TSPAN2; p=7×10-9) 
rs9349379 (6; PHACTR1; p=2×10-9) 
rs1024905 (12; FGF6; p=3×10-9) 
rs6478241 (9; ASTN2; p=1×10-10) 
MA 6332 European ancestry cases;  
144883 European ancestry controls 
no genome-wide significant SNPs 
   
GWAS: genome-wide association studies; MO: migraine without aura; MA: migraine with aura. 
 
Figure 2-5 The biological pathways of 10 common genome-wide significant migraine susceptibility genes. 
 
39 
 
2.4. Depression 
Depression is a common mental health disorder usually referring to a dramatic decline in both 
moods and behaviours, with higher risks of functional impairment, mortality and service 
utilisation (226). According to the Global Burden of Disease Study 2010 (1), depression was 
regarded as the most burdensome disorder worldwide: MDD was the second leading cause of 
global YLDs (63.2 million, 8.1% of total global YLDs); and the other two common 
depression subtypes, bipolar disorder (12.9 million, 1.7% of total global YLDs) and 
dysthymia (11.1 million, 1.4% of total global YLDs), ranked as 18th and 19th of global YLDs, 
respectively. The increased burdens of depression consist of four parts: the general disability 
burdens (e.g., reduced quality of life, cognitive impairment), the family and social 
relationship burdens, the financial burdens, and the mortality burdens (227). The high 
mortality rate is particularly stark. For instance, a Sweden study observed that females and 
males with unipolar depressive disorders had higher standardised mortality ratios for suicide 
(Female: 27.0; Male: 20.9) (228). An Australian study (229) focused on analysing 5276 
community-dwelling elder males and reported a significant mortality hazard ratio (HR) of 
1.98 (95% CI: 1.61–2.43) for clinically depressive patients compared to health controls. 
Another meta-analysis (230) recruited 1813733 individuals (135007 depressive patients and 
1678726 non-depressive individuals) from 293 studies and found a significantly increased 
RR (RR=1.52, 95% CI: 1.45–1.59) for mortality in depressive patients compared to non-
depressive individuals. Depression, especially MDD, also proposes increased financial costs 
on general populations: a study from the US (231) reported that the economic costs of MDD 
were estimated at $173.2 billion in 2005 and increased at $210.5 billion in 2010. As such, 
numerous depression-related studies have been conducted during past decades. 
 
2.4.1 Diagnosis 
The classification of depression is a controversial topic. Generally, depression is widely 
accepted to be classified into two primary subtypes: unipolar depressive disorders and bipolar 
disorder (or manic depression). If an individual only had episodes of depression, they would 
be defined as suffering a unipolar depressive disorder; while if an individual had reported 
alternating episodes of depression and mania, they would be described as suffering a bipolar 
disorder. Based on the level of severity and chronicity, the unipolar depressive disorder can 
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be further divided into four subtypes: non-chronic MDD, chronic MDD, MiDD (non-chronic) 
and dysthymia (chronic) (232). MDD (or unipolar depression, clinical depression and simple 
depression) commonly refers to as depression. In this thesis, we mainly focus on unipolar 
depressive disorder. 
There are two widely used authoritative diagnostic criteria for depression: the DSM criteria 
published by the American Psychiatric Association (26), and the ICD criteria published by 
the WHO (27). According to the DSM-IV criteria, depression can be diagnosed based on nine 
typical symptoms described in Table 2-7. During a two-week period, most of the time and 
nearly every day, an individual who has presented five or more listed symptoms, including at 
least one of the two key symptoms (“depressed mood” and “loss of interest”), is preliminarily 
diagnosed with MDD. While an individual who has not satisfied the full criteria for MDD but 
still reports 2–4 symptoms, including at least one key symptom, is diagnosed with MiDD. 
From clinical view, MiDD is likely being a milder presentation of a recurrent MDD and 
seems to be a predictor for MDD (233). 
Table 2-7 DSM-based diagnostic symptoms for depression 
Abbreviation Description 
depressed mood Depressed mood most of the day and nearly everyday 
loss of interest Markedly diminished interest in almost all activities most of the day and nearly 
everyday 
weight or appetite change Loss or gain weight significant / decrease or increase appetite nearly everyday 
sleep disturbance Insomnia or hypersomnia nearly everyday 
agitation or retardation Psychomotor agitation or retardation noticed by others nearly everyday 
fatigue or loss of energy Felt losing energy or fatigue nearly everyday 
worthlessness or feel guilty Felt worthlessness or excessive guilt nearly everyday 
indecisiveness or diminish 
ability to concentrate 
Diminished ability to concentrate or think / indecisiveness nearly everyday 
suicide attempt Recurrent thoughts of death or a suicide attempt without a specific plan 
DSM: Diagnostic and Statistical Manual of Mental Disorders. 
Compared to the DSM criteria, only small changes are revised in the ICD criteria: the 
symptom “fatigue or loss of energy” is classified as one key symptom and an extra symptom 
“low self-confidence” is added in the symptom list. Depression status is diagnosed based on 
the reported numbers of symptoms: during a two-week period, most of the time and nearly 
every day, with at least two key symptoms, an individual who reports fewer than 4 
symptoms, 4 symptoms, 5–6 symptoms, or more than 6 symptoms, is diagnosed with non-
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depression, mild depression, moderate depression and severe depression, respectively. As 
recommended by the ICD, the mild depression is not considered as a clinical depression and 
thus regarded as equivalent to the MiDD; and the moderate and severe depression are 
considered to be equivalent to the MDD. 
 
2.4.2 Epidemiology 
2.4.2.1 Prevalence 
To date, numerous studies have been performed to investigate the prevalence of depression. 
As the prevalence of depression studied before 2010 has been reviewed elsewhere (234), in 
this thesis, we only selected DSM/ICD-based studies published from 2010 to the end of 
March 2016, and summarised the results in Table 2-8 for the lifetime prevalence (28-31, 234-
251) and Table 2-9 for the one-year prevalence (31, 235, 238, 242, 247, 250-288), separately. 
As can be seen from Table 2-8, the lifetime prevalence of general depression varies from 
12.1% in Indian populations (239) to 29.4% in Australian populations (244). This variation is 
likely caused by cultural differences, and variation in sample collection methods and 
diagnostic approaches. Compared to males, females appear to have a slightly higher lifetime 
prevalence of depression. Similar to general depression, the lifetime prevalence of MDD also 
varies widely, ranging from 1.2% to 6.1% in Asian populations and from 4.2% to 24.1% in 
Caucasian and Latin American populations. MDD also shows a substantially higher 
prevalence among females (1.6–7.6% in Asian populations and 7.1–31.3% in Caucasian and 
Latin American populations) compared to males (0.8–3.6% in Asian populations and 0.8–
15.7% in Caucasian and Latin American populations). Moreover, the prevalence of MDD 
seems to vary with age, regardless of populations (31, 237, 241, 245). Additionally, one study 
(250) indicated that individuals living in urban and rural areas may have different lifetime 
prevalence of MDD: individuals living in the urban US were more likely to have MDD 
compared to those living in the rural US. 
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Table 2-8 Lifetime prevalence of depression according to DSM/ICD criteria 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size Depression 
type 
Lifetime prevalence 
(95% CI) 
Cho, M.J (2010) DSM-IV based 
CIDI 
Korea Community-based 6510 MDD 5.6% (4.6–6.6%) 
[7.6% of females, 3.6% of males] 
Kleinberg, A (2010) MINI Estonia Population-based 6105 MDE 5.6% 
[7.1% of females, 4.0% of males] 
Park, J.H (2010) DSM-IV MINI Korea Community-based 
elder 
714 MiDD 5.5% (3.8–7.2%) 
[6.0% of females, 2.7% of males] 
MDD 5.4% (3.7–7.0%) 
[7.0% of females, 2.3% of males] 
Roh, M (2010) MINI Korea Community-based 7357 MDD 10.3% 
Sahoo, S (2010) MINI India Community-based 
male 
405 depression 12.1% 
Williams, L (2010) SCID Australia Community-based 
female 
1095 MDD 23.4% 
Sund, A.M (2011) DSM-IV MFQ Norway Community-based 
adolescent 
2432 depression 23% (18.1–28.8%) 
[31.1% of girls, 14.8% of boys] 
MDD 5.8% (3.9–8.6%) 
[10.7% of girls, 0.8% of boys] 
Chong, S.A (2012) WMH-CIDI Singapore Population-based 6616 MDD 5.8% of total; 
8.1% of Indians; 
5.5% of Chinese; 
4.5% of Malays 
Kessler, R.C (2012) DSM-IV CIDI US Community-based 9282 MDD 14.4% (13.4–15.4%) 
[18.1% of females, 10.4% of males] 
single MDD 4.1% (3.7–4.5%) 
[4.8% of females, 3.4% of males] 
recurrent 
MDD 
10.3% (9.5–11.1%) 
[13.2% of females, 7.3% of males] 
Liao, S.C (2012) WMH-CIDI Taiwan Community-based 10135 MDD 1.2% (0.8–1.6%) 
[1.6% of females, 0.8% of males] 
Murphy, J.A (2012) WMH-CIDI Australia Community-based 8841 depression 29.4% (25.6–33.3%) 
Woodward, A.T (2012) WMH-CIDI US (non-
Hispanic 
White) 
Community-based 
elder 
1130 MDD 13.2% (10.7–15.7%) 
US (African 
American) 
780 5.1% (3.5–6.7%) 
US (Caribbean 
Black) 
262 10.4% (0.4–20.4%) 
US (Latin 
American) 
498 12.7% (7.8–17.6%) 
US (Asian 
American) 
376 6.3% (3.0–9.6%) 
Nes, R.B (2013) CIDI Norway Population-based 
twins 
2794 MDD 14.1% 
[15.8% of females, 11.1% of males] 
Smith, D.J (2013) SCID UK Population-based 172751 probable 
single MDD 
6.4% 
probable 
recurrent 
MDD 
(moderate) 
12.2% 
probable 
recurrent 
MDD 
(severe) 
 
7.2% 
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Table 2-8 Lifetime prevalence of depression according to DSM/ICD criteria 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size Depression 
type 
Lifetime prevalence 
(95% CI) 
McCall-Hosenfeld, J 
(2014) 
WMH-CIDI US Population-based 5692 MDD 16.6% 
Avenevoli, S (2015) DSM-IV CIDI US Community-based 
adolescent 
10123 MDD 11.0% 
Calvo-Perxas, L (2015) PHQ-9 & MINI Spain Population-based 5068 single MDD 4.2% (3.7–4.8%) 
[5.5% of females, 2.8% of males] 
recurrent 
MDD 
24.1% (22.9–25.3%) 
[31.3% of females, 15.7% of males] 
Ishikawa, H (2015) WMH-CIDI Japan Community-based 4130 MDD 6.1% 
Liu, J (2015) SCID China Population-based 16032 MDD 3.6% (3.3–3.9%) 
[4.7% of females, 2.4% of males] 
Li, W (2015) DSM-IV CIDI China Community-based 
undergraduate 
1843 MDD 3.9% 
Weaver, A (2015) DSM-IV CIDI US (African 
American) 
Population-based 1508 MDD 10.4% (8.4–12.4%) of urban; 
13.1% (2.1–24.1%) of suburban; 
4.2% (2.4–6.0%) of rural 
US (non-
Hispanic 
White) 
349 19.1% (9.5–28.7%) of urban; 
20.9% (14.4–27.4%) of suburban; 
21.2% (15.7–26.7%) of rural 
Zhong, B.L (2015) DSM-IV MINI China Community-based 3031 MDD 5.1% (4.3–5.9%) 
MDD: Major Depressive Disorder; MiDD: Minor Depressive Disorder; MDE: Major Depressive Episode; 
DSM: Diagnostic and Statistical Manual of Mental Disorders; CIDI: Composite International Diagnostic 
Interview; MFQ: the Mood and Feelings Questionnaire; MINI: Mini International Neuropsychiatric Interview; 
PHQ-9: Patient Health Questionnaire-9; SCID: the Structured Clinical Interview for DSM-IV-TR. 
From Table 2-9, the one-year prevalence of depression is slightly lower than its lifetime 
prevalence, varying from 0.3% in urban China (286) to 39.1% in Kerala (India) (282), with 
higher prevalence in Caucasian populations compared to Asian populations. More studies 
were performed for MDD, with estimated one-year prevalence from 2.0% to 29.9%. The 
estimates also appear to be higher among Caucasian populations (at 2.8–29.9%, 3.3–36.6% of 
females and 2.2–19.7% of males) compared to Asian populations (at 2.0–11.3%). Only three 
studies (235, 275, 283) focused on investigating the sex-specific prevalence of MDD in Asian 
populations, which consistently revealed that females are 2 to 3 times more likely to suffer 
MDD compared to males. Notably, the one-year prevalence of MDD in African populations 
is much higher at 26.5% in Morocco (253), 26.3% in Kenya (272) and 28.2% in Nigeria 
(285). However, since only few African studies have been performed and two of these studies 
utilised a small sample size less than 200 participants, these findings still require 
confirmation in large samples. In addition, two studies (258, 268) show a similar one-year 
prevalence of MDD in Latin American populations compared to Caucasian populations, with 
an estimated prevalence at 15.3% in Brazil (268) and 17.6% in Honduras (258). Interestingly, 
Kim et al., (280) observed a higher prevalence at 30.3% (34.1% of females and 22.4% of 
44 
 
males) of Korean American elderly people (age 60 and older), suggesting environmental 
contributions to MDD prevalence estimation. 
Several studies focused on calculating the one-year prevalence of major depressive episode 
(MDE), which is an episodic period with MDD symptoms. The largest study by Kessler et 
al., (254) assessed the one-year prevalence of MDE from ten developed countries and seven 
developing countries and found no significant difference between developed countries and 
developing countries, and also between Caucasian populations and Asian populations. 
Generally, the one-year prevalence of MDE was similar to the estimate of MDD. 
 
Table 2-9 One-year prevalence of depression according to DSM/ICD criteria* 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size Depression type Lifetime prevalence 
(95% CI) 
Cho, M.J (2010) DSM-IV based 
CIDI 
Korea Community-based 6510 MDD 2.5% (1.9–3.1%) 
[3.2% of females, 1.7% of males] 
Goldney, R.D (2010) DSM-IV based 
PRIME-MD 
(interview) 
Australia (1998) 
Australia (2004) 
Australia (2008) 
Community-based 3010 
 
3015 
 
3034 
MDD 6.8% (5.9–7.7%) 
[8.1% of females, 5.4% of males] 
8.0% (7.0–8.9%) 
[10.1% of females, 5.8% of males] 
10.3% (9.2–11.4%) 
[11.7% of females, 8.8% of males] 
Kadri, N (2010) MINI Morocco Population-based 5935 MDD 26.5% 
[34.3% of females, 20.4% of males] 
Kessler, R.C (2010) WMH-CIDI Total Developed 
Countries 
Community-based 52485 MDE 5.5% (5.3–5.7%) 
Belgium 2419 5.0% (4.0–6.0%) 
France 2894 5.9% (4.7–7.1%) 
Germany 3555 3.0% (2.4–3.6%) 
Israel 4859 6.1% (5.2–6.8%) 
Italy 4712 3.0% (2.6–3.4%) 
Japan 4129 2.2% (1.4–3.0%) 
Netherlands 2372 4.9% (3.9–5.9%) 
New Zealand 12790 6.6% (6.0–7.2%) 
Spain 5473 4.0% (3.4–4.6%) 
US 9282 8.3% (7.7–8.9%) 
Total Developing 
Countries 
30110 5.9% (5.5–6.3%) 
Brazil 5014 10.4% (9.2–11.6%) 
Colombia 4426 6.2% (5.4–7.0%) 
India 2992 4.5% (3.7–5.3%) 
Lebanon 2857 5.5% (4.1–6.9%) 
Mexico 5782 4.0% (3.4–4.6%) 
South Africa 4315 4.9% (4.1–5.7%) 
Ukraine 4724 8.4% (7.2–9.6%) 
Roh, M (2010) MINI Korea Community-based 7357 MDD 6.5% 
Serrano-Blanco, A (2010) SCID Spain Community-based 3815 MDD 29.9% (26.8–33.0%) 
[36.0% of females, 19.7% of males]  
Scott, K.M (2010) CIDI New Zealand Community-based 12992 MDE 6.6% (6.0–7.2%) 
[8.1% of females, 4.9% of males] 
45 
 
Serrano-Blanco, A (2010) SCID Spain Community-based 3815 MDD 9.6% (8.0–11.2%) 
[12.1% of females, 5.4% of males] 
Verger, P (2010) CIDI (short form) France Community-based 
student 
1723 MDD 8.9% (7.2–10.9%) 
[10.0% of girls, 7.0% of boys] 
Wulsin, L (2010) PHQ-9 
(interview) 
Honduras Community-based 
female 
415 MDD 17.6% 
Andersen, I (2011) DSM-IV based 
MDI 
Denmark (2000) Population-based 4759 MDD 2.0% (1.6–2.5%) 
[1.9% of females, 2.2% of males] 
Denmark (2006) 4.9% (4.3–5.6%) 
[5.4% of females, 4.3% of males] 
Glaesmer, H (2011) PHQ-9 
(self-report) 
Germany Population-based 
elder 
1659 MiDD 3.8% 
[3.3% of females, 4.4% of males] 
MDD 2.8% 
[3.3% of females, 2.2% of males] 
Chan Chee, C (2012) CIDI (short form) France Community-based 
adolescent 
7110 MDE 9.6% (8.6–10.6%) 
Chen, S (2012) PHQ-9 SCID China Community-based 1275 MDD 11.3% (9.3–15.7%) 
Chong, S.A (2012) WMH-CIDI Singapore Population-based 6616 MDD 2.2% of total; 
4.0% of Indians; 
2.0% of Chinese; 
2.0% of Malays 
Hidaka, S (2012) DSM-III-R GDS Japan Community-based 
elder 
1888 MDE 4.5% (3.4–6%) 
Kessler, R.C (2012) DSM-IV CIDI US Community-based 9282 MDD 7.1% (6.3–7.9%) 
single MDD 1.4% (1.2–1.6%) 
recurrent MDD 5.7% (5.1–6.3%) 
Li, C (2012) PHQ-8 CATI China Population-based 203478 depression 9.2% (8.9–9.5%) 
PHQ-8 CAPI 6.3% (5.1–7.5%) 
Sidana, S (2012) PHQ-9 based on 
PRIME-MD 
India Community-based 
student 
237 depression 21.5% 
 MDD 7.6% 
Amamou, B (2013) ICD-10 CIDI French Community-based 1246 MDE 26.4% 
Chen, L (2013) DSM-IV SCID China Community-based 
undergraduate 
5245 MDD 4.0% 
Coelho, C.L (2013) CES-D 
(interview) 
Brazil Community-based 3007 depression 28.3% 
[36.9% of females, 19.1% of males] 
MDD 15.3% 
[20.6% of females, 9.6% of males] 
Hermans, H (2013) IDS (self-report) 
PAS-ADD 
(interview) 
Netherland Community-based 990 MDD 7.6% (5.2–11.0%) 
Kinyanda, E (2013) DSM-IV MINI Uganda Community-based 
children 
1587 depression 8.6% (7.2–10.1%) 
MDE 7.6% (5.2–11.0%) 
Yan, Z,Y (2013) DSM-IV MINI China Community-based 784 depression 13.1% (10.7–15.5%) 
MDD 6.9% (5.1–8.7%) 
Aillon, J.L (2014) MINI Kenya Community-based 169 MDD 26.3% (21.3–31.3%) 
single MDD 9.0% (5.7–12.3%) 
recurrent MDD 17.3% (13.0–21.7%) 
Forlani, C (2014) CAMDEX-R Italy Population-based 359 depression 25.1% (20.6–29.6%) 
[24.3% of females, 25.8% of males] 
Goodwin, R.D (2014) WHO CIDI US (1991) Population-based 8098 MDD 15.7% of females, 10.9% of males 
US (2001) 9882 18.6% of females, 11.8% of males 
Senarath, U (2014) PHQ-9 Sri Lanka Community-based 12841 mild depression 13.3% (12.7–13.9%) 
MDD 4.5% (4.1–4.9%) 
[5.1% of females, 3.6% of males] 
Sokratous, S (2014) CES-D 
(self-report) 
Cyprus Community-based 
undergraduate 
1500 depression 27.9% 
[29.5% of females, 24.3% of males] 
Amarasuriya, S.D (2015) PHQ-9 
(self-report) 
Sri Lanka Community-based 
undergraduate 
4304 depression 13.5% (12.5–14.5%) 
MDD 9.3% (8.4–10.2%) 
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Avenevoli, S (2015) DSM-IV CIDI US Community-based 
adolescent 
10123 MDD 7.5% 
[10.7% of females, 4.6% of males] 
Ishikawa, H (2015) WMH-CIDI Japan Community-based 4130 MDD 2.2% 
Jo, S.J (2015) DSM-IV 
(interview) 
Korea Community-based 184 depression 14.1% (9.1–19.2%) 
MDD 5.4% (2.1–8.7%) 
Kausar, N (2015) DSM-IV 
(self-report) 
Pakistan Community-based 1110 depression 5.3% 
Kim, M.T (2015) PHQ-9 
(interview) 
Korea (Korean 
American elderly) 
Community-based 1118 depression 30.3% 
[34.1% of females, 22.4% of males] 
Markkula, N (2015) CIDI Finland Population-based 5806 MDD 7.4% (5.7–9.0%) 
Nakulan, A (2015) ICD-10  
(interview) 
Kerala Community-based 220 depression 39.1% (32.6–45.9%) 
Park, J.E (2015) DSM-IV CIDI Korea (2001) Community-based 1256 MDD 2.1% 
[4.4% of females, 0.6% of males] 
Korea (2011) 1066 3.6% 
[5.0% of females, 2.3% of males] 
Topuzoglu, A (2015) CIDI (short form) Turkey Community-based 4011 MDD 8.2% (7.4–9.1%) 
[11.0% of females, 4.4% of males] 
Weaver, A (2015) DSM-IV CIDI US  
(African 
American) 
Population-based 1508 MDD 5.3% (3.3–7.3%) of urban; 
5.2% (2.5–7.9%) of suburban; 
1.5% (0.9–2.1%) of rural 
US  
(non-Hispanic 
White) 
349 3.7% (0.4–7.0%) of urban; 
10.6% (3.2–18.0%) of suburban; 
10.3% (2.9–17.7%) of rural 
Zhong, B.L (2015) DSM-IV MINI China Community-based 3031 MDD 1.4% (1.0–1.8%) 
Maske, U.E (2016) CIDI German Community-based 7987 MDD 9.9% of females, 4.2% of males 
Fela-Thomas, A (2016) DSM-IV SADS Nigeria Community-based 156 MDD 28.2% 
[36.4% of females, 23.8% of males] 
Guerra, M (2016) ICD-10 
(self-report) 
Cuba Population-
based 
2944 depression 4.9% (4.1–5.7%) 
[6.1% of females, 2.6% of males] 
Dominican 
Republic 
2011 13.8% (12.3–15.3%) 
[15.2% of females, 11.1% of males] 
Puerto Rico 1918 2.3% (1.7–3.0%) 
[2.8% of females, 1.2% of males] 
China (Urban) 1160 0.3% (0–0.6%) 
[0.5% of females, 0% of males] 
China (Rural) 1002 0.7% (0.2–1.2%) 
[0.5% of females, 0.9% of males] 
India (Urban) 1003 3.9% (2.7–5.1%) 
[3.7% of females, 4.3% of males] 
India (Rural) 999 12.6% (10.5–14.7%) 
[12.1% of females, 13.2% of males] 
Nigeria 914 0.5% (0.1–1.0%) 
[0.6% of females, 0.5% of males] 
Ribeiro Dos Santos, E 
(2016) 
PHQ-9 
(interview) 
Brazil Community-
based 
1601 depression 19.1% (17.2–21.1%) 
[22.2% of females, 16.0% of males] 
*interpretations were same as Table 2-8. ICD: the International Statistical Classification of Diseases and Related 
Health Problems; CAMDEX-R: the Cambridge Mental Disorders of the Elderly Examination Revised; CAPI: 
Computer-assisted Personal Interviewing; CATI: Computer-assisted Telephone Interviewing; CES-D: the 
Centre for Epidemiology Studies Depression scale; IDS: the Inventory of Depressive Symptomatology; MDI: 
Major Depression Inventory; PAS-ADD: the Psychiatric Assessment Schedule for Adults with a Developmental 
Disability; PRIME-MD: the Mood Module of the Primary Care Evaluation of Mental Disorders; SADS: the 
Schedule for Affective Disorder and Schizophrenia; WMH: the World Mental Health survey. 
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2.4.2.2 Pathophysiology of depression 
The pathophysiology of depression is complex and still not clear. The monoaminergic system 
is widely accepted as the cornerstone of depression aetiology (41), which proposed that 
depression is probably caused by a functional deficiency of brain monoamine 
neurotransmitters including norepinephrine, serotonin (5-HT) and dopamine, while mania is 
due to a functional excess of these neurotransmitters. 
The dysfunction of noradrenergic system is related to regulating cognition and motivation 
that is correlated with social symptoms of depression; the low level of dopamine in plasma is 
involved in some depressive symptoms such as diminishing abilities on concentrating, 
thinking and memory, and feeling a lack of pleasure and motivations (289); and an abnormal 
reduction of serotonin of cortical and subcortical brain regions shows a strong relationship 
with sleep disturbance and depressed mood (290). 
The imbalance of these neurotransmitters is likely caused by the abnormal process of 
chemical transmission, which is widely known as a foundation of central nervous system 
(CNS), including synthesis, signaling, and termination of neurotransmitter. According to the 
fact that the pre-synapse and post-synapse (basically used to connect communication of 
neurons) are related to regulating CNS, the dysfunction of synaptic transmission is thought to 
be the main cause of imbalance of neurotransmitters, which is probably due to the 
dysfunction of the transporters for neurotransmitter reuptake or neurotransmitter receptors. 
Indeed, most effective antidepressants are based on the inhibition of reuptake of these 
neurotransmitters and/or antagonism of presynaptic inhibitory neurotransmitter receptors. 
There is some evidence supporting this hypothesis: a compensatory down-regulation of the 
norepinephrine transporter NET would reduce the norepinephrine at the synapse (291) while 
a compensatory up-regulation of the dopamine receptor D2 might decrease dopamine 
transmission (292); and the progressive desensitization of 5-HT1A (a subtype of 5-HT 
receptor, an autoreceptor on the soma and dendrites) can increase serotonin transmission and 
thus make an antidepressant effect (290). Other biochemical effects may also play a role in 
inducing imbalance of neurotransmitters. For instance, the dysregulation of tyrosine 
hydroxylase (a rate-limiting enzyme involved in catecholamine biosynthesis) likely decreases 
metabolism of norepinephrine and density of norepinephrine in the locus coeruleus (part of 
the brainstem involved with physiological responses to stress and panic), and also restrain the 
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expression in dopaminergic neurons (293). Also, low levels of L-Tryptophan and vitamin B6 
deficiency are thought to play a role in decreasing synthesis of serotonin (294). 
Other hypotheses for pathophysiology of depression are also worth further consideration, 
including dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, dysregulation of the 
glutamate system, and dysfunction of GABAergic systems and BDNF (see Chapter three). 
The dysfunction of the HPA axis is assumed to be related to depression through the 
corticotropin-releasing hormones (or corticotropin-releasing factors that are related to 
regulating stress response) (293) and GABAergic system (295). The dysregulation of 
glutamate system is based on the observations that patients with MDD are found to have 
lower glutamate levels (296) and some antidepressants are involved in reducing glutamate 
release through dysfunction of N-methyl-D-aspartate glutamate receptor (297). 
 
2.4.3 Genetics of depression 
2.4.3.1 Heritability of depression 
Similar to migraine, the heritability of depression was frequently calculated in Caucasian 
populations. As summarised in Table 2-10 (32, 33, 298-311), the heritability was estimated at 
around 37–48% for depression and 33–58% for MDD, respectively. All the studies 
consistently reported that the additive genetic factors and unique environmental factors made 
contributions on susceptibility to either depression or MDD, and no significant effects came 
from non-additive genetic factors or non-unique environmental factors. Based on the most 
powerful study in Sweden (32), the heritability of MDD was provided at 37%, 42% for 
females and 29% for males. Indeed, females showed noteworthy higher heritability of either 
depression or MDD than males (female: 41–67% of depression, 36–44% of MDD; male: 1–
28% of depression, 18–39% of MDD). Moreover, it is also worth noting that so far two 
studies concentrated on assessing the heritability of depression based on Asian populations––
Sri Lankan (307) and American Vietnamese (310). Both studies provided an estimated 
heritability close to those Caucasian studies, indicating a similar genetic basis of depression 
among different populations. 
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2.4.3.2 Genetic risk loci predisposing to depression 
To date, limited success has been achieved in identifying genetic risk loci associated with 
depression. Although multiple linkage studies (312-315) were performed and suggested 
several risk loci linked to MDD, most of these findings were inconsistent. For instance, 
Holmans et al., (314) conducted a genome-wide linkage scan by using 297 families with 
MDD cases after excluding family members with bipolar disorder. As a result, a significant 
linkage was identified on chromosome 15q25.3-26.2 by using logistic regression adjusted for 
sex. However, no other studies replicated this region. The 12q23 region was the only risk 
locus repeatedly found to be linked with depression in a study of 110 Utah pedigrees (312) 
and another study of 497 sibling pairs (315). Interestingly, this region was also observed to be 
related to bipolar disorder (316). Considering bipolar disorder shares signs and symptoms 
with depression, the 12q23 linked locus remains a strong candidate for harbouring a genetic 
risk factor(s) for unipolar depressive disorder. 
On the other hand, a number of candidate genes had been consistently identified to be 
associated with depression risk in case-control studies. The largest case-control meta-analysis 
performed by Lopez-Leon et al., (36) collected 183 MDD-related studies and found five 
candidate genes with significantly higher ORs, namely APOE (19q13.2), G protein subunit 
beta 3 (GNB3, 12p13), MTHFR (1p36.3), SLC6A3 (5p15.3) and SLC6A4 (17q11.2). Among 
those, the MTHFR, SLC6A3 and SLC6A4 were repeatedly associated (34, 35, 37, 38, 317). 
The polymorphisms of MTHFR likely cause problems in the synthesis and presynaptic 
release of dopamine due to a low level of folate, which is involved in triggering various CNS 
diseases (318). The polymorphisms of SLC6A3 may play a role in dopamine export rates 
from the synaptic cleft (319) and thus decrease motivation and attention in depression (289). 
And the polymorphisms of SLC6A4 are possibly related to the functional reduction of the 5-
HT level, which can effectively remit some depressive symptoms such as sleep disturbance 
and depressed mood (290). For other two candidate risk genes, the causal link between APOE 
and depression is not clear, assumptions are correlated with lipoprotein metabolism, cognitive 
function, and immunoregulation (the regulation of immune responses) via Alzheimer disease 
(85); and GNB3 may induce depression by its encoded β3-subunit of heterotrimeric guanine-
binding protein transmit signals (320). Other candidate genes associated with depression risk 
will be discussed in Chapter three. 
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Table 2-10 Heritability of depression based on twin study 
Author (year) Diagnostic 
criteria 
Country Population 
source 
Sample size 
(N of twins) 
Depression 
type 
Heritability (95% CI) 
[best fitting model] 
Clifford, C.A (1984)^ MHQ UK Population-based 572 depression 48% (31–65%) 
Female: 67% (27–100%) 
Male: 1% (0–27%) 
McGue, M (1997) CAMDEX Denmark Population based 
elder 
406 depression 34% [AE] 
Female: 41% [AE] 
Male: 21% [AE] 
Lyons, M (1998) DSM-III-R based 
interview 
US Population-based 
male (VETSA) 
3372 MDD 36% (25–47%) [AE] 
Bierut, L.J (1999) DSM-III-R based 
interview 
Australia Population-based 
ATR 
2662 MDD Female: 44% (29–53%) [AE] 
Male: 24% (0–39%) [AE] 
DSM-IV based 
interview 
Female: 36% (15–46%) [AE] 
Males: 18% (0–36%) [AE] 
Kendler, K.S (1999) DSM-III-R based 
interview 
US Population-based 
VTR 
3790 MDD Female: 39% (30–47%) [AE] 
Male: 39% (30–47%) [AE] 
Kendler, K.S (2001) DSM-III-R based 
SCID 
US Population-based 
VTR 
858 MDD 1 year#: 41% (27–54%) [AE] 
6 month: 41% (26–55%) [AE] 
3 month: 35% (16–52%) [AE] 
1 month: 34% (11–55%) [AE] 
Glowinski, A.L (2003) DSM-IV based 
interview 
US Population-based 
female adolescent 
(MOAFTS) 
3416 MDD 40% (24–55%) [AE] 
Rijsdijk, F.V (2003) GHQ UK Population-based St 
Thomas’ UK Adult 
Twin Registry 
2400 depression 42% (36–48%) [AE] 
Kendler, K.S (2006) DSM-IV based 
CIDI 
Sweden Population-based 
STR 
15493 MDD 37% (31–42%) [AE] 
Female: 42% (36–47%) [AE] 
Male: 29% (19–38%) [AE] 
Orstavik, R.E (2007) DSM-IV based 
interview 
Norway Population-based 
young adult 
(NIPHTP) 
2794 depressive 
personality 
disorder 
Female: 49% (41–57%) [AE] 
Male: 25% (12–40%) [AE] 
Ball, H.A (2009) WHO CIDI Sri Lanka Population-based 
adult 
3908 depression Female: 64% (50–76%) [AE] 
Male: 28% (8–48%) [AE] 
Mosing, M.A (2009) DSM-IV 
questionnaire 
Australia Population-based 
ATR 
5440 MDD 33% (30–42%) [AE] 
Nes, R.B (2013) DSM-IV based 
CIDI 
Norway Population-based 2794 MDD 58% (44–69%) [AE] 
Duncan, A.E (2014) DSM-IV based 
interview 
US (total) Population-based 
female (MOAFTS) 
3776 MDD 43% (33–53%) [AE] 
US (African-
American) 
550 56% (29–78%) [AE] 
US (European-
American) 
3226 41% (29–52%) [AE] 
Toomey, R (2015) CES-D US (Vietnam) Population-based 
male (VETSA) 
1231 depression 37% (29–45%) [AE] 
Viktorin, A (2016) The Edinburgh 
Postnatal 
Depression Scale 
Sweden Population-based 
female (STR) 
3427 perinatal 
depression 
54% (35–70%) [AE] 
DSM: Diagnostic and Statistical Manual of Mental Disorders; ATR: Australian Twin Registry; MOAFTS: the 
Missouri Adolescent Female Twin Study; VETSA: the Vietnam Era Twin Study of Aging; STR: Swedish Twin 
Registry; MHTR: the Maudsley Hospital Twin Registry; NIPHTP: the Norwegian Institute of Public Health 
Twin Panel; VTR: Virginia Twin Registry; MHQ: the Middlesex Hospital Questionnaire; GHQ: General Health 
Questionnaire. ^heritability was estimated by Falconer formula. #this study calculated heritability based on four 
time durations. 
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Limited findings were also reported from previous depression GWAS (39, 40, 321-335) (see 
Table 2-11). Kohil et al., (327) found the first genome-wide significant SNP rs1545843 
(p=1×10-9) associated with MDD. However, this finding is likely false-positive because only 
a small number of participants (353 cases and 366 controls) were recruited in the analysis and 
no other GWAS replicated this result. The large MDD GWAS performed by the Psychiatric 
Genomics Consortium (PGC) (333) used 18759 participants (9240 cases and 9519 health 
controls) but still failed to identify any genome-wide significant risk loci with MDD 
susceptibility. Until now, the most successful MDD GWAS, performed by Hyde et al., (40) 
recruited more than 300,000 participants of European ancestry from 23andMe and robustly 
identified 15 genome-wide significant loci covering 17 independent SNPs with MDD risk 
after joint-analysing with previous PGC MDD GWAS. Recently, another MDD GWAS 
completed by the CONVERGE (39) successfully observed two genome-wide significant 
SNPs––rs12415800 (p=2×10-8, near SIRT1) and rs35936514 (p=1×10-8, mapped in an intron 
of LHPP)––by analysing 5303 recurrent severe MDD cases (two or more episodes) and 5337 
health controls from Han Chinese female populations. The polymorphisms of SIRT1 are 
related to MDD risk possibly through abnormal mitochondrial biogenesis (336) or regulating 
activation of the monoamine oxidase A to decrease serotonin levels (337). While little is 
known about the polymorphisms of LHPP, it may increase depression risk by interactive 
functions via 5-HT1A (338). Nevertheless, these results still need further studies to replicate 
and certificate. 
The failures of depression GWAS are considered to be caused by the underpowered sample 
size. Although more than 18000 participants had been recruited in the PGC MDD study, the 
statistical power is still not enough to capture SNPs with tiny effects. Indeed, it has been 
recommended by Levinson et al., (339) that at least 75000 cases are needed to identify such 
SNPs at genome-wide significance level, and the required sample size is expected to reduce 
in line with increased genetic homogeneity of depression cases, which may partly explain the 
success of CONVERGE study. 
 
 
 
 
52 
 
Table 2-11 Summary of recent GWAS on depression 
Author (year) Migraine type Sample size 
(discovery phase) 
Genome-wide significant SNPs  
(chromosome, reported genes, and p-value)  
Sullivan, P.F (2009) MDD 1738 European ancestry cases;  
1802 European ancestry controls 
no genome-wide significant SNPs 
Lewis, C.M (2010) MDD 1636 European ancestry cases;  
1594 European ancestry controls 
no genome-wide significant SNPs 
Muglia, P (2010) MDD 1359 European ancestry cases; 
1782 European ancestry controls 
no genome-wide significant SNPs 
Rietschel, M (2010) MDD 597 European ancestry cases;  
1295 European ancestry controls 
no genome-wide significant SNPs 
Terracciano, A (2010) depression 3972 Sardinian and 839 European 
ancestry individuals 
no genome-wide significant SNPs 
Aragam, N (2011) MDD 1726 cases, 1630 controls no genome-wide significant SNPs 
Kohli, M.A (2011) MDD 353 European ancestry cases; 
366 European ancestry controls 
rs1545843 (12; SLC6A15; p=1×10-9) 
Shi, J (2011) MDD 1020 European ancestry cases; 
1636 European ancestry controls 
no genome-wide significant SNPs 
Shyn, S.I (2011) MDD 3957 European ancestry cases; 
3428 European ancestry controls 
no genome-wide significant SNPs 
Power, R.A (2012) depression 2746 European ancestry cases;  
1584 European ancestry controls 
no genome-wide significant SNPs 
Wray, N.R (2012) MDD 2431 European ancestry cases;  
3673 European ancestry controls 
no genome-wide significant SNPs 
Hek, K (2013) depression 34549 European ancestry individuals no genome-wide significant SNPs 
Power, R.A (2013) MDD 805 European ancestry cases;  
805 European ancestry controls 
no genome-wide significant SNPs 
Major Depressive 
Disorder Working Group 
of the Psychiatric, 
GWAS Consortium 
(2013) 
MDD 9240 European ancestry cases;  
9519 European ancestry controls 
no genome-wide significant SNPs 
Converge consortium 
(2015) 
MDD 5303 Chinese female cases; 
5337 Chinese female controls 
rs12415800 (10; SIRT1; p=2×10-8) 
rs35936514 (10; LHPP; p=1×10-8) 
Okay, A (2016) depressive 
symptoms 
161460 European ancestry individuals rs7973260 (12; KSR2; p=2×10-9) 
rs62100776 (18; DCC; p=9×10-9) 
Hyde, C.L. (2016) MDD 75607 European ancestry cases, 
231747 European ancestry controls 
rs10514299 (5; TMEM161B, MEF2C; p=1×10-15) 
rs1518395 (2; VRK2; p=4×10-12) 
rs2179744 (22; L3MBTL2; p=6×10-11) 
rs11209948 (1; NERG1; p=8×10-11) 
rs454214 (5; TMEM161B, MEF2C; p=1×10-9) 
rs301806 (1; RERE; p=2×10-9) 
rs1475120 (6; HACE1, LIN28B; p=4×10-9) 
rs10786831 (10; SORCS3; p=8×10-9) 
rs12552 (13; OLFM4; p=8×10-9) 
rs6476606 (9; PAX5; p=1×10-8) 
rs8025231 (15; MEIS2, TMCO5A; p=1×10-8) 
rs12065553 (1; intergenic variant; p=1×10-8) 
rs1656369 (3; RSRC1, MLF1; p=1×10-8) 
rs4543289 (5; intergenic variant; p=1×10-8) 
rs2125716 (12; SLC6A15; p=3×10-8) 
rs2422321 (1; NEGR1; p=3×10-8) 
rs7044150 (9; KIAA0020, RFX3; p=4×10-8) 
GWAS: genome-wide association studies; MDD: major depressive disorder. 
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2.5 Comorbid migraine and depression 
Numerous previous studies, including population- or community-based cross-sectional and 
longitudinal studies, and genetic studies, have provided evidence for an association between 
migraine and depression. General details of cross-sectional and longitudinal studies are 
summarised in Table 2-12. 
 
2.5.1 Cross-sectional studies 
Despite of different sample sources and diagnostic approaches, most epidemiological studies 
revealed an increased risk for depression (especially MDD) in migraineurs compared to non-
migraineurs, and an increased risk for migraine (especially MA) in depressive patients 
compared to non-depressive individuals. 
Up to now, the Canadian Community Health Survey (CCHS) provided the largest sample size 
(N=22856381) on evaluating the association between migraine and depression. Molgat et al., 
(43) found that migraineurs had a significantly higher prevalence of MDE (17.6%, 95% CI: 
16.6–18.6%), compared to general population (7.4%, 95% CI: 7.2–7.6%) and other 
participants reporting chronic medical conditions (7.8%, 95% CI: 7.5–8.0%). According to 
the same CCHS cohort, Fuller-Thomson et al., (44) selected 132947 participants in 2005 and 
observed a significant increased odds for depression in migraineurs (male: OR=2.0, 95% CI: 
1.7–2.4; female: OR=1.9, 95% CI: 1.7–2.1), adjusted for the socio-demographic variables 
(e.g., age, race, education level, and marital status) and disability status. Zwart et al., (45) 
conducted another large population-based Nord-Trondelag Health Study (N=47257) and 
found that the OR of depression was significantly higher in individuals with migraine 
(OR=2.7, 95% CI: 2.3–3.2) and non-migrainous headache (OR=2.2, 95% CI: 2.0–2.5), 
compared to the health controls, adjusted for age, sex and education level. Furthermore, from 
the Zabut Aging Project (N=1436), Camarda et al., (46) reported that 47.2% of migraineurs 
presented to have mild-to-moderate depressive symptoms compared to 15.8% of controls 
(p<0.0001, OR=4.7, 95% CI: 3.1–7.0) adjusted for socio-demographic variables. 
Additionally, Hung et al., (47) also observed an extremely higher percentage (48.3%) of 
MDD patients who had reported a history of migraine. 
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Some studies focused on investigating the association between depression and different 
subtypes of migraine including MO, MA, chronic migraine and episodic migraine. For 
instance, Wang et al., (48) observed that MDD was significantly correlated with MO 
(OR=4.2, 95% CI: 1.1–16.3) and MA (OR=13.9, 95% CI: 2.6–73.1), from a community-
based student sample adjusted for age and sex. A more recent case-control study in the UK 
(49) also revealed that the ORs for MA, MO and probable migraine associated with 
depression were estimated at 5.6 (95% CI: 3.5–9.0), 3.7 (95% CI: 2.2–6.1) and 3.6 (95% CI: 
2.7–5.0), respectively. Additionally, Rist et al., (50) analysed 36016 female participants from 
the Women’s Health Study (WHS) and found that the age-adjusted RRs of incident 
depression were 1.44 (95% CI: 1.32–1.56) for non-migraine headache individuals, 1.53 (95% 
CI: 1.35–1.74) for MA individuals, 1.40 (95% CI: 1.25–1.56) for MO individuals and 1.56 
(95% CI: 1.37–1.77) for individuals with any history of migraine, compared to the health 
controls. Lastly, a Brazil study (53) found that the 21.5%, 37.2% and 27.1% patients with 
severe chronic migraine more likely presented a severe, moderate or mild depression, 
respectively, with higher frequency on sadness (81.0%), irritability (84.3%) and fatigue 
(81.4%). 
Patients with chronic migraine seem to have a much higher risk for suffering depression 
compared to patients with episodic migraine. For instance, a Brazil study (54) provided 
strong evidence for the association between depression and chronic migraine, where 
participants with chronic migraine had significantly higher Beck Depression Inventory (BDI) 
scores compared to either the health controls (p<0.001) or participants with episodic migraine 
(p=0.002). From the American Migraine Prevalence and Prevention (AMPP) study, Buse et 
al., (51) observed that individuals with chronic migraine were approximately twice as likely 
to suffer depression compared to individuals with episodic migraine (OR=2.0, 95% CI: 1.7–
2.4). Based on the same sample (N=24000), Ashina et al., (52) also reported a depression-
dose effect, where an increased risk of chronic migraine was calculated for participants with 
moderate depression (OR=1.8, 95% CI: 1.3–2.5), moderately severe depression (OR=2.4, 
95% CI: 1.5–3.6), and severe depression (OR=2.5, 95% CI: 1.5–4.2), compared to 
participants with no depression or mild depression. 
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Table 2-12 Summary of cross-sectional and longitudinal studies on association 
between migraine and depression* 
Author (Year) Study type Diagnostic Criteria Population source Country Sample size Key findings 
Zwart, J.A (2003) Cross-sectional Migraine: ICHD  
(self-report) 
Depression: HADS-D 
Population-based Norway 47257 ORs of depression were significantly for migraineurs (2.7) and subjects with 
non-migrainous headache (2.2). 
Hung, C.I (2005) Cross-sectional Migraine: ICHD-II 
(interview) 
Depression: MINI and 
HAMD 
Population-based Taiwan 151 48.3% MDD patients reported a history of migraine. 
Mercante, J.P (2005) Cross-sectional Migraine: ICHD 
(interview) 
Depression: BDI 
Community-based Brazil 70 58.7% and CM patients are found obtaining moderate or severe depression. 
Molgat, C.V (2005) Cross-sectional Migraine: self-report 
Depression: CIDI 
Community-based Canada 22856381 17.6%, 7.4% and 7.8% MDE patients were found in migraineurs. 
Wang, S.J (2007) Cross-sectional Migraine: ICHD-II 
interview 
Depression: DSM-IV 
MINI 
Community-based 
adolescents 
Taiwan 122 ORs of MDD were significantly estimated at 13.9 in MA patients and 4.2 in 
MO patients. 
Camarda, C (2008) Cross-sectional Migraine: IHS-based 
interview 
Depression: CES-D 
Population-based Italy 1436 OR of depressive symptoms was significant for migraineurs (4.7). 
Samaan, Z (2009) Cross-sectional Migraine: IHS-based 
interview 
Depression: DSM-IV 
SCAN 
Community-based UK 2110 ORs of MA, MO, and probable migraine were significantly estimated at 5.6, 
3.7 and 3.6 in depression patients, respectively. 
Buse, D.C (2010) Cross-sectional Migraine: ICHD-II  
(self-report) 
Depression: PHQ-9 
Population-based US 24000 CM patients are twice likely to have depression than EM patients (OR=2.0). 
Ashina, S (2012) Cross-sectional Migraine: ICHD-II  
(self-report) 
Depression: PHQ-9 
Population-based US 24000 ORs of CM were significantly estimated for participants with moderate 
depression (1.8), moderately severe depression (2.4) and severe depression 
(2.5), compared to non-depression and mild depression 
Arita, J.H (2013) Cross-sectional Migraine: ICHD-II  
(self-report) 
Depression: BDI 
Community-based 
adolescents 
Brazil 137 CM patients show 8.8 BDI points higher than controls and 5.8 BDI points 
higher than EM patients 
Fuller-Thomson, E  
(2013) 
Cross-sectional Migraine: self-report 
Depression: CIDI 
Community-based Canada 132947 ORs of depression were significant 1 for male (2.0) and female (1.9) 
migraineurs. 
Rist, P.M (2013) Cross-sectional Migraine: ICHD (self-
report) 
Depression: MHI-5 
Population-based US 36016 RRs of depression were significantly estimated at 1.44 for non-migraine 
headache, 1.53 for MA, 1.40 for MO, and 1.56 for any migraine. 
Breslau, N (1994) Longitudinal Migraine: IHS-based 
questions 
Depression: DSM-III-R 
(interview) 
Population-based US 1007 RR for MDD was 3.2 in migraineurs; RR for migraine was 3.1 in MDD 
patients. 
Breslau, N (2000) Longitudinal Migraine: IHS-based 
interview 
Depression: DSM-IV 
based interview 
Population-based US 1287 HR for first-onset MDD was 2.4 in migraineurs; HR for first-onset migraine 
was 2.8 in MDD patients. 
Swartz, K.L (2000) Longitudinal Migraine: IHS-based 
interview 
Depression: DSM-III 
(interview) 
Community-based US 1343 Higher OR for MDD was observed in migraineurs (OR=3.1, 95% CI: 2.0–
4.8) under cross-sectional level, but became non-significant (OR=0.7, 95% 
CI: 0.2–2.0) by a logistic regression. 
Breslau, N (2003) Longitudinal Migraine: IHS-based 
questions 
Depression: CIDI 
Population-based US 1186 MDD predicted the status of first-onset migraine (OR=3.4); migraine 
predicted the status of first-onset MDD (OR=5.8). 
Mongini, F (2003) Longitudinal Migraine: IHS 
Depression: DSM-III-R 
(interview) 
Community-based Italy 82 Significant bidirectional association between depression and migraine 
frequency and severity. 
Modgill, G (2012) Longitudinal Migraine: interview 
Depression: CIDI 
Population-based Canada 15254 HR of MDE is 1.6 in migraineurs; HR of migraine is 1.4 in MDE patients 
*same interpretation as Table 2-3 and Table 2-8. MHI: the Mental Health Inventory; BDI: Beck Depression 
Inventory. 
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2.5.2 Longitudinal studies 
While a large number of cross-sectional studies successfully confirmed the association 
between migraine and depression, scientists were also interested in the potential causation 
between these two diseases, in other words, whether migraine is caused by depression or 
whether migraine triggers depression. Based on evidence from six longitudinal studies (55-
60), the association between migraine and depression is considered to be bidirectional, with 
one disorder increasing the risk for the other, and vice versa. 
Breslau et al., (55) performed the first longitudinal study of young adults (N=1007; aged 21 
to 30) to investigate the history of co-occurrence between migraine and MDD. The author 
found the RR for MDD in migraineurs was estimated at 3.2 (95% CI: 2.3–4.6) and RR for 
migraine in MDD patients was slightly lower at 3.1 (95% CI: 2.0–5.0), adjusted for sex and 
education. Similar conclusions were found in their subsequent study (57), where the HR for 
the first-onset MDD was 2.4 (95% CI: 1.8–3.0) in migraineurs and the HR for the first-onset 
migraine was 2.8 (95% CI: 2.2–3.5) in patients with MDD. Breslau et al., (56) conducted 
another longitudinal study by recruiting 1186 individuals aged from 25 to 55. The results still 
revealed that the status of first-onset MDD could predict the status of first-onset migraine 
(OR=3.4, 95% CI: 1.4–8.7) in the follow-up 2 years, but not the status of other severe 
headaches (OR=0.6, 95% CI: 0.1–4.6). Similarly, the initial status of first-onset migraine 
rather than other severe headaches could predict the future status of MDD (OR=5.8, 95% CI: 
2.7–12.3). This bidirectional association was also identified by Modgill et al., (58). From the 
Canadian National Population Health Survey (N=15254), the authors showed that 
migraineurs had a significant HR of 1.6 (95% CI: 1.3–1.9) for developing MDE and a 
borderline nominal HR of 1.4 (95% CI: 1.0–1.9) in patients with MDE for developing 
migraine, adjusted for sex, age and all the other chronic health-related items. Moreover, 
another longitudinal study by Mongini et al., (59) observed a potential bidirectional 
association between depression and migraine frequency (p=0.0051) and severity (p=0.033) 
after 6 to 7 years. Although one US study (60) failed to repeat these findings, it is possibly 
due to the influences from other comorbid psychological diseases like panic disorder and 
social phobia, which were jointly analysed in the study. 
Overall, previous longitudinal studies consistently indicate a bidirectional association 
between migraine and depression, with individuals with migraine or severe headache are 1 to 
6 times more likely to suffer from depression, especially MDD, compared to non-
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migraineurs; and the reverse, with individuals suffering depression 1 to 4 times more likely to 
experience migraine. 
 
2.5.3 Genetic studies 
Following the epidemiological studies, three twin and family studies (61-63) reported 
significant evidence for shared genetic components between two diseases. Firstly, Schur et al. 
(63) utilised bivariate SEM in a US sample of 758 MZ and 306 DZ female twin pairs to 
estimate a trait-specific heritability of 52% (95% CI: 11–66%) for self-reported doctor’s 
diagnosis of depression and 44% (95% CI: 18–55%) for self-reported doctor’s diagnosis of 
migraine headache, and the authors estimated that 20% of the variance in depression and 
migraine was due to shared genetics (i.e., bivariate heritability of 20%) and 4% of the unique 
environmental component is shared. A second twin study using 223 MZ male, 100 DZ male, 
602 MZ female, 286 DZ female, and 280 DZ opposite sex Dutch twin pairs (61) estimated a 
heritability of 45% for LCA-derived migrainous headache and 55% for anxious depression, 
and estimated a genetic correlation between migrainous headache and anxious depression of 
0.30 (95% CI: 0.18–0.43). Additionally, a family-based study in a large Dutch genetic isolate 
utilised IHS diagnostic criteria and reported significant heritability estimates for MO 
(h2=0.77, 95% CI: 0.38–1.00), MA (h2=0.96, 95% CI: 0.51–1.00), and all migraine (h2=0.56, 
95% CI: 0.26–0.86), which all decreased (albeit non-significantly) after adjustment for 
symptoms of depression or use of antidepressant medication (62). Interestingly, a comparison 
of the heritability scores for depression between patients with migraine and controls found 
evidence for shared genetic factors only between MA and depression. Lastly, a significant 
correlation in genetic risk across migraine and MDD was revealed by a recent GRS analysis 
(64). 
Numerous genetic studies were performed to identify the common genes as well as their 
potential mechanisms underlying migraine and depression, which has been summarised in 
our published works (65). For instance, the polymorphisms of the s allele of the 5-HTTLPR 
(serotonin-transporter-linked polymorphic region) located in SLC6A4 and MTHFR C677T 
have provided the most consistent evidence for association with both migraine and 
depression. These candidate genes deserve future studies to replicate in larger and more 
powerful samples. Due to the failures of most previous depression GWAS, no common 
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genome-wide significant genetic locus has been identified to be associated with co-occurring 
migraine and depression. However, the rs11172113 in LRP1 may warrant further 
investigations as it shows strong association with risks for migraine (p=3.94×10-19) (16) and 
some evidence for association with MDD (p=1.35×10-3) (39) in large independent GWAS. 
More details on genetics of comorbid migraine and depression are provided in Chapter three. 
 
2.5.4 Mechanisms on comorbid migraine and depression 
So far the mechanisms underlying the association between migraine and depression are still 
poorly understood. Due to the fact that both migraine and depression are moderately heritable 
(with estimated heritability at 30–50%), environmental trigger factors are believed to play a 
crucial role in the susceptibilities to both diseases. Indeed, migraine is found to be caused by 
a number of potential environmental trigger factors such as weather change, dietary habit 
change, and menstruation particularly for females. For instance, a recent study conducted by 
Yang et al., (340) observed a significant difference in headache incidence associated with 
temperature change (16.5% during winter and 9.6% during summer, p<0.01), from 63 
migraineurs and 3 patients with probable migraine, suggesting the association between 
migraine susceptibility and temperature sensitivity. As surveyed by Kelman (341), 75.9% of 
the migraineurs diagnosed according to the ICHD-2 reported environmental triggers (with the 
top three most frequently reported triggers being related to stress, hormones, and eating 
habits), and this figure increased to 94.6% when patients were asked a specific list of triggers. 
Furthermore, depression is also likely due to some environmental trigger factors, such as 
long-term loneliness, bereavement, disabling injury and job loss. As an example, Park et al., 
(342) found that stressful life events occurred earlier than the development of depressive 
episode according to samples collected from five Asian countries/regions. More recently, 
using genetic risk score (GRS) analysis in a British sample (1605 MDD cases and 1064 
health controls), both stressful life events (p=2.19×10-4) and childhood trauma (p=5.12×10-20) 
were observed to be significantly correlated with developing MDD (343). Together, 
identifying the shared environmental trigger factors between migraine and depression is 
important, because of its great significance in predicting onset of migraine, depression, and 
comorbid migraine and depression; and its potential for providing novel insights into the 
mechanisms as well as the developments of the paradigm of pre-emptive therapy for both 
diseases. 
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From the genetic perspective, genetic findings from twin and family studies (61-63) indicate 
that the co-occurrence of two diseases can be explained, at least partly, by their shared 
underlying genetically determined disease mechanisms. Based on the observations from 
biological studies, these shared genetically mechanisms are likely involved in molecular 
pathogeneses of regulating neurotransmitters (e.g., serotonin, dopamine), glutamate and 
ovarian hormones (65). However, it is still unclear whether these shared genetic variance are 
due to either the same genetic and environmental factors (i.e., same genetic and 
environmental factors account for susceptibility to both migraine and depression 
[pleiotropy]), or their potential causation (i.e., genetic and environmental factors cause a 
primary disease which results in a secondary disease) (344). 
According to this conceptual view, there are three commonly hypothesised mechanisms of 
comorbid migraine and depression (66). Firstly, migraine is fully caused by depression. In 
such case, the disturbances of chronic depression may facilitate the brain pain state. Some 
negative symptoms of depression (e.g., insomnia, anorexia) can induce the activation of 
meningeal nociceptors via the parasympathetic pathway, which is assumed to form the 
migraine nociceptive signals (345). Evidence for this theory can be found from some 
therapeutic observations: antidepressants can partly remit migraine severity, despite of its 
widely varied effectiveness (67-69). As an example, Hung et al., (346) identified a significant 
improvement on health-related quality of life among both “pure” MDD patients and 
comorbid MDD and migraine patients after treating with antidepressants. Furthermore, the 
first-generation tricyclics antidepressants (TCAs), such as amitriptyline, were observed to 
decrease the migraine frequency by promoting the transmission of serotonergic and 
noradrenergic and thus blocking the activation of the trigeminovascular system (347). 
Secondly, migraine causes the development of depression. In such case, the persistent 
disabling headache pain is supposed to bring negative psychiatric reactions. Possible 
evidence for this hypothesis is based on the observation that migraine attacks often coincide 
with menses for female migraineurs, during which time migraine may influence mood 
disturbances via ovarian hormones or neurotransmitters (348). 
Thirdly, shared components produce the co-occurrence of both. In such case, shared genetic 
and environmental factors may lead to common physical conditions and brain patterns. 
Clinicians believe that both migraine and depression are considered as biological 
sensitisations of the CNS. Migraine is an autonomic manifestation and depression is an 
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effective manifestation. Through brain structure alterations and neurological dysfunctions, 
accompanied with long-term negative variations on physical and cognitive functioning, either 
migraine or depression can be triggered by their overlapping risk factors. The observed 
bidirectional association between two diseases better support this hypothesis. 
Interestingly, some studies suggest that migraine with and migraine without depression may 
have different genetic aetiologies. Gudmundsson et al., (70) used a full-brain magnetic 
resonance imaging (MRI) and found substantially smaller volumes of total brain volume, 
grey matter and white matter in patients with comorbid migraine and depression, compared to 
the patients with “pure” migraine or “pure” depression. Moreover, Ligthart et al., (64) drew 
similar conclusions by using a GRS analysis. The authors revealed a significant genetic 
overlap between migraine and MDD and suggested a distinct genetic aetiology between 
“pure” migraine and “pure” MDD. 
Although plenty of studies tried to address the pathophysiology underlying co-occurring 
migraine and depression, currently their mechanisms are still far from clear. Considering both 
migraine and depression show strong familial aggregation with moderate heritability, further 
research to elucidate the underlying mechanisms by identifying and characterising their 
shared genetic and environmental influences is warranted. 
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Chapter 3: Genetic epidemiology of 
migraine and depression 
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Abstract 
Background: Migraine and major depressive disorder (commonly referred to as depression) 
are both common disorders with a significant impact on society. Studies in both clinical and 
community-based settings have demonstrated a strong relationship between migraine and 
depression. In addition to complicating the diagnosis, depression that is comorbid with 
migraine may lower treatment adherence, increase risk of medication overuse and is 
associated with migraine chronification, thus leading to higher direct and indirect costs and 
poorer health-related outcomes with increased disability. 
Aim: The aim of this review is to summarise the current knowledge on the genetic 
epidemiology of migraine and depression and the possible biological mechanisms underlying 
their comorbidity.  
Methods: We present a narrative review reporting on the current literature. 
Results and conclusion:  Epidemiological findings indicate that there is a bidirectional 
relationship between migraine and depression, with one disorder increasing the risk for the 
other and vice versa, suggesting shared biological mechanisms. Twin and family studies 
indicate that this bidirectional relationship can be explained, at least partly, by shared 
underlying genetically determined disease mechanisms. Although no genes have been 
robustly associated with the aetiology of both migraine and depression, genes from 
serotonergic, dopaminergic and GABAergic systems together with variants in the MTHFR 
and BDNF genes remain strong candidates. 
 
Keywords 
Migraine; depression; genetic; epidemiology; comorbid  
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Introduction 
Migraine is a common neurovascular disorder characterised by debilitating episodic 
headaches, comprised of two major subtypes, migraine with aura (MA) and migraine without 
aura (MO) (2). Approximately 23–30% (33–43% of all women and 13–18% of all men) will 
have recurring attacks of migraine during their life (349-351), with a female-to-male 
prevalence ratio ranging from 1.5:1 to 3.3:1 across the lifetime (71, 122, 349, 352). From 
twin studies, it is known that migraine has on average 46% heritability (7), while from family 
and population association studies, the neural and vascular nature of such genetic component 
was recently reviewed (353). 
Major Depressive Disorder (MDD) is a psychiatric illness with lifetime prevalence estimates 
varying from 3% in Japan to 16.9% in the USA, with the majority in the range of 8–12% 
(354, 355). Like migraine, MDD is twice as common among females than males (356, 357). 
MDD patients are diagnosed based on the presence of associated symptoms such as loss of 
interest, depressed mood and suicidal ideation (358). The seriousness of such manifestations 
impacts society at a level that ranked MDD as the second leading cause of disability 
worldwide in 2013 (351). Also similar to migraine, the extent of the genetic component in 
MDD is estimated to be around 40–50% based on twin studies (359). 
In spite of heterogeneous methodologies, epidemiological studies have been consistent in 
establishing an increased risk of depression in individuals with a history of migraine (43, 45, 
52, 360-362). For instance, some studies (45, 360) reported that migraine sufferers were two- 
to three-times more susceptible to suffering from depression than their health counterparts, 
and the prevalence of MDD in migraineurs was significantly higher than in non-migraineurs, 
especially for migraineurs aged 18−38 years (43). Furthermore, other studies have shown that 
once the migraine-depression comorbidity is established, there is a bidirectional dose-
response, that is, the exacerbation of either one of these disorders is associated with the 
subsequent aggravation of symptoms in the other (52, 361, 362). 
Longitudinal studies provide evidence of the temporal nature and direction of this 
relationship. Migraineurs have been shown to be 1.4–6-times more likely to experience a first 
onset of depression than non-migraineurs (44, 45, 50, 56, 363); and MDD patients are around 
1.6–3.4-times more likely to develop migraine, particularly MA, than non-depressed 
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individuals (52, 56, 57). These studies support a bidirectional association hypothesis in which 
the occurrence of one disorder would increase the risk of first onset of the other, presuming 
the existence of shared genetic and environmental factors between migraine and depression 
(56, 58). Alternatively, a causal theory, which assumes the genetic and environmental factors 
of one disorder (e.g., migraine) account for the other (e.g., depression), has been proposed 
(57). 
This review focuses on describing the current knowledge of the genetic aspects of comorbid 
migraine-depression and the possible biological mechanisms underlying this relationship. 
Identifying genetic overlap across phenotypes can help determine whether our current 
classification/categorisation of diseases is valid or whether genetic similarities traverse 
current divisions. This will be reflected in the development of more specific and effective 
treatments, for instance, the prescribed beta-blockers for migraine may exacerbate depression 
(364), or tricyclic antidepressants may prompt mania in bipolar patients (365). Additionally, 
when risk is correlated across phenotypes, pooled analyses will be better powered than 
individual-disorder analyses, thus improving the detection of genetic risk factors. 
The first section of this review summarises the most relevant twin and family studies that 
support the shared genetic components between migraine and depression. The second section 
emphasises candidate gene studies whose results implicate common genetic variants in 
migraine and depression, whether in their comorbid or independent state, in relation to 
different cellular processes. The third section provides a current summary of single 
nucleotide polymorphisms (SNPs) identified by genome-wide association studies (GWAS) of 
migraine and depression, and discusses potential common SNP loci underlying these two 
conditions. Lastly, we discuss the main findings and provide recommendations for future 
studies of comorbid migraine and depression. 
 
Twin and family studies 
Twin and family studies provide a natural experiment to investigate the genetic and 
environmental vulnerability to complex traits such as migraine and depression, based on the 
principle that phenotype variance is affected by genetic factors, environmental factors, and 
their interplay (366). Heritability is the proportion of phenotypic variation between 
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individuals in a population that is attributable to individual genetic differences. The shared 
genetic components underlying two traits can be explained by the proportion of variation in a 
population due to shared genetics (i.e., bivariate heritability) and their genetic correlation 
(i.e., the genetic covariance normalised by the trait-specific heritabilities). 
For instance, Schur et al., (63) performed a bivariate structural equation modelling in a 
community-based sample of 758 monozygotic (MZ) and 306 dizygotic (DZ) female twin 
pairs to estimate a trait specific heritability of 44% (95% CI: 18−55%) for migraine and 52% 
(95% CI: 11−66%) for depression, and the authors estimated that 20% of the variance in 
migraine and depression is due to shared genetics (i.e., bivariate heritability of 20%). In other 
words, the genetic factors accounting for 44% of the variance in migraine also account for 
20% of the variance in depression. A second study using 825 MZ and 666 DZ twins (61), 
estimated a heritability of 45% for migraine and 55% for anxious depression—a disorder 
highly correlated with MDD (367)––and determined that most (54%) of the covariance 
between migraine and anxious depression was explained by shared genetic factors. This study 
also estimated a genetic correlation between migraine and anxious depression of 0.30 (95% 
CI: 0.18−0.43). These findings indicate the comorbidity of migraine and depression can be 
explained, at least partly, by shared genetic factors. 
Most recently, Ligthart et al., (64) utilised genetic risk score (GRS) analysis and revealed a 
signiﬁcant correlation in genetic risk across migraine and MDD. The GRS approach 
estimates genetic overlap across two traits by comparing trait values for one trait to a GRS for 
another trait. For example, a GRS for MDD was calculated in a ‘target’ sample of migraine 
cases and controls as a weighted count of MDD risk-associated SNP alleles identiﬁed in a 
‘discovery’ MDD GWAS (111) for sets of SNPs with varying levels of signiﬁcance (i.e., 
p<0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0). Despite not diﬀerentiating 
between true- and false-positive SNP risk eﬀects, such GRS analyses, using thousands of 
SNPs, are known to capture more genetic variance (compared to using a small number of 
highly signiﬁcant SNPs) when there are more SNPs with smaller p-values than expected 
under the null hypothesis. That is, the excess in SNPs with smaller p-values reﬂects the true 
trait-associated polygenic signal, for which current GWAS simply do not have suﬃcient 
power to implicate at a genome-wide signiﬁcant level. This novel study also provides 
evidence to suggest that, at least in a subset of individuals, migraine may be a result of MDD, 
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and that migraine with and migraine without comorbid MDD may have diﬀerent genetic 
aetiologies. 
Although twin and family studies provide strong evidence for shared genetic components 
between migraine and depression, these studies are unable to identify the specific genetic 
(DNA sequence) variants. The identification of common specific genetic variants for 
migraine and depression has excellent potential to improve our understanding of the aetiology 
of migraine and comorbid depression, and can be conducted by two main approaches: i) 
candidate gene association studies; and ii) GWAS. 
 
Candidate gene association studies 
CGAS can implicate genetic variants in a putative candidate gene by comparing their 
occurrence in individuals with the trait (cases) to their occurrence in individuals without the 
trait (controls) (98). Due to their relatively simple study design and low cost, CGAS have 
historically been the primary approach that has been used to investigate the role of genes in 
the pathogeneses of complex disorders such as migraine and depression. Candidate genes are 
selected based on their known and/or predicted biological function and potential to integrate 
with current theories of pathophysiology. In this paper, we performed a comprehensive 
review of CGAS for migraine (i.e., we searched PubMed using the terms “migraine” and 
“candidate gene study”). We then searched PubMed to identify overlapping CGAS for 
depression (using the terms “depression”, one migraine candidate gene [e.g. “SLC6A4”], and 
“candidate gene study”). Table 3-1 presents a summary of the identified candidate gene 
studies that have been carried out in migraine and depression. The overlapping candidate 
genes suggest potential shared mechanisms underlying migraine and depression, possibly via 
serotonin and dopamine dysfunction, folate metabolism, GABAergic system and growth 
factor activity. 
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 Table 3-1 Genes that have undergone association studies in both migraine and depression 
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Serotonin transporter SLC6A4 and Tryptophan hydroxylase 2 TPH2 
Serotonin or 5-hydroxytryptamine (5-HT) dysfunction has been implicated in both migraine 
and depression pathogenesis. The serotonin transporter gene SLC6A4 (or 5-HTT, SERT; 
located on chromosome 17), particularly its 44-bp degenerate repeat polymorphic region (i.e. 
serotonin-transporter-linked polymorphic region) 5-HTTLPR (with two common variations: 
short variant [s allele] and long variant [l allele]), is related with modulating neuronal 
expression of 5-HT transporter (368) and plays an important role in the serotonergic system. 
Migraine risk is possibly increased with lower levels of 5-HT, which can influence cortical 
spreading depression variance via excitability of the visual cortex (221), the central 
neurochemical imbalance via vasoconstriction (369), and the nociceptive trigeminal 
inhibition tension suppression system (370). Furthermore, some antidepressants, related with 
the functional reduction of 5-HT level, can effectively remit some depressive symptoms like 
sleep disturbance and depressed mood (290) and also reduce migraine attack frequency (347). 
Previous studies had reported both positive and negative results regarding the association 
between 5-HTTLPR and migraine/depression susceptibility (34-36, 212, 371, 372). In terms 
of migraine, for instance, Juhasz et al (371) found a borderline nominal association between 
the 5-HTTLPR s allele and migraine (OR=1.45; 95% CI: 1.00–2.12; p=0.049). However, the 
association was not significant (p=0.12) when comparing 5-HTTLPR genotypes. Positive 
association was also identified from a recent meta-analysis (212) which showed 5-HTTLPR 
was significantly associated with European female migraineurs carrying the s allele 
(OR=2.02; 95% CI: 1.24–3.28). In terms of depression, a recent Korean study (34) detected 
that both s allele and genotype frequencies of 5-HTTLPR were significantly associated with 
depression (adjusted p=0.050 of allelic association; adjusted p=0.015 of genotypic 
association). In a haplotype analysis (35), a significant association was reported between 5-
HTTLPR TA haplotype (tagging s allele) and MDD (OR=1.14; 95% CI: 1.04−1.25). 
Moreover, a large meta-analysis by Lopez-Leon et al., (36) reviewed 183 case-control genetic 
association studies of MDD and identified a significant OR at 1.11 (95% CI: 1.04−1.19) for 
SLC6A4 5-HTTLPR s allele compared with l allele. To date, the only study (372) that 
investigated 5-HTTLPR with respect to comorbid migraine and depression failed to identify 
an association between 5-HTTLPR and either migraine attack frequency or depression risk. 
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As a rate-limiting enzyme involved in 5-HT biosynthesis, tryptophan hydroxylase 2 (TPH2; 
located on chromosome 12) is possibly relevant to migraine and depression susceptibility, via 
reduction of 5-HT levels. Two studies have focused on investigating the association between 
TPH2 with migraine risk (373, 374). Jung et al., (373) revealed that two possible TPH2 
SNPs––rs1487275 (OR=0.47; 95% CI: 0.25−0.89) and rs1386486 (OR=0.56; 95% CI: 
0.33−0.94)––were associated with migraine but the results became non-significant after 
Bonferroni correction. However, a significant association between TPH2 haplotype 
(TTGGG) and migraine was observed (adjusted p=0.043), particularly for MO (adjusted 
p=0.006), although another study failed to replicate this association (374). Some studies have 
reported TPH2 polymorphisms associated with depression onset (375, 376). As an example, 
Zill et al., (375) performed the first analysis of TPH2 on MDD. In this study, TPH2 SNP 
rs1386494 was found to be associated with MDD (adjusted p=0.012); and three TPH2 
haplotypes (CGGCAATGAT, ATACGACGAT, and CGGTAGTAGA) produced significant 
association with MDD (adjusted p value<0.0001). Another study (376) identified one 
significant associated TPH2 haplotype (AGTT) tagging SNP rs11178997 A allele (adjusted 
p=0.001) and significant differences of this haplotype distribution between cases and controls 
(adjusted p=0.002). However, a more recent study (377) failed to identify associations of 
TPH2 SNPs rs7305115 and rs4290270, from Chinese MDD patients and controls. 
These studies suggest that, at least in Caucasian populations, the s allele of SLC6A4 5-
HTTLPR is possibly associated with an increased risk for both migraine and depression. 
However, we note that there were several negative results for association between 5-
HTTLPR and migraine, and no positive report for Asians, implying this association may be 
race-specific. A similar pattern of results for TPH2 suggests that TPH2 SNPs may only 
contribute to the risk for migraine and depression in Caucasian populations. 
 
Dopaminergic neurotransmission 
A growing body of evidence suggests that a dysfunctional dopaminergic system may be the 
mechanism underlying the symptoms of yawning and somnolence (“sleepiness”) in migraine 
(378) and lack of motivation and attention in depression (289). This hypothesis is further 
supported by the use of dopamine agonists and antagonists as migraine (379) and depression 
(319) treatments in current medical practices and by the coexistence of these two disorders 
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with disorders such as Parkinson’s disease (380), whose aetiology has been strongly 
associated with dopamine depletion (381). 
Although inconsistent, genetic studies support a plausible role of dopaminergic systems in 
migraine and depression. Particular interest has been given to polymorphisms in the 
dopamine D2 receptor (DRD2) gene, related with activation and sensitization of the 
trigeminovascular complex (382). The NcoI C to T allelic variant located in exon 6 was 
evaluated in one study where migraine subjects were also tested for depression and other 
mood disorders. In this study, individuals carrying the NcoI C allele had significantly more 
MA and MDD than the NcoI T allele carriers (p<0.00002) (383). Similar results from 
“migraine only” populations were reported by the same authors in an independent MA cohort 
(p<0.005) (384) and by Ghosh et al., in a total migraine sample (adjusted p=0.04) (217). 
However, other studies (216, 385, 386) did not replicate the association of the DRD2 NcoI 
polymorphism with migraine. 
Studies carried out independently in patients with migraine and depression have implicated a 
48-bp variable number tandem repeat (VNTR) polymorphism located in exon 3 in the 
dopamine D4 receptor (DRD4) gene (218, 387, 388). A meta-analysis by Lopez-Leon et al., 
reported a higher risk for MDD in 2-repeat allele carriers (OR=1.73; 95% CI: 1.29−2.32) 
(387), while Mochi et al., (218) found a significantly increased frequency of the 4-repeat 
allele in a sample MO patients (adjusted p=0.0009). However, another study did not find an 
association between the DRD4 48-bp VNTR and migraine (388). 
While dopamine exerts its effects by binding and activating different subtypes of receptors, 
the termination of the stimulation signal on the synaptic and extrasynaptic membranes is 
given by the interaction with dopamine transporters (DAT) (319). Polymorphisms in DAT1 
(also known as SLC6A3), have been investigated due to their possible influence on dopamine 
export rates from the synaptic cleft (319). Firstly, the A allele of SNP rs40184, a variant 
located in exon 14 of DAT1, was associated with MA (OR=0.81; 95% CI: 0.69−0.95) (214). 
Although no subsequent studies have tested for an association between rs40184 and migraine 
without aura, one study reported a higher risk of depression (p=0.003) in Russian male 
adolescents who have experienced maternal rejection and are carrying the AA genotype 
(317). Noticeably, in this study, the A allele was more abundant in cases, thus opposing the 
protective effect detected in migraine patients. Association studies testing a VNTR 
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polymorphism located in the 3’ untranslated region of SLC6A3, have produced negative 
results for migraine (389) and inconsistent results for depression (36). 
The dopamine beta-hydroxylase (DBH) gene encodes an enzyme involved in maintaining 
balance of dopaminergic neurotransmission by catalysing the conversion of dopamine to 
norepinephrine (390). An Australian study (391) described a significantly different (adjusted 
p value=0.019) allele distribution of the DBH dinucleotide (AC) repeat in migraineurs. This 
polymorphism is in high linkage disequilibrium with a 19-bp insertion/deletion (rs72393728) 
in the same gene, whose D (deletion) allele was reported associated with female migraineurs 
(OR=1.50; 95% CI: 1.08–2.08) (216) . Remarkably, the same allele seems to increase 
susceptibility to MDD in a Han Chinese population (OR=1.72; 95% CI: 1.20−2.47) (392). 
In the light of previous reports, dopaminergic system may play a complex role in both 
migraine and depression susceptibilities via multiple polymorphisms including 48-bp VNTR 
in DRD4, rs40184 in DAT1 and rs72393728 in DBH. However, it is still ambiguous whether 
these variants act independently or interact to increase risk for migraine and depression. 
Thus, attention should focus on larger studies in order to replicate these results and better 
define the role of these variations in the aetiology of migraine and depression. 
 
MTHFR 
The MTHFR gene encodes the methylenetetrahydrofolate reductase enzyme (MTHFR), 
which catalyses the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, the most abundant circulating form of folate. In turn, folate is a co-
substrate for the synthesis of methionine from homocysteine; MTHFR dysfunction has been 
associated with pain in migraine via hyperhomocysteinemia (220) and with different central 
nervous systems disorders, including depression, by limiting the synthesis and presynaptic 
release of dopamine as a consequence of low folate levels (318). 
Numerous studies have tested for an association between the C677T polymorphism 
(rs1801133) with migraine and depression susceptibility (36-38, 393-396). This SNP causes 
the synthesis of a thermolabile MTHFR variant characterised by reduced activity. A meta-
analysis by Rubino et al., showed that the T allele provided susceptibility to MA (OR=1.66; 
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95% CI: 1.06−2.59)(393). These results were later replicated by another meta-analysis 
reporting increased susceptibility for MA in TT genotype carriers (OR=1.48; 95% CI: 
1.02−2.13). Interestingly, this association was not found when only populations of Caucasian 
ancestry were analysed, prompting the conclusion of an association driven by the one Asian 
cohort included in the study (OR=6.54; 95% CI: 2.54−16.81) (394). This observation was 
further confirmed by the most recent and largest meta-analysis of 17 studies (395). In this 
study, Liu et al., identified a significant association between the T allele and migraine risk 
exclusively in the Asian population (OR=1.62; 95% CI: 1.13−2.32), particularly stronger in 
the MA subgroup (OR=2.00; 95% CI: 1.01−3.95). Remarkably, a number of MTHFR gene 
association results in depressed individuals greatly resemble those obtained in migraineurs 
(36-38). For instance, in the latest meta-analysis, Wu et al., (38) reported that Asian 
individuals carrying the 677T allele had an increased risk to suffering from depression 
(OR=1.76; 95% CI: 1.30−2.38) compared to Caucasians (OR=1.15; 95% CI: 1.01−1.31). 
Although, no studies have specifically investigated the C677T variant in a comorbid migraine 
and depression sample, Samaan et al., (396) compared 447 individuals with migraine to 1402 
individuals without migraine recruited from a genetic case-control association study of 
recurrent major depression. In this study, the MTHFR C677T polymorphism was associated 
with MA that remained significant after adjusting for age, sex and depression status 
(OR=1.31, 95% CI: 1.01−1.70). 
In summary, the C677T polymorphism in MTHFR has been reported to be associated with 
both migraine and depression risk, with stronger effects in Asian compared to Caucasian 
populations. The association is strongest with migraine and especially MA, and it has been 
suggested that low folate levels may induce aura symptoms (397). 
 
GABA receptor GABRQ and GABRA3 
The activation of gamma-aminobutyric acid (GABA) A receptor by GABA inhibits 
neurotransmission signalling by means of the Cl- channels permeabilisation and the 
subsequent establishment of an inhibitory postsynaptic potential (398). Thus, the GABAergic 
system not only regulates the excitability of nociceptive neurons and pain threshold in the 
trigeminal nucleus caudalis, which is related with migraine pathogenesis, but also exerts its 
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inhibitory action on the hypothalamus-pituitary-adrenal axis (HPA-axis), involved in 
depression (295). Furthermore, the GABAergic system seems to play a role in modulating 
ovarian hormone fluctuations (e.g., estrogen and progesterone) (399), which may explain 
why both migraine and depression are more prevalent in females than in males. 
Two chromosomal regions in particular––15q11-13 and the Xq24-28, containing genes 
encoding the GABA A receptor subunits––have been the focus of association studies since 
earlier linkage analyses suggested a possible relationship with migraine (400, 401). For 
example, Quintas et al., demonstrated an association with migraine for SNP rs3810651 in 
GABRQ (OR=4.07; 95% CI: 1.71−9.73); and SNP rs3902802 (OR=0.41; 95% CI: 0.21−0.78) 
and rs2131190 (OR=0.53; 95% CI: 0.32−0.88) in GABRA3. The GABRQ and GABRA3 genes 
are both located on chromosome Xq24-28 and encode the γ- and α3-GABAA subunits, 
respectively (215). However, another study in an Australian sample did not replicate these 
findings (402). Strikingly, SNP rs3810651––a missense variation in exon 9 of GABRQ––has 
been separately associated (OR=5.26; 95% CI: 1.68−16.49) with MDD patients who were 
given antidepressants for 6 weeks (403). Additionally, Henkel et al., reported a significantly 
different allelic distribution (p≤0.0001) of the dinucleotide (CA) repeat polymorphism, 
located in intron 8 of GABRA3, among female unipolar depression patients (404). 
Although only a small number of studies have focused on investigating the GABAergic 
system with respect to migraine and depression risk, it is nonetheless worth noting that 
different genetic variants in GABRA3 and the same variant (rs3810651) in GABRQ have been 
associated with an increased risk of migraine and depression. 
 
Brain derived neurotrophic factor BDNF 
By means of dopaminergic and serotonergic neurons modulation, BDNF rules regions 
implicated in pain, mood and behaviour in the central nervous system (405). Here lies the 
implication of this gene in migraine and depression pathogenesis. Although no previous 
studies evaluate the relationship between genetic variants and comorbid migraine-depression, 
a number of independently performed association studies suggest a possible effect on the two 
phenotypes. 
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The BDNF rs2049046 T allele has been associated with MA (p=0.0125) in an Australian 
sample (406), and although no individual SNP analysis have replicated this result, one study 
reported a higher risk of migraine (OR=1.88; 95% CI: 1.20−2.93) in double heterozygotes 
rs2049046-AT and rs1553005-GC, the latter being a SNP located in Calcitonin Gene-Related 
Peptide (CGRP) (219). The rs2049046 SNP has also been associated with antidepressant 
efficacy in depressed patients (407). The Val66Met (rs6265) is another well studied 
polymorphism in the BDNF gene. It has been suggested that Met-allele carriers secrete less 
BDNF protein than their counterparts, and that among others, they might have an increased 
risk to suffering from depression (408). However, there is a lack of positive findings on this 
matter, and so far, no plausible role has been attributed to the Val66Met polymorphism (406) 
in migraine. Rather, the BDNF SNP rs2049046 seems to be associated with both migraine 
and depression susceptibility. One migraine-related study suggested an interaction between 
rs2049046 and rs1553005, however this finding awaits replication. 
 
Genome-wide association studies 
GWAS have proven to be a powerful approach to detect common variants associated with 
complex disease (409). To date, six GWAS have been completed in migraine and are 
reviewed in detail elsewhere in this issue (410). Anttila et al., (15) reported the first migraine 
GWAS SNP locus––rs1835740––near MTDH and PGCP on 8q22.1 (p=5.38×10-9), using a 
large case-control sample of European ancestry (2731 MA cases and 10747 controls). The 
largest published study, utilising 23285 migraine cases and 95425 population-matched 
controls, reported five novel SNP loci (near AJAP1, near TSPAN2, in FHL5, in C7orf10, near 
MMP16) and confirmed seven previously implicated SNP loci (in PRDM16, in MEF2D, in 
TRPM8, near TGFBR2, in PHACTR1, in ASTN2, and in LRP1) significantly associated with 
migraine (p<5×10-8) (16). 
Despite MDD having a similar heritability to migraine, until the present year, attempts to 
robustly identify genetic risk variants for MDD have been unsuccessful (333). Thus, in what 
is considered by some as the “beginning of the beginning for the genetic dissection of MDD” 
(411), the China Oxford and VCU Experimental Research on Genetic Epidemiology 
(CONVERGE) consortium published a GWAS wisely designed to overcome the limitations 
faced by previous attempts (412). Selecting 5303 Han Chinese women with recurrent and 
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severe MDD and 5337 health female controls, the authors reported significant association 
(p<5×10-8) with SNP rs12415800 (in SIRT1) and rs35936514 (in LHPP), implicated in 
mitochondria functioning and transcription signalling, respectively. Importantly, both 
rs12415800 (p=7.71×10-4) and rs35936514 (p=1.68×10-4) were convincingly replicated in a 
separate Han Chinese cohort of 3231 cases with recurrent MDD, and 3186 controls. Although 
this is the first time that a mitochondrial gene has been implicated in depression, the 
dysfunction of this organelle as key factor in the onset of depression was previously 
hypothesised by the same authors and others (413). Interestingly, migraine has also been 
linked to mitochondrial dysfunction and recent studies have implicated mtDNA variants 
(414), albeit located in different genes. 
Recently, SNP rs1160720 (near NBEA on 13q13.3) was found to be significantly associated 
with comorbid bipolar disorder and migraine (p=2.97×10-8) by comparing 460 bipolar 
migraineurs and 914 bipolar patients without migraine (415). Although bipolar disorder 
shares signs and symptoms with depression, association of this SNP was not observed 
(p>0.05) in the 2013 Psychiatric Genomics Consortium (PGC) MDD GWAS (333) 
(https://www.med.unc.edu/pgc/files/resultfiles/pgc.mdd.2012-04.zip) and the 2013 
International Headache Genetics Consortium (IHGC) migraine GWAS (16). 
The GWAS-implicated genetic risk loci for migraine and MDD are both novel and recent; 
hence, candidate gene studies are yet to be performed in order to determine whether they 
contribute to both migraine and depression individually and/or comorbid migraine and 
depression. However, our interrogation of published and publicly available MDD GWAS 
summary results indicate the most significant SNP associated with migraine in the 2013 
IHGC migraine GWAS (rs11172113 within LRP1 on 12q13; p=3.94×10-19), is also associated 
with MDD (p=1.35×10-3) in the recent (2015) Han Chinese MDD GWAS (412) 
(https://www.med.unc.edu/pgc/files/resultfiles/converge.MDD.summary_stats.2Sep2015.tbl.
gz), with the same allele (T) associated with increased risk for both migraine and depression 
(see Table 3-2 and Table 3-3). The LRP1 gene is expressed in many tissues including brain 
and is known to modulate synaptic transmission. 
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Table 3-2 Association results for genome-wide significant migraine risk loci 
IHGC migraine 
reported genes 
Strongest 
SNP 
Chromosome A1 A2 MAF IHGC migraine  
(all migraine samples) 
PGC MDD CONVERGE MDD 
OR p-value OR p-value OR p-value 
PRDM16 rs2651899 1 C T 0.41 1.09 4.35 × 10-14 0.98 0.3119 1.00 0.8129 
Near AJAP1 rs10915437 1 G A 0.36 0.95 6.13 × 10-4 0.98 0.4632 0.99 0.1412 
Near TSPAN2 rs12134493 1 A C 0.12 1.14 4.79 × 10-14 1.01 0.8637 0.99 0.6685 
MEF2D rs2274316 1 C A 0.36 1.07 1.42 × 10-8 0.99 0.7326 1.00 0.9083 
TRPM8 rs6741751 2 A G 0.10 0.87 3.34 × 10-13 0.99a1 0.7003 0.99 0.5498 
Near TGFBR2b rs6790925 3 T G 0.38 1.05 8.74 × 10-5 1.00 0.9935 0.99 0.0706 
PHACTR1 rs9349379 6 G A 0.41 0.93 4.60 × 10-8 1.04 0.0796 1.00a3 0.6868 
FHL5 rs13208321 6 A G 0.22 1.10 1.35 × 10-11 1.02 0.5082 0.99 0.2644 
c7orf10 rs4379368 7 T C 0.11 1.11 1.07 × 10-9 1.07 0.0495 0.99 0.0867 
Near MMP16 rs10504861 8 T C 0.16 0.96 3.53 × 10-3 1.03a2 0.2692 1.00 0.6709 
ASTN2 rs6478241 9 A G 0.38 1.06 4.43 × 10-7 1.00 0.9630 1.00 0.7014 
LRP1 rs11172113 12 C T 0.43 0.90 3.94 × 10-19 1.00 0.8769 0.97 0.0013 
OR and p-value are associated with minor allele (A1). A1: minor allele; A2: other allele; SNP: single nucleotide 
polymorphism; MAF: minor allele frequency; MDD; major depressive disorder; OR: odds ratio. aThe strongest 
SNP is not available in the MDD association studies. Alternatively, we select their correlated SNP (highest 
linkage disequilibrium (LD) and closest distance): a1rs7577262 (LD r2=1); a2rs6990990 (LD r2=0.943); 
a3rs13211739 (LD r2=0.347). bOne candidate gene study reported the non-significant (p-value=0.452) 
association between TGFBR2 and the medication free MDD patients (25 cases; 25 controls). 
 
Table 3-3 Association results for genome-wide significant MDD risk loci 
CONVERGE 
MDD reported 
genes 
Strongest 
SNP 
Chromosome 
 
A1 A2 
 
MAF 
 
CONVERGE MDD IHGC migraine  
(all migraine samples) 
OR p-value OR p-value 
SIRT1 rs12415800 10 A G 0.45 1.15 2.53 × 10-10 – – 
LHPP rs35936514 10 T C 0.26 0.84 6.45 × 10-12 1.02a 0.2597 
OR and p-value are associated with minor allele (A1). MDD: major depressive disorder; A1: minor allele; A2: 
other allele; SNP: single nucleotide polymorphism; MAF: minor allele frequency; OR: odds ratio. –: The 
correlated SNP has LD r2 lower than 0.1. aThe strongest SNP is not available in the migraine association results. 
Alternatively, we select their correlated SNP (highest LD and closest distance): rs12264955 (LD r2=0.425). 
 
Concluding remarks 
Twin and family studies have provided strong evidence for a common genetic component 
underlying migraine and depression comorbidity, and suggest that migraine with and 
migraine without comorbid MDD may have different genetic aetiologies. Indeed, recent 
results from full-brain magnetic resonance imaging finding comorbid migraine and MDD 
associated with smaller brain tissue volumes compared to having one or neither of these 
conditions (70); provide further support that migraineurs with MDD may represent a distinct 
clinical phenotype. 
Despite the strong evidence for shared genetic components between migraine and depression, 
no specific genetic variant has shown unequivocal association with risk for both migraine and 
depression. Among the candidate gene variants tested, the s allele of the 5-HTTLPR 
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polymorphism located in SLC6A4 and MTHFR C677T have provided the most consistent 
evidence for association with both migraine and depression. The 48-bp VNTR in DRD4, 
rs72393728 in DBH, rs40184 in DAT1, rs3810651 in GABRQ, and rs2049046 in BDNF also 
deserve consideration for future study in larger, more powerful samples. Similarly, our 
observation that rs11172113 in LRP1 is associated with risk for migraine (p=3.94×10-19) and 
MDD (p=1.35×10-3) in large independent GWAS, warrants further investigation. In addition, 
the diﬀerent results observed for Caucasian and Asian CGAS samples may be complicated by 
the lower prevalence observed in Japan for both migraine (145) and depression (355); hence, 
larger studies in both Caucasian and Asian populations are required. 
It is important to reiterate that none of these candidate genes and their risk loci were 
associated with both migraine and MDD by GWAS data at either genome-wide significant 
(p<5×10-8) or suggestive (p<1×10-5) significance level. A similar conclusion was drawn from 
the study by de Vries et al (416), which reported no experiment-wide significant results for 
the selected candidate genes previously associated with migraine. The most likely reason for 
GWAS not supporting previously implicated candidate genes, concerns the typical small 
sample sizes used in candidate gene studies, which increase the chance of generating both 
false-positive and false-negative results (417). Other explanations include the possibility that 
candidate gene findings may be specific to a particular sample, which due to differences in 
ascertainment, may not be observed in large heterogeneous GWAS case samples. However, 
published methods for the candidate gene studies indicate similar ascertainment and 
diagnoses to those used in GWAS. Additionally, candidate gene studies often focus on a 
limited number of variants in a target gene that may not be well-represented (‘tagged’) in the 
GWAS genotyping arrays. As a consequence, candidate gene variants, especially with minor 
allele frequencies (MAF) lower than 0.05−0.10, may be less likely to be identified by GWAS 
which utilise common (‘tag’) SNPs. Finally, publication bias is another potential source of 
false-positive findings in candidate gene studies, mainly caused by the fact that studies with 
positive results are more likely to be published than those with negative results. The 
specificity in the diagnosis will also likely play a key role in future candidate and genome-
wide association study designs. The utility of such is provided by the use of female-only 
severe recurrent depression cases in the only successful MDD GWAS (412). 
Given the strong evidence for shared genetic risk across migraine and depression, association 
analysis in migraine should benefit from careful screening/diagnosis of migraine cases and 
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controls for depression, and vice versa, to allow subgroup and adjusted analyses. Indeed, as 
illustrated by studies of the C677T variant in MTHFR, once the comorbidity adjustments 
were performed, the association remained only in the MA population, suggesting that 
previous associations to this gene with depression may have been confounded by the 
presence of MA in the depressed cohort. 
SNPs in candidate gene studies should also possess a good rationale for their selection. This 
will minimize negative outcomes and allow the further confirmation of previous associated 
variants from GWAS or other candidate genes studies. Finally, we encourage the 
implementation of new technologies like whole-genome sequencing to comprehensively 
assess genetic variation across (implicated) regions to identify the likely causal genetic risk 
factors. 
We believe that improved study design utilizing appropriate sample size, detailed 
phenotyping of both cases and controls, stratification by migraine type and depression 
status/symptoms, and adjustment for comorbid and genetically correlated traits, will be key to 
determining the genetic factors which underlie the greater than 20% of genetic variance 
shared between migraine and depression. 
 
Article highlights  
• Migraine and depression are comorbid disorders with a large burden in society. The 
amount of genetic variation shared between migraine and depression has been 
estimated to be at least 20%. 
• Genes from serotonergic, dopaminergic and GABAergic systems together with 
variants in the MTHFR and BDNF genes have been implicated in the aetiology of 
migraine and depression. 
• Currently, no genes have been robustly associated with the aetiology of both migraine 
and depression. Future studies should make use of large, well characterised samples 
of migraine cases with comorbid depression.  
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Chapter 4: Familial aggregation of 
migraine and depression: insights 
from a large Australian twin sample 
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Abstract 
Objectives: This research examined the familial aggregation of migraine, depression and 
their co-occurrence. 
Methods: Diagnoses of migraine and depression were determined in a sample of 5319 
Australian twins. Migraine was diagnosed by either self-report, the ID migraineTM Screener, 
or International Headache Society (IHS) criteria. Depression was defined by fulfilling either 
major depressive disorder (MDD) or minor depressive disorder (MiDD) based on the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. The relative risks 
(RR) for migraine and depression were estimated in co-twins of twin probands reporting 
migraine or depression to evaluate their familial aggregation and co-occurrence. 
Results: An increased RR of both migraine and depression in co-twins of probands with the 
same trait was observed, with significantly higher estimates within MZ twin pairs compared 
to DZ twin pairs. For cross-trait analysis, the RR for migraine in co-twins of probands 
reporting depression was 1.36 (95% CI: 1.24–1.48) in MZ pairs and 1.04 (95% CI: 0.95–
1.14) in DZ pairs; and the RR for depression in co-twins of probands reporting migraine was 
1.26 (95% CI: 1.14–1.38) in MZ pairs and 1.02 (95% CI: 0.94–1.11) in DZ pairs. The RR for 
strict IHS MO/MA in co-twins of probands reporting MDD was 2.23 (95% CI: 1.81–2.75) in 
MZ pairs and 1.55 (95% CI: 1.34–1.79) in DZ pairs; and the RR for MDD in co-twins of 
probands reporting IHS MO/MA was 1.35 (95% CI: 1.13–1.62) in MZ pairs and 1.06 (95% 
CI: 0.93–1.22) in DZ pairs. 
Conclusions: We observed significant evidence for a genetic contribution to familial 
aggregation of migraine and depression. Our findings suggest a bidirectional association 
between migraine and depression, with an increased risk for depression in relatives of 
probands reporting migraine, and vice versa. However, the observed risk for migraine in 
relatives of probands reporting depression was considerably higher than the reverse. These 
results add further support to previous studies suggesting that patients with comorbid 
migraine and depression are genetically more similar to patients with only depression than 
patients with only migraine. 
 
Key words: migraine, depression, relative risk, familial aggregation, bidirectional association 
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Migraine, a recurrent disabling headache accompanied by chronic and episodic 
manifestations, is one of the most complex neurological disorders (418). Multiple cross-
sectional studies (43-46, 50-53) have consistently observed that migraine often co-occurs 
with depression, a psychological disorder characterised by dramatic decline in both mental 
and physical conditions (226). 
Also supported by some Caucasian population-based longitudinal studies (55-58), the 
association between migraine and depression is considered to be bidirectional, with migraine 
or severe headache increasing up to a 3-fold higher population relative risk (RR) of suffering 
depression, and vice versa. Another longitudinal study (59) also revealed a potential 
bidirectional association between depression and migraine frequency and severity. While one 
US study (60) failed to repeat these results, possibly due to the influence of other comorbid 
psychological disorders, such as panic disorder and social phobia, which were jointly 
analysed in the study. 
Although repeatedly observed, little is known about the mechanisms underlying the 
association between migraine and depression. An increased RR (i.e. RR>1) of one trait, 
evaluated from twin and family samples, has been identified in relatives of probands 
reporting the same trait, for both migraine (193-199) and depression (419-423). These results 
provide strong evidence on familial aggregation in migraineurs and depressive patients. The 
variation in estimated RRs among these studies is likely due to the different diagnostic 
approaches and study populations. For instance, the lifetime prevalence of migraine was 
calculated 20–28% (424-426) based on the ID migraineTM Screener criteria (73) but reduced 
at approximately 12% (427, 428) based on the International Headache Society (IHS) criteria 
(2); and Caucasian populations had significant higher migraine and depression morbidity than 
African and Asian populations (429, 430). 
Significant familial aggregation of one trait indicates the presence of shared genetic and/or 
environmental factors in susceptibility of the trait. A considerable genetic contribution can be 
further determined after excluding environmental factors. Because both monozygotic (MZ) 
and dizygotic (DZ) twins share similar living resources and environment, they are considered 
to experience the same environmental factors. Therefore, the observation of higher RRs 
within MZ twin pairs compared to DZ twin pairs provides evidence for a genetic contribution 
in susceptibility of the trait. For example, a significant higher RR for prostate cancer within 
male MZ pairs (RR=12.3, 95% CI: 8.4–18.1) compared to male DZ pairs (RR=3.1, 95% CI: 
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1.9–4.9) (431), indicates a significant contribution of genetic factors to the risk of prostate 
cancer. 
The heritability of migraine and depression are both estimated at approximately 50% (7, 
359), indicating both genetic and environmental factors play an important role in their 
development. Therefore, extending RR analyses in MZ and DZ twin pairs across both 
migraine and depression provides a natural experiment to determine the existence of shared 
genetic components between the two traits. Ours is the first such study to use a large 
population-based Australian twin sample to examine the association between migraine and 
depression. 
In this paper, we first examine the familial aggregation of migraine, depression and their co-
occurrence. We next compare relative risks estimated in MZ twin pairs to those estimated in 
DZ twin pairs to provide evidence for the contribution of genetic factors towards their risk. 
 
Materials and methods 
Samples 
As shown in Figure 4-1, participants were drawn from three Australian twin cohorts based at 
QIMR Berghofer Medical Research Institute (432, 433). Subjects with migraine and 
depression status were selected and constituted the “merged migraine sample” (N=38279) 
and “merged depression sample” (N=60170), respectively. Definitions of migraine and 
depression were homogenized across the cohorts. Subjects also answered questions regarding 
demographic characteristics (e.g., sex, date of birth, zygosity), via semi-structured telephone 
interview and/or questionnaire. After combining the two merged samples and removal of 
non-twins and twins with missing status of either migraine or depression, a total of 5319 twin 
pairs (2456 MZ and 2863 DZ pairs) remained for analysis. 
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 Figure 4-1 The flow chart of selected twin sample. 
 
Assessment of migraine 
Migraine symptom information ranged from single answer self-report (‘yes’ or ‘no’) of 
migraine, the ID Migraine™ Screener (73) —three questions shown to accurately identify 
93% of people with migraines, to detailed IHS diagnostic criteria (the International 
Classification of Headache Disorders, ICHD-3) (2). For the collection of detailed ICHD-3 
diagnostic criteria (see Table 4-1), participants answering ‘yes’ to ever having ‘migraine or 
recurrent attacks of headache’ (screening positive), then answered a number of questions 
relating to their symptoms. Diagnosis were determined for the two major varieties of 
migraine: 1.1 migraine without aura (MO) and 1.2 migraine with aura (MA, primarily 
comprising 1.2.1 Typical aura with migraine headache), which account for 90-95% of all 
IHS MO/MAs (122). 
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After careful merging of all available migraine information, lifetime diagnoses for migraine 
were made subject to data availability, according to i) IHS ICHD-3 MO/MA diagnostic 
criteria, ii) the ID Migraine™ Screener, or iii) self-reported migraine. Hence, migraine status 
was measured in four categories according to these three criteria: non-migraine, self-report 
migraine (i.e., participants with positive status of self-reported measurement but negative or 
unknown status of the other two criteria), ID migraine (i.e., participants with positive status 
ID migraineTM Screener criteria but negative or unknown IHS-based migraine status) and IHS 
MO/MA (i.e., participants with positive status of IHS-based migraine). The ‘broad’ migraine 
status (i.e., any migraine) was defined when participants had reported at least one positive 
migraine status; and the ‘narrow’ migraine status was strict to the IHS MO/MA status. 
 
Assessment of depression 
Participants were first asked two screening questions “Has there ever been two weeks or 
more when you were depressed or down most of the day, nearly every day?” and “Has there 
ever been two weeks or more when you were a lot less interested in most things or unable to 
enjoy the things you used to enjoy, most of the day, nearly every day?”. With at least one 
positive response, participants then answered additional questions (see Table 4-1). Lifetime 
depression was diagnosed according to the third and revised edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-III-R) (26) criteria: during two-week period, 
participants who had positive responses of more than five symptoms were diagnosed 
suffering major depressive disorder (MDD) and participants who had 2-4 positive responses 
were diagnosed suffering minor depressive disorder (MiDD). Therefore, in our study, 
depression status was measured in three categories: non-depression, MiDD, and MDD. 
Participants with either MiDD or MDD were defined to have the ‘broad’ depression status 
(i.e., any depression), and the MDD status was used as the narrow depression status. 
 
Analyses 
Of total 5319 twin pairs included in the target sample, we stratified them into 5 subgroups 
according to sex and zygosity: female MZ pairs, male MZ pairs, female DZ pairs, male DZ 
pairs and opposite sex DZ pairs. RRs were calculated as the statistical ratio by comparing the 
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frequency of a target disorder occurring in co-twins of probands and that occurring in co-
twins of health controls, which was calculated from the cross-tabulations of proband–co-twin 
pairs (see Appendix B Table B1–B6). RR for migraine and depression was estimated in co-
twins of twin probands reporting migraine or depression to evaluate their familial aggregation 
and co-occurrence. 
Age at onset for migraine and depression was not available, therefore the “survey age”, 
representing the age when subjects participated in the survey, was used to adjust for potential 
age effects. To investigate whether age would influence RR estimation, logistic regression 
analyses were performed to calculate the effect of age in four analyses (i.e., migraine in co-
twins of probands reporting migraine, depression in co-twins of probands reporting 
depression, migraine in co-twins of probands reporting depression, and depression in co-
twins of probands reporting migraine). Probands were randomly selected as the first 
interviewed twin for the same-sex MZ/DZ pairs; while for the opposite sex DZ pairs, RR 
estimates were obtained for selecting the female twin as well as the male twin as proband, to 
estimate cross-sex RRs. 
We estimated RRs and their 95% confidence intervals (CIs) for migraine (i.e., self-report 
migraine, ID migraine, IHS MO/MA and any migraine) and depression (i.e., MDD and any 
depression) to assess their familial aggregation. We then separately estimated the RRs of 
migraine in co-twins of probands with depression and the RRs of depression in co-twins of 
probands with migraine, for broad diagnosis (i.e., any migraine and any depression) and 
narrow diagnosis (i.e., IHS MO/MA and MDD) respectively. All the analyses were 
performed using either SPSS (v22) or Rstudio (434). 
 
Results 
Demographics 
As shown in Table 4-2, based on 10638 individuals (6584 females and 4054 males) from the 
twin sample, the lifetime prevalence was estimated at 45% for any migraine and 42% for any 
depression. Consistent with previous findings (5, 301, 427, 435), the lifetime prevalence of 
IHS MO/MA migraine and DSM-III-R-based MDD was estimated at 14% and 34%, 
respectively. Generally, females showed higher lifetime prevalence than males, the 
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differences were small for self-report migraine but increased for ID migraine and especially 
IHS MO/MA. Both any depression and MDD also demonstrated higher lifetime prevalence in 
females than in males, whereas the lifetime prevalence of MiDD was higher in males 
compared to females. 
Table 4-1 The survey questions of IHS-based migraine and DSM-based 
depression 
IHS-based migraine 
Code Abbreviation Question 
A ≥ 5 attacks How many (migraine/episodes of headache) have you had during 
your lifetime? 
B 4-72 hours On average, how long (does/did) a typical (migraine/headache) 
episode? 
C1 Unilateral location Do the headaches usually occur on one side of the head?  
C2 Pulsating quality Would you describe the headache pain you usually experience as: 
throbbing, pulsating or pounding? 
C3 Moderate/severe pain 
intensity 
Would you describe the pain associated with your headaches 
as: mild, moderate, severe or unbearable? 
C4 Aggravation by physical 
activity 
Are your headaches aggravated by walking up or down stairs or 
similar routine physical activity?  
D1 Nausea and/or vomiting Have you ever had recurrent attacks of any of the following: nausea, 
vomiting or diarrhoea? 
D2 Photophobia and 
phonophobia 
Do you experience enhanced sensitivity to light/smell? 
Aura_A ≥ 2 attacks with aura How many headaches with these kinds of aura symptoms have you 
had during your lifetime? 
Aura_B Visual/speech/sensory aura Have you ever had: visual disturbances lasting several minutes? 
Difficulties to speak? One sided numbness or weakness? 
Aura_C1 Spreads ≥ 5 minutes How fast does your visual disturbance develop: the symptom is at its 
worst/strongest right away (less than 1-2 minutes); or it gets 
worse/expands after more than 4 minutes? 
Aura_C2 Last 5–60 mins How long does your visual disturbance last: the symptom lasts less 
than one minute; it lasts more than one minute but less than one 
hour; it lasts more than one hour? 
Aura_C3 Duration within 60 mins How visual disturbances and headache connected in time are: 
headaches follow the symptom within one hour; headaches do not 
follow the symptom until later; headaches and symptom occur 
simultaneously; or headaches come before the symptom? 
DSM-based depression 
Code Abbreviation Question 
A1 Depressed mood Has there ever been two weeks or more when you were depressed or 
down most of the day, nearly every day? 
A2 Loss of interest Has there ever been two weeks or more when you were a lot less 
interested in most things or unable to enjoy the things you used to 
enjoy most of the day, nearly every day? 
B1 Weight/appetite change Did you have a change in weight/appetite? 
B2 Sleep disturbance Did you have more trouble sleeping than usual? 
B3 Psychomotor 
agitation/retardation 
Were you so fidgety or restless that you were unable to sit 
still?/Were you talking or moving much more slowly than is normal 
for you? 
B4 Fatigue/loss of energy Were you feeling a loss of energy or more tired than usual? 
B5 Worthlessness/feel guilty Were you feeling excessively guilty or that you were a bad 
person?/Were you feeling that you were a failure or worthless? 
B6 Indecisiveness/diminish 
ability to concentrate 
Were you having trouble thinking or concentrating?/Was it hard to 
make decisions about everyday things? 
B7 Suicide attempt Were frequently thinking about death? 
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The mean “survey age” was estimated at 36±11 years, ranging from 18 to 89 years. The 
logistic regressions under all four analyses indicated age does not significantly influence risk 
for migraine and depression in our sample (p>0.05). Therefore, we present RRs without age 
adjustment. 
Table 4-2 lifetime prevalence of migraine and depression based on 
Australian twin sample 
 
Lifetime prevalence 
Migraine Depression 
self-
report 
migraine 
ID 
migraine 
IHS 
MO/MA 
any-mig MiDD MDD any-dep 
Total sample 15.39% 16.07% 13.99% 45.44% 7.76% 34.30% 42.07% 
Female 15.98% 19.58% 17.68% 53.24% 7.50% 37.68% 45.19% 
Male 14.43% 10.36% 7.99% 32.78% 8.19% 28.81% 37.00% 
any-mig: any migraine; any-dep: any depression. 
 
Familial aggregation 
As shown in Table 4-3, we observed a significantly increased RR (RR=1.73, 95% CI: 1.62–
1.85) for any migraine in co-twins of probands reporting any migraine, compared with co-
twins of non-migraine controls. The RR for any migraine was significantly higher within MZ 
pairs (RR=2.07, 95% CI: 1.88–2.27) compared to DZ pairs (RR=1.47, 95% CI: 1.34–1.62). 
Similarly, regardless of migraine diagnosis (i.e., self-report migraine, ID migraine, IHS 
MO/MA or any migraine), an increased RR was consistently found in the total sample, and a 
significant higher RR was calculated within MZ pairs compared to DZ pairs. Although, RRs 
calculated in DZ pairs for self-report migraine and ID migraine were not statistically 
significant, most likely due to their reduced diagnostic reliability and smaller sample size. In 
addition, most RRs calculated within same-sex DZ pairs were slightly higher than that 
calculated within DZ pairs, suggesting the presence of sex-specific effects in familial 
aggregation. Furthermore, RR for migraine increased in line with the reliability of migraine 
diagnosis, with no significant difference in RR between self-report migraine and ID migraine; 
but a significantly higher RR for IHS MO/MA. This pattern of results was observed in all 
zygosity subgroups. 
Regarding depression, although any depression comprised two types of depression, MDD and 
MiDD, because of the relatively small number of MiDD patients (N=826 participants), we 
focus on results for MDD and any depression. Similar to migraine, an increased RR for 
depression in co-twins of probands reporting depression was observed for both MDD 
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(RR=1.75, 95% CI: 1.63–1.89) and any depression (RR=1.53, 95% CI: 1.43–1.63) in the total 
sample. These RRs significantly increased to 2.35 (95% CI: 2.10–2.62) for MDD and 1.89 
(95% CI: 1.72–2.08) for any depression in MZ pairs, and significantly decreased to 1.36 
(95% CI: 1.23–1.51) for MDD and 1.27 (95% CI: 1.17–1.39) for any depression in DZ pairs, 
respectively. RRs calculated in all zygosity subgroups also remained significant and a slightly 
higher RR was observed within same-sex DZ pairs compared to DZ pairs. Also similar to 
migraine, the RRs in DZ pairs for the narrow diagnosis (MDD) were higher although not 
statistically significant, compared to RRs for the broader any depression. 
Table 4-3 Relative risks (and 95% CI) of single-trait and number of proband–co-twin 
pairs [n] in different twin samples 
 
Sample 
Migraine Depression 
self-report 
migraine  
ID migraine IHS MO/MA any-mig MDD any-dep 
Total sample 1.63 (1.38 - 1.91) [2868] 2.05 (1.75 - 2.39) [2867] 6.51 (5.57 - 7.62) [2639] 1.73 (1.62 - 1.85) [5319] 1.75 (1.63 – 1.89) [4534] 1.53 (1.43 – 1.63) [5319] 
MZ 2.09 (1.67 - 2.61) [1349] 2.81 (2.32 - 3.39) [1391] 10.42 (8.06 - 13.46) [1176] 2.07 (1.88 - 2.27) [2456] 2.35 (2.10 – 2.62) [2096] 1.89 (1.72 – 2.08) [2456] 
DZ 1.28 (1.01 - 1.62) [1519] 1.26 (0.96 - 1.65) [1476] 4.74 (3.88 - 5.78) [1463] 1.47 (1.34 - 1.62) [2863] 1.36 (1.23 – 1.51) [2438] 1.27 (1.17 – 1.39) [2863] 
Same-sex DZ 1.55 (1.15 - 2.09) [841] 1.45 (1.04 - 2.03) [806] 4.35 (3.45 - 5.50) [844] 1.62 (1.45 - 1.81) [1653] 1.39 (1.23 – 1.58) [1414] 1.31 (1.18 – 1.46) [1653] 
MZ F-F 1.88 (1.45 - 2.45) [768] 2.27 (1.84 - 2.80) [843] 10.40 (7.45 - 4.52) [685] 1.85 (1.66 - 2.06) [1623] 2.30 (2.03 – 2.61) [1401] 1.89 (1.69 – 2.11) [1623] 
MZ M-M 2.31 (1.51 - 3.54) [581] 3.64 (2.36 - 5.61) [548] 8.16 (4.99 - 13.34) [491] 2.21 (1.82 - 2.69) [833] 2.33 (1.86 – 2.91) [695] 1.86 (1.55 – 2.22) [833] 
DZ F-F 1.58 (1.09 - 2.28) [438] 1.41 (0.99 - 2.02) [451] 3.25 (2.52 - 4.19) [510] 1.49 (1.31 - 1.68) [1064] 1.24 (1.07 – 1.44) [902] 1.14 (1.00 – 1.29) [1064] 
DZ M-M 1.42 (0.86 - 2.35) [403] 0.66 (0.21 - 2.03) [355] 5.46 (3.02 - 9.89) [334] 1.55 (1.23 - 1.94) [589] 1.68 (1.32 – 2.14) [512] 1.73 (1.42 – 2.11) [589] 
DZ F-M 0.97 (0.65 - 1.45) [678] 1.16 (0.74 - 1.81) [670] 5.63 (3.88 - 8.19) [619] 1.25 (1.06 - 1.47) [1210] 1.33 (1.11 – 1.59) [1024] 1.23 (1.06 – 1.42) [1210] 
DZ M-F 0.97 (0.67 - 1.40) [678] 1.12 (0.79 - 1.61) [670] 3.74 (2.95 - 4.73) [619] 1.17 (1.04 - 1.31) [1210] 1.27 (1.09 – 1.47) [1024] 1.19 (1.05 – 1.34) [1210] 
CI: confidence interval; any-mig: any migraine; any-dep: any depression; DZ F-M pairs: opposite sex DZ pairs 
with female as probands; DZ M-F pairs: opposite sex DZ pairs with male as probands. 
 
Association between migraine and depression 
For the broad diagnoses (Table 4-4) in the total sample, co-twins of probands reporting any 
depression had a significantly increased RR (RR=1.18, 95% CI: 1.11–1.26) for any migraine 
compared to co-twins of controls. The reverse was also true, with the RR for any depression 
significantly increased (RR=1.12, 95% CI: 1.05–1.20) in co-twins of probands reporting any 
migraine compared to co-twins of controls, thus indicating a bidirectional association 
between the two disorders. The RR for any migraine in co-twins of probands reporting any 
depression was higher than the reverse. The bidirectional association became more significant 
within MZ pairs, with an RR for any migraine in co-twins of probands reporting any 
depression of 1.36 (95% CI: 1.24–1.48) and RR for any depression in co-twins of probands 
reporting any migraine was 1.26 (95% CI: 1.14–1.38). Similar to some of the single-trait RR 
estimates, the cross-trait RR estimates decreased in DZ twin pairs and became non-
significant, and RRs in same-sex DZ pairs were increased compared to opposite-sex DZ 
91 
 
pairs. Also, significantly higher cross-trait RRs were observed within MZ pairs compared to 
DZ pairs for any migraine in co-twins of probands reporting any depression and vice versa, 
suggesting the presence of shared genetic components between any migraine and any 
depression. 
For the narrow diagnoses (Table 4-4), a bidirectional association between IHS MO/MA and 
MDD was also found and was more significant compared to the broad diagnosis in the total 
sample and MZ pairs. The RRs for IHS MO/MA in co-twins of probands reporting MDD was 
1.67 (95% CI: 1.46–1.92) in the total sample and 2.23 (95% CI: 1.81–2.75) in MZ pairs; 
while the RRs for MDD in co-twins of probands reporting IHS MO/MA was 1.25 (95% CI: 
1.13–1.37) in the total sample and 1.55 (95% CI: 1.34–1.79) in MZ pairs. In contrast, results 
in DZ pairs suggest a unidirectional association, with a significant RR for IHS MO/MA in co-
twins of probands reporting MDD at 1.35 (95% CI: 1.13–1.62) and a non-significant RR for 
MDD in co-twins of probands reporting IHS MO/MA at 1.06 (95% CI: 0.93–1.22), 
respectively. Compared to DZ pairs, MZ pairs always provided significantly higher RRs for 
IHS MO/MA in co-twins of probands reporting MDD and the reverse. The difference in RRs 
calculated in MZ and DZ pairs was larger for the narrow diagnoses compared to the broad 
diagnoses. Notably, the observed risk for IHS MO/MA in co-twins of probands reporting 
MDD was considerably higher than the reverse, for total sample, MZ pairs and DZ pairs. 
 
Discussion 
Familial aggregation of migraine and depression? 
Previous Caucasian population-based family studies (193-199) consistently reported familial 
aggregation of migraine in first-degree relatives of probands, with highly variable RRs 
ranging from 1.40 to 13.82, largely due to differences in migraine types (e.g., MA, familial 
hemiplegic migraine), diagnostic approaches (e.g., IHS-based self-report questionnaire or 
interview) and sample selection. Our results from DZ pairs are equivalent to proband–first-
degree RR estimates from the general population, and are in line with previous RR estimates 
based on IHS MO/MA and any migraine status. By comparing our results for strict IHS 
MO/MA to results for the broader definitions of migraine, self-report migraine and ID 
migraine status, clearly demonstrates such expected sensitivity of RR and familial 
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aggregation analysis of migraine to the diagnostic approach. Our finding of significantly 
higher RR for migraine within MZ pairs than DZ pairs, provides strong evidence for a genetic 
contribution to migraine susceptibility. 
Table 4-4 Relative risks (and 95% CI) of cross-trait and number of 
proband–co-twin pairs [n] in different twin samples 
 
Sample 
Proband – co-twin 
Broad diagnosis Narrow diagnosis 
any-dep – any-mig any-mig – any-dep MDD – IHS MO/MA IHS MO/MA – MDD 
Total sample 1.18 (1.11 – 1.26) [5319] 1.12 (1.05 – 1.20) [5319] 1.67 (1.46 – 1.92) [3450] 1.25 (1.13 – 1.37) [3287] 
MZ 1.36 (1.24 – 1.48) [2456] 1.26 (1.14 – 1.38) [2456] 2.23 (1.81 – 2.75) [1506] 1.55 (1.34 – 1.79) [1473] 
DZ 1.04 (0.95 – 1.14) [2863] 1.02 (0.94 – 1.11) [2863] 1.35 (1.13 – 1.62) [1944] 1.06 (0.93 – 1.22) [1814] 
Same-sex DZ 1.07 (0.96 – 1.19) [1653] 1.06 (0.95 – 1.18) [1653] 1.39 (1.12 – 1.71) [1082] 1.04 (0.88 – 1.22) [1068] 
MZ F-F 1.28 (1.16 – 1.40) [1623] 1.18 (1.06 – 1.32) [1623] 2.19 (1.75 – 2.75) [934] 1.42 (1.21 – 1.66) [925] 
MZ M-M 1.52 (1.25 – 1.86) [833] 1.30 (1.08 – 1.56) [833] 1.69 (0.99 – 2.88) [572] 1.46 (0.99 – 2.17) [548] 
DZ F-F 1.01 (0.90 – 1.13) [1064] 1.03 (0.90 – 1.16) [1064] 1.17 (0.94 – 1.46) [668] 0.94 (0.78 – 1.13) [666] 
DZ M-M 1.08 (0.85 – 1.37) [589] 0.99 (0.80 – 1.23) [589] 1.81 (1.09 – 3.00) [414] 1.17 (0.78 – 1.75) [402] 
DZ F-M 1.02 (0.87 – 1.20) [1210] 0.96 (0.83 – 1.12) [1210] 1.38 (0.97 – 1.98) [862] 1.10 (0.88 – 1.38) [746] 
DZ M-F 0.97 (0.86 – 1.09) [1210] 1.02 (0.89 – 1.16) [1210] 1.12 (0.86 – 1.45) [746] 1.22 (0.99 – 1.50) [862] 
CI: confidence interval; any-mig: any migraine; any-dep: any depression; DZ F-M pairs: opposite sex DZ pairs 
with female as probands; DZ M-F pairs: opposite sex DZ pairs with male as probands. 
 
Previous studies on measuring clustering of depression often utilized ORs rather than RRs. 
The OR for depression in first-degree relatives of depressive probands have been calculated 
at approximately 2-3 in Caucasian population-based family samples (419-423). Assuming a 
depression prevalence of between 20% and 50%, ORs ranging from 2 to 3 are estimated to be 
equivalent to RRs of approximately 1.11–1.50 (using Odds Ratio to Risk Ratio Conversion, 
http://clincalc.com/Stats/ConvertOR.aspx). Thus, our RR estimates for depression from DZ 
pairs are in agreement with published findings, and support the familial aggregation of 
depression. Our finding of significantly higher RR for depression within MZ pairs compared 
to DZ pairs, provides strong evidence for a genetic contribution to depression. 
Although the difference in RRs between DZ F-M pairs (opposite sex DZ pairs with female as 
proband) and DZ M-F pairs (opposite sex DZ pairs with male as proband) for migraine and 
depression are not significant, the risks for migraine and depression are consistently larger in 
male co-twins of affected female probands compared to female co-twins of affected male 
probands. These results suggest the possible influence of sex-specific effects (i.e., effects 
expressed in one sex but not the other) that may include genetic (G), environmental (E) 
and/or interacting (G×E) effects. 
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Bidirectional association between migraine and depression? 
In line with previous findings (55-59), results from analysis of broad diagnoses in the total 
sample indicate a bidirectional association between migraine and depression, with an 
increased RR for any migraine in co-twins of probands reporting any depression, and vice 
versa. The association became stronger when analysing the more narrow diagnoses of IHS 
MO/MA and MDD. 
The observed risk for migraine in relatives of probands reporting depression was 
considerably higher than the risk for depression in relatives of probands reporting migraine. 
These results were observed for both broad and narrow diagnoses, and remained when 
calculating RRs by averaging over selecting either twin one or twin two as proband, thus 
ensuring our results are robust to proband selection within twin pairs. These findings provide 
further support to findings from a recent analysis of single nucleotide polymorphism (SNP) 
genotype data indicating that patients with comorbid migraine and depression are genetically 
more similar to patients with only depression than patients with only migraine (64). 
Regardless of the diagnostic approach, the association between migraine and depression was 
stronger within MZ twin pairs compared to DZ pairs, thus providing strong evidence for a 
genetic contribution to familial aggregation of migraine and depression. 
 
Strengths and weaknesses 
Ours is the only study to use a large population-based twin design to provide strong evidence 
for a genetic contribution to the familial aggregation and co-occurrence of migraine and 
depression. Another advantage of this study concerned the utilization of multiple approaches 
to diagnose migraine and depression. Comparing results from different diagnostic definitions 
allowed us to demonstrate both the sensitivity and validity of RR and familial aggregation 
analysis of migraine and depression across different diagnostic criteria. 
However, there are some limitations to note. First and foremost, both migraine and 
depression status were diagnosed using self-reported questionnaire data, as opposed to the 
gold-standard of clinical-based interviews by neurologists or psychologists. Although our 
approach may result in some misclassification of migraine and depression status, it is not 
feasible to perform clinic-based interviews in samples larger enough to provide sufficient 
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power for such familial aggregation studies. Moreover, our approach enabled narrow 
diagnoses of migraine and depression that satisfy clinically accepted criteria. Furthermore, 
our estimated lifetime prevalence of IHS MO/MA and DSM-III-R-based MDD are in a good 
agreement with published estimates (5, 301, 427, 435). Secondly, we did not separate IHS 
MO/MA into MO and MA. However, given our previous findings indicating a strong familial 
aggregation and genetic overlap between MO and MA, we believe our approach provides the 
most powerful and sensible use of the data to examine the relationship between migraine and 
depression. Thirdly, probands of twin pairs were selected randomly as the twin who first 
entered the survey rather than birth order. However, considering twins essentially share the 
same family environment and the fact we obtain identical RRs and conclusions when 
selecting the second (other) twin as the proband, indicates our random selection approach to 
be valid. Another limitation relates to our use of “survey age” rather than age of onset. 
However, given our samples were comprised of adults past the typical age of onset, and our 
logistic regression analyses found no association between survey age and migraine and/or 
depression, we do not believe this to be an important issue. 
 
Conclusions 
In summary, this study used a large Australian population-based twin sample and found 
significant evidence for a genetic contribution to the familial aggregation of migraine and 
depression. Our findings also suggest a bidirectional association between migraine and 
depression, with an increased risk for depression in relatives of probands reporting migraine, 
and vice versa. However, the observed risk for migraine in relatives of probands reporting 
depression was considerably higher than the reverse. These results add further support to 
previous studies suggesting that patients with comorbid migraine and depression are 
genetically more similar to patients with depression compared to patients with migraine. 
A better understanding of the genetic architecture of comorbid migraine and depression has 
excellent potential to improve our understanding of the relationship between migraine and co-
occurring depression and inform treatment strategies. For example, identifying patients most 
at risk of comorbid migraine and depression and chronic migraine (due to medication 
overuse), and identifying subgroups of patients for whom a particular treatment or treatment 
combination may be most effective (e.g., episodic vs. chronic migraine, depressed vs. non-
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depressed, those with high analgesic use). Hence, future studies should focus on 
characterising and identifying the genetic and environmental factors contributing to co-
occurring migraine and depression.  
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Chapter 5: Shared genetic factors 
underlie migraine and depression 
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Abstract 
Migraine frequently co-occurs with depression. Using a large sample of Australian twin pairs, 
we aimed to characterise the extent to which shared genetic factors underlie these two 
disorders. Migraine was classified using three diagnostic measures, including self-reported 
migraine, the ID migraine™ screening tool, or migraine without aura (MO) and migraine 
with aura (MA) based on International Headache Society (IHS) diagnostic criteria. Major 
depressive disorder (MDD) and minor depressive disorder (MiDD) were classified using the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. Univariate and 
bivariate twin models, with and without sex-limitation, were constructed to estimate the 
univariate and bivariate variance components and genetic correlation for migraine and 
depression. The univariate heritability of broad migraine (self-reported, ID migraine or IHS 
MO/MA) and broad depression (MiDD or MDD) was estimated at 56% (95% confidence 
interval [CI]: 53–60%) and 42% (95% CI: 37–46%), respectively. A significant additive 
genetic correlation (rG=0.36, 95% CI: 0.29–0.43) and bivariate heritability (h2=5.5%, 95% 
CI: 3.6–7.8%) was observed between broad migraine and depression using the bivariate 
Cholesky model. Notably, both the bivariate h2 (13.3%, 95% CI: 7.0–24.5%) and rG (0.51, 
95% CI: 0.37–0.69) estimates significantly increased when analysing the more narrow 
clinically-accepted diagnoses of IHS MO/MA and MDD. Our results indicate that for both 
broad and narrow definitions, the observed comorbidity between migraine and depression can 
be explained almost entirely by shared underlying genetically determined disease 
mechanisms. 
 
Keywords: migraine, depression, twin study, heritability, genetic correlation, bivariate 
heritability 
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Migraine and depression are common complex disorders that share a higher than expected 
co-occurrence (1, 436). Previous longitudinal studies (55-59) identified a bidirectional 
association between migraine and depression, with one disorder increasing the relative risk 
for the other, and vice versa. However, the aetiology underlying the two disorders is still 
poorly understood. 
Previous twin and family studies consistently observed a moderate genetic effect on 
susceptibilities of the two disorders, with heritability (h2) estimates of around 30–50% for 
both migraine (7, 204, 437) and depression (33, 301, 309). Several studies also found 
evidence for shared genetic components between migraine and depression (61-64). Firstly, 
Schur et al. (63) utilised bivariate structural equation modelling (SEM) in a US sample of 758 
monozygotic (MZ) and 306 dizygotic (DZ) female twin pairs to estimate a trait-specific 
heritability of 52% (95% confidence interval [CI]: 11–66%) for self-reported doctor’s 
diagnosis of depression and 44% (95% CI: 18–55%) for self-reported doctor’s diagnosis of 
migraine headache, and the authors estimated that 20% of the variance in depression and 
migraine is due to shared genetics (i.e., bivariate heritability of 20%) and 4% of the unique 
environmental component is shared. A second twin study using 223 MZ male, 100 DZ male, 
602 MZ female, 286 DZ female, and 280 DZ opposite sex Dutch twin pairs (61) estimated a 
heritability of 45% for latent class analysis (LCA)-derived migrainous headache and 55% for 
anxious depression—a measure consisting of a factor score based on several measures of 
anxiety, depression, and neuroticism—and estimated a genetic correlation (rG) between 
migrainous headache and anxious depression of 0.30 (95% CI: 0.18–0.43). Additionally, a 
family-based study in a large Dutch genetic isolate utilised International Headache Society 
(IHS) diagnostic criteria and reported significant heritability estimates for migraine without 
aura (MO) (h2=0.77, 95% CI: 0.38–1.00), migraine with aura (MA) (h2=0.96, 95% CI: 0.51–
1.00), and all migraine (h2=0.56, 95% CI: 0.26–0.86), which all decreased (albeit non-
significantly) after adjustment for symptoms of depression or use of antidepressant 
medication (62). Interestingly, a comparison of the heritability scores for depression between 
patients with migraine and controls found evidence for shared genetic factors only between 
MA and depression. Lastly, a significant correlation in genetic risk across migraine and major 
depressive disorder (MDD) was revealed by a recent genetic risk score (GRS) analysis (64). 
Although providing consistent evidence for shared genetic components between migraine and 
depression, the twin and family studies performed to date utilised a wide variety of 
approaches and diagnostic measures which complicate their interpretation and comparison. 
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Furthermore, the shared genetic variance might be described by either the same genetic and 
environmental factors (i.e., same genetic and environmental factors account for susceptibility 
of both migraine and depression [pleiotropy]), or their potential causation (i.e., genetic and 
environmental factors cause a primary disorder which results in a secondary disorder) (344). 
In addition, some studies (200, 301) report a higher genetic basis for migraine and depression 
in females compared to males, suggesting sex may play a role in the variation of the shared 
genetic components. 
Therefore, this study utilised a variety of diagnostic measures and performed SEM (90) with 
and without sex-limitation in a large Australian population-based twin sample to i) estimate 
the trait-specific heritability of migraine and depression; ii) estimate the shared genetic 
components between migraine and depression; and iii) investigate whether the shared genetic 
components are due to the same genetic factors or due to one disorder causing the other. 
 
Materials and methods 
Samples 
As detailed in Figure 4-1, participants were drawn from three Australian twin cohorts based 
at QIMR Berghofer Medical Research Institute (432, 433). Subjects with migraine and 
depression status were selected and constituted the “merged migraine sample” (N=38279) 
and “merged depression sample” (N=60170), respectively. Definitions of migraine and 
depression were homogenised across the cohorts. Subjects also answered questions regarding 
demographic characteristics (e.g., sex, date of birth, zygosity), via semi-structured telephone 
interview and/or questionnaire. After combining the two merged samples and removal of 
non-twins and twins with missing status of either migraine or depression, a total of 5319 twin 
pairs (2456 MZ and 2863 DZ pairs) remained for analysis. 
 
Assessment of migraine 
Migraine symptom information ranged from single answer self-report (‘yes’ or ‘no’) of 
migraine, the ID Migraine™ Screener (73)—three questions shown to accurately identify 
93% of people with migraines, to detailed IHS diagnostic criteria (the International 
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Classification of Headache Disorders, ICHD-3) (2). For the collection of detailed ICHD-3 
diagnostic criteria (see Table 4-1), participants answering ‘yes’ to ever having ‘migraine or 
recurrent attacks of headache’ (screening positive), then answered a number of questions 
relating to their symptoms. Diagnoses were determined for the two major varieties of 
migraine: 1.1 migraine without aura (MO) and 1.2 migraine with aura (MA, primarily 
comprising 1.2.1 Typical aura with migraine headache), which account for 90-95% of all 
IHS migraines (122). 
After careful merging of all available migraine information, lifetime diagnoses for migraine 
were made subject to data availability, according to i) self-reported migraine, ii) the ID 
Migraine™ Screener, or iii) IHS ICHD-3 MO/MA diagnostic criteria. Hence, migraine status 
was measured in four categories according to these three criteria: non-migraine, self-report 
migraine (i.e., participants with positive status of self-reported measurement but negative or 
unknown status of the other two criteria), ID migraine (i.e., participants with positive status 
ID migraineTM Screener criteria but negative or unknown IHS-based migraine status) and IHS 
MO/MA (i.e., participants with positive status of IHS-based migraine). The ‘broad’ migraine 
status (i.e., any migraine) was defined when participants had reported at least one positive 
migraine status; and the ‘narrow’ migraine status was restricted to the clinically-accepted 
diagnosis of IHS MO/MA. 
 
Assessment of depression 
Participants were first asked two screening questions “Has there ever been two weeks or 
more when you were depressed or down most of the day, nearly every day?” and “Has there 
ever been two weeks or more when you were a lot less interested in most things or unable to 
enjoy the things you used to enjoy, most of the day, nearly every day?”. With at least one 
positive response, participants then answered additional questions (see Table 4-1). Lifetime 
depression was diagnosed according to the third and revised edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-III-R) (26) criteria: during two-week period, 
participants who had positive responses of more than five symptoms were diagnosed 
suffering MDD and participants who had 2-4 positive responses were diagnosed suffering 
minor depressive disorder (MiDD). Therefore, in our study, depression status was measured 
in three categories: non-depressed, MiDD, and MDD. Participants with either MiDD or MDD 
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were defined to have the ‘broad’ depression status (i.e., any depression), and the MDD status 
was used as the narrow clinically-accepted diagnostic measure of depression. 
 
Statistical analysis 
All the analyses were performed in RStudio (434). The concordance of migraine and 
depression for MZ and DZ twins were calculated by polychoric correlation—a measurement 
quantifying association between two ordinal variables that have an underlying bivariate 
normal distribution. Polychoric correlations were estimated using the R package polycor 
(https://cran.r-project.org/web/packages/polycor/index.html). The polychoric correlation, 
assumes that underlying the observed polychotomous distribution of affection status, there 
exists a continuous, normally distributed latent (non-observable) liability. That is, the 
polychoric correlation is an estimate of the correlation between two latent variables, where 
each latent variable is assumed to have a bivariate normal distribution. A χ2 goodness-of-fit 
test is used to test whether the multiple threshold model provides a good fit to the observed 
data (i.e., compares the observed frequencies to those predicted by the model). 
A classical twin study was used to estimate the genetic and environmental contributions to 
the susceptibility of a target trait. The proportion of the phenotypic variance due to genetic 
differences is termed the heritability (92). The model assumes the total phenotypic variance is 
comprised of the variances from additive genetic factors (A), non-additive (dominance) 
genetic factors (D), non-unique (shared) environmental factors (C) and unique environmental 
factors (E). MZ twins share 100% of their A, D and C, while DZ twins share 50% of A, 25% 
of D, and 100% of C on average (91). According to these principles, the proportions of 
genetic and environmental contributions can be estimated by comparing concordance 
between MZ and DZ twins using structural equation modelling (SEM) (90). Using the R 
package OpenMx (75) twin models were initially generated for the broad definitions of 
migraine and depression, and subsequent models utilised more specific and narrow 
definitions by excluding individuals from the analysis. 
Univariate analyses were first used to examine model fit and characteristics, and estimate 
trait-specific variance components for migraine and depression. The liability threshold model, 
adjusted by age and sex, was applied to each trait. Specifically, when analysing broad 
migraine and broad depression, univariate models were built independently as a comparison: 
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the first (‘one-threshold’) model was built using one threshold to separate two phenotype 
categories: non-migraine and broad migraine; and non-depressed and broad depression. The 
second (‘two-threshold’) model was built using two thresholds to separate three phenotype 
categories: non-migraine, self-report/ID migraine and IHS MO/MA; and non-depressed, 
MiDD and MDD. When analysing IHS MO/MA and MDD, one threshold was utilised to 
separate two phenotype categories for migraine (i.e., non-migraine and IHS MO/MA) and 
depression (i.e., non-depressed and MDD). Starting with the full model (ACE/ADE), the 
reduced models (AE, CE) were then built by systematic removal of latent variables from the 
model. We selected the best fitting model using the likelihood-ratio test and comparing the 
Akaike’s information criterion (AIC) values. 
The univariate model can then be extended to the bivariate Cholesky model (74), to estimate 
the shared genetic variance components between two traits by calculating their genetic 
correlation and bivariate heritability. The genetic correlation (rG) between two traits is 
defined as 𝑟𝑟G = ℎ1×22 /�ℎ12ℎ22, where ℎ1×22  represents the genetic covariance between two 
traits, and ℎ12 and ℎ22 are the heritability of trait 1 and trait 2. The bivariate heritability (h
2) 
stands for the proportion of genetic overlap between the heritability of trait 1 and trait 2. The 
bivariate Cholesky models were built referring to the best fitting models of univariate 
analyses for migraine and depression. By comparing results from analysis of broad migraine 
and depression to results using more narrow diagnoses, we can examine the influence of 
using different diagnostic measures on the univariate and bivariate estimates of genetic and 
environmental variance components. 
In addition, sex-limitation models (76) for both univariate and bivariate analyses were 
constructed to explore the potential influence of sex-specific effects on the genetic liability to 
migraine and depression. A general non-scalar sex-limitation model was firstly built, 
including latent variables for females (i.e., Af, Cf and Ef) and males (i.e., Am, Cm and Em) and 
an specific additive genetic component for males which does not correlate with the female 
component (i.e., AmS). The reduced non-scalar sex-limitation model was then constructed by 
removing the additional specific additive genetic variable. A restricted scalar effects sex-
limitation model was also built, which assumes that all the latent variables for males are 
linked with the latent variables for females by a scalar effect k (i.e., Af=kAm, Cf=kCm, 
Ef=kEm). The best fitting model was selected by the likelihood ratio test and comparing the 
AIC values. 
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Following the bivariate analyses, two approaches were used to test whether potential 
causation or the same genetic factors between migraine and depression best explain the 
shared genetic components between the two traits (344). Firstly, under the hypothesis of 
causation, one disorder would increase risk for the other via both genetic and environmental 
factors. Hence, both the genetic and environmental correlations between two conditions 
should be significant; otherwise, the hypothesis of causation is invalid. A second approach 
focuses on checking the presence of causal environmental factors. Briefly, in MZ twins the 
intrapair differences in trait 1 should be associated with intrapair differences in trait 2. The 
absence of this association between the intrapair differences in trait 1 and trait 2 falsifies the 
hypothesis of direct causation (i.e., one trait causing the other), whereas the presence of this 
association would support the causal hypothesis because it excludes confounding by genetic 
factors (i.e., the twins are genetically identical). Using this ‘MZ twin intrapair differences’ 
model, we computed the differences of migraine status of an MZ twin and his or her co-twin. 
For example, non-migraine, self-report/ID migraine and IHS MO/MA were coded as 0, 1 and 
1; and non-depressed, MiDD and MDD were coded as 0, 1 and 1, respectively. For each MZ 
twin pair, the intrapair difference was then calculated as either -1, 0 or 1 for broad migraine 
and -1, 0 or 1 for broad depression. The intrapair differences for migraine were then 
regressed on the intrapair differences for depression. Significant regression coefficients 
would be compatible with the causal hypothesis, whereas nonsignificant regression analysis 
would falsify this hypothesis. 
 
Results 
Demographics and twin concordance of migraine and depression 
The mean age of 10638 individuals was 36±11 years when they participated in the survey, 
with a range from 18 to 89 years (Table 4-2). Age was used as a covariate in model fitting. 
The lifetime prevalence was evaluated at 45% for broad migraine (53% of females, 33% of 
males) and 42% for broad depression (45% of females, 37% of males), respectively. 
Whereas, 14% of participants (18% of females, 8% of males) were diagnosed suffering IHS 
MO/MA and 34% of participants (38% of females, 29% of males) were diagnosed as MDD. 
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The polychoric correlations for MZ twins were always higher than DZ twins for the broad 
diagnoses of migraine and depression (Table 5-1), suggesting genetic contributions to both 
disorders. Importantly, none of the multiple-threshold model goodness-of-fit tests (one for 
each zygosity group) were significant at the 5% level. Therefore, these results support the 
validity of the multiple threshold model for the migraine and depression classifications, and 
indicate that they can both be conceptualized as different levels of severity on a single 
dimension of liability. The polychoric correlations estimated for the three-category migraine 
and depression classifications (i.e., non-migraine, self-report/ID migraine and IHS MO/MA; 
and non-depressed, MiDD and MDD) were higher than those estimated for the two-category 
classifications (i.e., non-migraine and broad migraine; and non-depressed and broad 
depression), indicating the three-category classifications better capture the familial 
aggregation of the two disorders. Similar to the analysis of broad diagnoses, the estimated 
correlations for the more narrow clinically-accepted diagnoses of IHS MO/MA and MDD 
were higher within MZ than DZ twins. Furthermore, the increased difference between MZ 
and DZ correlations indicates a stronger genetic influence to IHS MO/MA and MDD. 
 
Results from broad diagnoses analyses 
Univariate analyses 
Four SEMs (ACE, AE, CE and ADE) were built to examine the genetic architecture of broad 
migraine and depression, based on either the one-threshold (two-category classification) 
model or two-threshold (three-category classification) model. No differences in threshold 
liability distributions were observed within twin pairs and across zygosity groups for 
migraine and depression. Constraining the threshold distributions to be equal in males and 
females resulted in a significant deterioration in fit for migraine (p-value=5.16×10-61 for the 
one-threshold model; p-value=1.58×10-68 for the two-threshold model) and depression (p-
value=7.64×10-11 for the one-threshold model; p-value=8.82×10-14 for the two-threshold 
model) when compared to a model of separate sex thresholds. We also observed that the sex 
differences in threshold distributions could be accounted for by a single set of liability 
thresholds for males plus a displacement to account for the observed higher prevalence in 
females for migraine and depression. 
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Table 5-1 Polychoric correlations for migraine and depression according to 
twin zygosity 
Two category broad classification* 
Broad migraine 
Zygosity [N] MZFF [1623] MZMM [833] DZFF [1064] DZMM [589] DZFM [1210] 
𝜌𝜌polychoric (sd) 0.45 (0.03) 0.43 (0.05) 0.31 (0.05) 0.25 (0.07) 0.12 (0.05) 
95% CI (0.39–0.52) (0.33–0.53) (0.23–0.40) (0.12–0.38) (0.03–0.21) 
Broad depression 
Zygosity [N] MZFF [1623] MZMM [833] DZFF [1064] DZMM [589] DZFM [1210] 
𝜌𝜌polychoric (sd) 0.43 (0.03) 0.37 (0.05) 0.10 (0.05) 0.34 (0.06) 0.13 (0.05) 
95% CI (0.37–0.50) (0.27–0.47) (3×10-3–0.19) (0.22–0.46) (0.04–0.21) 
Three category broad classification^ 
Broad migraine 
Zygosity [N] MZFF [1623] MZMM [833] DZFF [1064] DZMM [589] DZFM [1210] 
𝜌𝜌polychoric (sd) 0.52 (0.02) 0.42 (0.04) 0.36 (0.03) 0.30 (0.06) 0.28 (0.04) 
95% CI (0.47–0.57) (0.33–0.51) (0.30–0.43) (0.19–0.41) (0.21–0.36) 
Broad depression 
Zygosity [N] MZFF [1623] MZMM [833] DZFF [1064] DZMM [589] DZFM [1210] 
𝜌𝜌polychoric (sd) 0.46 (0.03) 0.37 (0.05) 0.12 (0.04) 0.29 (0.06) 0.13 (0.04) 
95% CI (0.40–0.52) (0.28–0.47) (0.04–0.21) (0.17–0.40) (0.05–0.22) 
Two category narrow classification# 
IHS MO/MA 
Zygosity [N] MZFF [722] MZMM [498] DZFF [583] DZMM [348] DZFM [642] 
𝜌𝜌polychoric (sd) 0.84 (0.03) 0.69 (0.08) 0.48 (0.06) 0.50 (0.11) 0.60 (0.06) 
95% CI (0.79–0.89) (0.54–0.84) (0.36–0.59) (0.29–0.71) (0.49–0.71) 
MDD 
Zygosity [N] MZFF [1401] MZMM [695] DZFF [902] DZMM [512] DZFM [1024] 
𝜌𝜌polychoric (sd) 0.53 (0.03) 0.45 (0.06) 0.15 (0.05) 0.30 (0.07) 0.16 (0.05) 
95% CI (0.47–0.60) (0.34–0.55) (0.05–0.25) (0.16–0.44) (0.06–0.26) 
𝜌𝜌polychoric: polychoric correlation; 95% CI: 95% confidence interval; sd: standard deviation; MZFF: female MZ 
twins; MZMM: male MZ twins; DZFF: female DZ twins; DZMM: male DZ twins; DZFM: opposite-sex DZ 
twins; N: number of twin pairs. 
*Two phenotype categories for broad migraine: non-migraine and self-report/ID migraine/IHS MO/MA; two 
phenotype categories for broad depression: non-depressed and MiDD/MDD. 
^Three phenotype categories for broad migraine: non-migraine, self-report/ID migraine and IHS MO/MA; three 
phenotype categories for broad depression: non-depressed, MiDD and MDD. 
#Two phenotype categories for narrow migraine: non-migraine and IHS MO/MA; two phenotype categories for 
narrow depression: non-depressed and MDD. 
 
For both migraine and depression, the AE model provided a more plausible and parsimonious 
fit than other models (Appendix C, Table C-1). In line with the polychoric correlation results, 
the two-threshold model consistently produced higher heritability estimates (with narrower 
confidence intervals) for migraine and depression compared to the one-threshold model. We 
therefore concentrate on results from the two-threshold model. For the two-threshold AE 
model (Table 5-2), the univariate heritability was estimated at 56% (95% CI: 53–60%) for 
migraine and 42% (95% CI: 37–46%) for depression. The non-scalar sex-limitation model 
without specific additive genetic effects for males provided the best fit to the data. Females 
had a higher heritability estimate for migraine and depression compared to males, however  
the sex difference did not reach statistical significance at the 5% level, and the male-female 
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genetic correlation was estimated at 0.92 (95% CI: 0.64–1.0) for migraine and 0.60 (95% CI: 
0.20–1.0) for depression. 
 
Bivariate analyses 
Bivariate Cholesky SEMs were utilised to estimate variance components shared between 
migraine and depression. As for the univariate SEM analyses, the two-threshold AE/AE 
model best fit the data. The trait-specific heritability of broad migraine (56%) and depression 
(42%) were essentially the same as the estimates from the univariate analyses (Table 5-2 and 
Table 5-3). Importantly, a significant additive genetic correlation (rG=0.36, 95% CI: 0.29–
0.43) and bivariate heritability (h2=5.5%, 95% CI: 3.6–7.8%) was observed between migraine 
and depression. The unique environmental correlation was not significant (rE=0.05, 95% CI: -
0.01–0.11) and the bivariate unique environmental variance was very small (VE=0.15%, 95% 
CI: 0.00034–0.72%). Under the sex-limitation model, no significant difference in rG and h2 
was observed between females and males. 
A path diagram portraying this best fitting Cholesky model is displayed in Figure 5-1. The 
principal genetic features of the model are explained as follows. Firstly, the common additive 
genetic factors accounting for 56% (95% CI: 53–60%) of the variance in migraine also 
account for 5.5% (95% CI: 3.6–7.8%) of the variance in depression. Secondly, specific 
additive genetic factors account for 37% (95% CI: 32–41%) of the variance in broad 
depression. Individual (non-shared) environmental factors explain the remaining variance in 
liability to migraine and depression. 
Table 5-2 Univariate analyses for broad migraine and broad depression with 
and without sex-limitation based on two-threshold model 
 
Disorders 
 
Total sample Sex-limitation Female Male 
A E A E A E 
Broad  
migraine^ 
0.57 
(0.53–0.60) 
0.44 
(0.40–0.47) 
0.60 
(0.55–0.64) 
0.40 
(0.36–0.45) 
0.49 
(0.40–0.55) 
0.52 
(0.45–0.60) 
Broad 
depression^ 
0.42 
(0.37–0.46) 
0.58 
(0.54–0.63) 
0.44 
(0.38–0.50) 
0.56 
(0.50–0.62) 
0.40 
(0.32–0.48) 
0.60 
(0.52–0.68) 
A: additive genetic factors; E: unique environmental factors. 
^Three phenotype categories for broad migraine: non-migraine, self-report/ID migraine and IHS MO/MA; three 
phenotype categories for broad depression: non-depressed, MiDD and MDD. 
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Results from narrow diagnoses analyses 
Univariate analyses 
To improve the sensitivity of true positive cases and specificity of true negative controls for 
migraine and depression, we next performed SEM analyses for the more narrow clinically-
accepted diagnoses of IHS MO/MA and MDD. As for the broad diagnoses, no differences in 
threshold liability distributions were observed within twin pairs and across zygosity groups 
for IHS MO/MA and MDD and single set of liability thresholds could be utilised for males 
with a displacement to account for the observed higher prevalence in females. The heritability 
of IHS MO/MA was estimated after excluding individuals with the broader ID migraine and 
self-report definitions, by selecting only individuals who provided responses to the ICHD-3 
based questionnaire for MO/MA. Although the number of twins analysed reduced from 5319 
to 2793 (Table 5-4), the best fitting ACE model data (see Appendix C, Table C-2) estimated a 
heritability of 59% (95% CI: 43–76%) for IHS MO/MA. Similarly, the heritability of MDD 
was calculated based on the subset of individuals who were diagnosed with non-depressed or 
MDD (i.e., removing the cases of MiDD; sample size decreased from 5319 to 4534 twin 
pairs). For the best fitting AE model (Appendix C, Table C-2), the heritability was estimated 
at 49% (43–54%) for MDD. For both IHS MO/MA and MDD, the non-scalar sex-limitation 
model after removing the specific additive genetic variable for males provided the best fit to 
our data, with an estimated male-female genetic correlation of 1 (95% CI: 0.31–1.0) for IHS 
migraine and 0.64 (95% CI: 0.23–1.0) for MDD. Although heritability estimates were slightly 
higher in females compared to males, sex-limitation models indicated no significant 
heritability differences between females and males. 
Table 5-3 Bivariate analyses for broad migraine and broad depression with 
and without sex-limitation based on two-threshold model 
 
Disorders 
 
Total sample Sex-limitation Female Male 
A E A E A E 
Broad  
migraine^ 
0.56  
(0.53–0.60) 
0.44  
(0.40–0.47) 
0.60  
(0.55–0.64) 
0.40  
(0.36–0.45) 
0.49  
(0.41–0.56) 
0.51  
(0.44–0.59) 
Broad 
depression^ 
0.42  
(0.37–0.47) 
0.58  
(0.53–0.63) 
0.44  
(0.38–0.50) 
0.56  
(0.50–0.62) 
0.40  
(0.31–0.48) 
0.60  
(0.52–0.69) 
Bivariate 
variance 
0.055  
(0.036–0.078) 
1.5×10-3  
(3.4×10-6–7.1×10-3) 
0.047  
(0.026–0.074) 
4.1×10-6 
(4.1×10-6–4.2×10-6) 
0.058  
(0.024–0.11) 
7.3×10-3 
(2.1×10-5–0.028) 
Correlation 0.36  
(0.29–0.43) 
0.050  
(-0.011–0.11) 
0.32  
(0.25–0.41) 
2.7×10-3  
(-0.075–0.080) 
0.38  
(0.25–0.52) 
0.11  
(5.4×10-3–0.21) 
A: additive genetic factors; E: unique environmental factors. 
^Three phenotype categories for broad migraine: non-migraine, self-report/ID migraine and IHS MO/MA; three 
phenotype categories for broad depression: non-depressed, MiDD and MDD. 
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Bivariate analyses 
The variance components shared between IHS MO/MA and MDD were next estimated using 
one-threshold bivariate Cholesky SEMs. As for the univariate SEMs, the ACE/AE bivariate 
Cholesky model provided the best overall fit for the combined IHS MO/MA and MDD 
sample (N=2406, see Appendix C, Table C-3, section 3). Similar to the univariate results, the 
trait-specific heritabilities from the bivariate model were increased relative to the broad 
diagnoses, being estimated at 53% (95% CI: 35–72%) for IHS MO/MA and 52% (95% CI: 
44–59%) for MDD (Table 5-5). Importantly, we observed a substantially increased additive 
genetic correlation (rG=0.51, 95% CI: 0.37–0.69) and bivariate heritability (h2=13.3%, 95% 
CI: 7.0–14.5%) between IHS MO/MA and MDD, compared to the results of broad migraine 
and depression. Sex-limitation models indicated no significant difference in rG and h2 
between females and males. 
The best fitting bivariate Cholesky model for IHS MO/MA and MDD is portrayed in the path 
diagram illustrated in Figure 5-2. The principal genetic features of this model are as follows. 
Firstly, the common additive genetic factors accounting for 53% (95% CI: 35–72%) of the 
variance in IHS MO/MA also account for 13% (95% CI: 7–24%) of the variance in MDD. 
Secondly, there are specific additive genetic factors accounting for 38% (95% CI: 26–48%) 
of the variance in MDD. Individual (non-shared) environmental factors explain the remaining 
variance in liability to IHS MO/MA and MDD. 
Table 5-4 Univariate analyses for IHS MO/MA and MDD with and without sex-limitation 
 
Disorders 
Total sample Sex-limitation 
Female Male 
A C E A C E A C E 
IHS 
MO/MA 
0.59 
(0.43–0.76) 
0.25 
(0.090–0.39) 
0.16 
(0.12–0.21) 
0.65 
(0.46–0.82) 
 
0.19 
(0.044–0.36) 
 
0.16 
(0.11–0.22) 
 
0.43 
(0.083–0.75) 
0.32 
(0.051–0.62) 
0.25 
(0.15–0.39) 
MDD 0.49 
(0.43–0.54) 
– 0.51 
(0.46–0.57) 
0.51 
(0.44–0.57) 
– 0.49 
(0.43–0.56) 
0.46 
(0.36–0.56) 
– 0.54 
(0.44–0.64) 
A: additive genetic factors; C: non-unique environmental factors E: unique environmental factors. 
Table 5-5 Bivariate analyses for IHS MO/MA and MDD with and without sex-limitation 
 
Disorders 
Total sample Sex-limitation 
Female Male 
A C E A C E A C E 
IHS 
MO/MA 
0.53 
(0.35–0.72) 
0.29 
(0.13–0.44) 
0.18 
(0.13–0.24) 
0.60 
(0.39–0.80) 
0.23 
(0.054–0.41) 
0.16 
(0.11–0.23) 
0.32 
(0.040–0.70) 
0.36 
(0.056–0.62) 
0.32 
(0.19–0.48) 
MDD 0.52 
(0.44–0.59) 
– 0.48 
(0.41–0.56) 
0.56 
(0.46–0.65) 
– 0.44 
(0.35–0.50) 
0.42 
(0.27–0.56) 
– 0.58 
(0.44–0.73) 
Bivariate 
variance 
0.13 
(0.070–0.25) 
– 2.0×10-4 
(8.6×10-11–0.018) 
0.094 
(0.038–0.20) 
  
– 0.016 
(5.7×10-7–0.074) 
0.13 
(0.020–0.52) 
– 0.047 
(1.6×10-6–0.18) 
Correlation 0.51 
(0.37–0.69) 
– -0.020 
(-0.19–0.15) 
0.41 
(0.26–0.60) 
– -0.19 
(-0.41–0.036) 
0.56 
(0.19–1) 
– 0.29 
(-8.5×10-4–0.56) 
A: additive genetic factors; C: non-unique environmental factors E: unique environmental factors. 
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Shared aetiology or direct causation? 
For both broad and narrow diagnoses, we found that the comorbidity between migraine and 
depression is best explained by a shared aetiology (including shared genetic factors) rather 
than a causal relationship. That is, the bivariate analyses found a significant genetic 
correlation and non-significant environmental correlation between migraine and depression. 
Furthermore, there was no significant association between the MZ intrapair differences for 
migraine and depression (p-value=0.67 for the two-category broad migraine/depression 
status; p-value=0.66 for the three-category broad migraine/depression status; and p-
value=0.73 for IHS MO/MA and MDD). 
 
Figure 5-1 Path diagrams of the bivariate Cholesky models for broad diagnoses. The square frame represents 
the observed trait and the circle frame represents the latent variable. AC and EC stand for the additive genetic 
variable and unique environmental variable common to migraine and depression; AS and ES stand for the 
additive genetic variable and unique environmental variable specific to depression. 
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Discussion 
This is the largest twin study to date on evaluating the genetic architecture of migraine and 
depression as well as their potential shared genetic components. Several findings are worth 
noting. 
Firstly, the heritability of broad migraine and depression was estimated at 56% and 42%, 
respectively, consistent with previous European population-based studies (7, 33, 204, 301, 
309, 437). This consistency extends to our finding of no significant non-additive genetic (D) 
and non-unique environmental (C) components. Also in line with previous findings (205), our 
results support the multiple threshold model, and indicate that different migraine 
classifications (self-report, ID migraine and IHS MO/MA) can be conceptualised as different 
levels of severity on a single dimension of liability. Analogously, MiDD and MDD exist as 
different severity levels on a single dimension of liability. These findings are nicely reflected 
by the three-category (two-threshold) model capturing more of the genetic contribution to 
both migraine and depression compared to the two-category (one-threshold) model. 
Therefore, broadening the migraine and depression phenotype in genetic studies by including 
individuals with sub-IHS diagnoses, such as self-reported and ID migraine, and sub-MDD 
diagnoses such as MiDD, should facilitate the identification of genetic risk factors due to 
improved power via increased sample size. That said, for the two-category definitions, the 
enhanced diagnostic sensitivity and specificity of narrow IHS MO/MA and MDD produced 
higher heritability estimates compared to the results from the one-threshold broad migraine 
and depression analyses, with heritability increasing from 48% to 59% for IHS MO/MA and 
from 40% to 49% for MDD, respectively. These latter results suggest that it might be 
important to model different diagnostic categories (e.g., via multinomial or ordinal logit 
models) to maximize power in genetic association studies. 
Secondly, and also in line with three previous twin and family-based studies (61-63), both 
additive genetic correlation and bivariate heritability between broad migraine and depression 
(rG=0.36, 95% CI: 0.29–0.43; h2=5.5%, 95% CI: 3.6–7.8%) were significantly detected, 
indicating the presence of shared genetic components between the two disorders. Not 
surprisingly, both rG and h2 substantially increased between IHS MO/MA and MDD 
(rG=0.51, 95% CI: 0.37–0.69; h2=13.3%, 95% CI: 7.0–24.5%). It is also worth noting that rG 
and h2 increase (see Appendix C, Table C-3, section 4) between broad migraine and MDD 
112 
 
(N=4534, rG=0.39, 95% CI: 0.30–0.47; h2=7.3%, 95% CI: 4.5–10.9%) and between IHS 
MO/MA and broad depression (N=2793, rG=0.46, 95% CI: 0.33–0.62; h2=9.7%, 95% CI: 
5.0–17.4%). These findings indicate that the shared genetic components between the two 
disorders can also be conceptualised on a single dimension of liability and exist regardless of 
the specific migraine and depression definition studies. Our finding of a slightly smaller 
bivariate heritability compared with the previous study of (63), is most likely due to 
differences in sample characteristics (e.g., the previous study only used female twins) and the 
diagnostic approaches and definitions of migraine and depression. 
 
Figure 5-2 Path diagrams of the bivariate Cholesky models for narrow diagnoses. The square frame represents 
the observed trait and the circle frame represents the latent variable. AC and EC stand for the additive genetic 
variable and unique environmental variable common to IHS MO/MA and MDD; AS and ES stand for the 
additive genetic variable and unique environmental variable specific to MDD. C stands for the non-unique 
environmental variable specific to IHS MO/MA. 
Thirdly, our results indicate that the co-occurrence of migraine and depression is most likely 
due to a shared aetiology comprising shared genetic factors that influence both disorders 
rather than one primary disorder causing the other secondary disorder. Contrastingly, a Dutch 
twin study by Ligthart et al., (61) suggested a causal bidirectional relationship between 
migraine and anxious depression. This study reported a significant environmental correlation 
between MZ intrapair differences for LCA-derived migraine and anxious depression using 
only MZ twin pairs discordant for both disorders. However, when only utilising discordant 
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MZ twin pairs in our study, the correlation between MZ intrapair differences for both broad 
and narrow migraine and depression was still non-significant (p-value=0.93 for the two-
category broad migraine/depression status; p-value=0.51 for the three-category broad 
migraine/depression status; and p-value=0.19 for IHS MO/MA and MDD). Comparison with 
the current findings is complicated due to the use of different diagnostic measures. Firstly, the 
Dutch twin study coded migraine status by utilising an empirically derived migrainous 
headache classification based on LCA clustering of reported IHS MO/MA symptoms, and the 
survey questionnaire did not include the questions corresponding to the MO-related symptom 
“unilateral location” and MA-related aura characteristic symptoms, compared to the 
questionnaire used in our study (see Table 4-1). Additionally, the Dutch study analysed the 
role of anxious depression which consisted of a factor score based on several measures of 
anxiety, depression, and neuroticism. Further research will be required to determine whether 
anxiety and/or neuroticism play a confounding role in co-occurrence of migraine and 
depression. 
Our study also has some limitations. Firstly, both migraine and depression status were 
diagnosed using self-reported questionnaire data, as opposed to the gold-standard of clinical-
based interviews by neurologists or psychologists. Although our approach may result in some 
misclassification of migraine and depression status, it is not feasible to perform clinic-based 
interviews in samples larger enough to provide sufficient power for such familial aggregation 
studies. Moreover, our approach enabled narrow diagnoses of migraine and depression that 
satisfy clinically accepted criteria. Furthermore, our estimated lifetime prevalence of IHS 
MO/MA and DSM-III-R-based MDD are in a good agreement with published estimates (5, 
301, 427, 435). In addition to the clinically accepted definitions of IHS MO/MA and DSM 
MDD, our study utilised other diagnostic measurements or criteria of migraine (i.e., self-
report migraine and ID migraine) and depression (i.e., MiDD) to both increase study power 
and examine the influence of different phenotypic distributions on genetic modelling of 
migraine and depression. Furthermore, we tested for the presence of causation by assuming 
that both variables were measured without error. Despite the high similarity of MZ twin pairs, 
any unique measurement error may break down any true environmental correlation, and any 
correlated measurement error may be mistakenly interpreted as causal variance. Thus, 
inclusion of measurement error or testing the direction of causation models is still required to 
make our inference more valid. Lastly, although this study did not analyse MO and MA 
separately, considering MO is the most common IHS MO/MA subtype and our results 
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supporting the multiple threshold model and single liability of dimension, our findings do not 
corroborate the previous observation of genetic overlap between depression and MA and not 
MO (62). 
Several conclusions can be drawn from our study. Firstly, genetic factors contribute 
significantly to the susceptibly to both migraine and depression, with no significant gender 
differences in the magnitude (sex-limitation) and no sex-specific effects (i.e., effects 
expressed in one sex but not the other) on risk for migraine and depression. Secondly, both 
univariate and bivariate heritability of migraine and depression increase with increased 
severity of the two disorders. Lastly, our results indicate that for both broad and narrow 
definitions, the observed comorbidity between migraine and depression can be explained by a 
shared aetiology (rather than a causal relationship) that almost entirely comprises shared 
underlying genetically determined disease mechanisms. The identification of shared 
underlying genetic factors will improve our understanding of the relationship between 
migraine and co-occurring depression and facilitate the detection of novel pathways and thus 
identify new targets for drug therapy.  
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Chapter 6: Migraine and major 
depressive disorder: heritability and 
genetic correlation captured by SNPs 
 
Abstract 
Objective: This project aims to identify genome-wide significant loci associated with major 
depressive disorder (MDD), and evaluate the single nucleotide polymorphism (SNP)-based 
heritability of migraine and MDD, and their genetic correlation. 
Methods: Three Genome-wide Association Study (GWAS) summary statistics were 
analysed, including a European population-based migraine GWAS by IHGC (the 
International Headache Genetics Consortium), a European population-based MDD GWAS by 
PGC (the Psychiatric Genomics Consortium) and a Han Chinese population-based MDD 
GWAS by CONVERGE (the consortium of China Oxford and Virginia Commonwealth 
University Experimental Research on Genetic Epidemiology). Meta-analysis of PGC MDD 
and CONVERGE MDD was conducted by METAL fixed-effect model and METASOFT 
Han and Eskin’s random-effects model. The linkage disequilibrium (LD) score regression 
was performed to estimate the SNP-based heritability of migraine and MDD, and their 
genetic correlation. 
Results: Meta-analysis identified 64 SNPs associated with MDD at the genome-wide 
suggestive significance level (p<1×10-5), with two (rs16924945 and rs7647854) almost 
reaching genome-wide significance (p<5×10-8). The SNP-based heritability was estimated at 
14% (95% confidence interval [CI]: 12–16%) for IHGC migraine, 25% (95% CI: 20–30%) 
for PGC MDD, and 47% (95% CI: 39–56%) for CONVERGE MDD. A significant genetic 
correlation was observed between IHGC migraine and PGC MDD (rG=0.18, p=0.028) and 
between PGC MDD and CONVERGE MDD (rG=0.23, p<0.001), but not between IHGC 
migraine and CONVERGE MDD. 
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Conclusions: Our study suggests two candidate genetic risk loci for MDD. A significant 
genetic correlation between migraine and MDD exists in European populations, providing 
molecular genetic support for a shared genetic aetiology underlying the two disorders. 
However, the contribution of shared genetic effects may differ across ancestral populations. 
 
Key words: migraine, MDD, genetic correlation, heritability, meta-analysis, GWAS 
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Introduction 
Migraine and major depressive disorder (MDD) are two of the most frequent complex 
diseases worldwide. Each affects approximately 10–20% of the global population and more 
females compared to males (51, 354, 438, 439). A number of previous longitudinal studies 
(55-59) reveal a bidirectional association between migraine and MDD. This strong 
association highly aggravates burdens on quality of life and work efficiency of patients, their 
relatives and society in general (1). 
Although twin and family studies indicate a moderate heritability for migraine and MDD 
with estimates ranging from 30 to 50% (7, 301) and point to the presence of shared genetic 
components underlying two conditions (61-63), the scientific understanding on the aetiology 
of their association is unclear. 
Numerous genome-wide association studies (GWAS) have been conducted for migraine (15-
19, 21) and MDD (321-324, 326-328, 331, 333, 334, 412) with contrasting success. With 
respect to migraine, the largest migraine GWAS performed by the International Headache 
Genetics Consortium (IHGC) (16) identified 12 SNPs associated with migraine susceptibility 
at genome-wide significance level (p<5×10-8) from 23285 migraine cases and 95425 health 
controls. In contrast, most MDD GWAS have had limited success. So far, the largest MDD 
GWAS completed by the Psychiatric Genomics Consortium (PGC) (333) recruited 9240 
MDD cases and 9519 health controls, but failed to find any genome-wide significant loci 
associated with MDD. A recent MDD GWAS performed by the consortium of China Oxford 
and Virginia Commonwealth University Experimental Research on Genetic Epidemiology 
(CONVERGE) (412) utilised 5303 recurrent and severe MDD cases and 5337 health controls 
originating from Han Chinese female populations and successfully identified two genome-
wide significant SNPs. However, these results await confirmation in additional samples and 
thus far do not appear to be associated with MDD in Caucasian populations. 
As suggested by Levinson et al., (339), failures of MDD GWAS are most likely caused by 
insufficient study power. The authors recommended that at least 75000 cases may be required 
to identify risk SNPs of MDD at a genome-wide significance level, with this estimate 
expected to reduce in line with an increase in genetic homogeneity of MDD cases, which may 
partly explain the success of the CONVERGE MDD study. Hence, combined analysis of the 
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PGC MDD and CONVERGE MDD may provide an opportunity to identify novel genetic 
risk variants for MDD. 
The recently developed statistical approaches of linear mixed model (LMM) (112) and 
linkage disequilibrium (LD) score regression (79, 113) enable estimation of SNP-based 
heritability (h2SNP) of a target single-trait and genetic correlation (rG) across two traits using 
GWAS summary statistics. For example, using bivariate LMM, Vattikuti et al., (440) 
observed a significant rG between body mass index and waist to hip ratio (rG=0.75 for related 
individuals and 0.91 for unrelated individuals), and between fasting triglycerides and high-
density lipoprotein (rG=-0.45 for related individuals and -0.57 for unrelated individuals), 
based on the Atherosclerosis Risk in Communities population. Another recent study (441) 
applied LMM to calculate genetic correlation among five psychiatric disorders from the PGC 
GWAS summary statistics. Briefly, the authors observed that MDD showed a significant 
genetic correlation with schizophrenia (rG=0.43, se=0.06), bipolar disorder (rG=0.47, 
se=0.06) and attention-deficit/hyperactivity disorder (rG=0.32, se=0.07). Furthermore, using 
LD score regression, Sullivan et al., (113) calculated rG among 25 traits or diseases using 
their GWAS summary statistics and reported multiple findings. For instance, anorexia 
nervosa was found to be significant genetically correlated with adult obesity (rG=-0.20, 
p=4×10-6) and schizophrenia (rG=0.19, p=1.5×10-5). Recently, Anttila et al., (442) applied LD 
score regression to analyse genetic correlation among different neurological and psychiatric 
disorders from multiple GWAS. Importantly, the author identified that MDD was 
significantly correlated with migraine (rG=0.22, p=9×10-6) and MO (rG=0.17, p=0.046), but 
not MA (rG=0.096, p=0.34). 
In this project, we aim to i) identify genetic variants on MDD risk by meta-analysis of PGC 
MDD and CONVERGE MDD; and ii) evaluate SNP-based heritability of migraine and 
MDD, and their genetic correlation using LD score regression using summary statistics from 
2013 IHGC migraine, 2013 PGC MDD and 2015 CONVERGE MDD GWA studies. 
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Materials and Methods 
Study sample 
IHGC migraine 
The 2013 IHGC migraine GWAS sample (http://www.headachegenetics.org) (16) includes 
29 European clinic- and population-based samples comprising a total of 23285 migraine 
cases and 95425 the health controls. Migraine phenotypes were diagnosed by questionnaires 
or clinical interviews according to the International Headache Society (IHS) criteria (2). For 
each sample, genotypes were independently generated, QCd and imputed using the CEU 
(Utah Residents with Northern and Western European Ancestry) HapMap release 21 or 22 
reference panels. After further quality control and SNP filtering, a meta-analysis was 
performed utilising the Genome-wide Association Meta-Analysis (GWAMA) program using 
a fixed-effect model. After excluding SNPs with heterogeneous SNP effects, association 
results for a total of 1855272 SNPs remained. 
 
PGC MDD 
The 2013 PGC MDD GWAS sample (http://pgc.unc.edu) (333) gathered 18759 unrelated 
participants of European ancestry (9240 MDD cases and 9519 health controls) from nine 
MDD GWA case-control samples. All MDD cases were diagnosed by a structured clinical 
interview or clinical-based checklist according to the Diagnostic and Statistical Manual of 
Mental Disorders, fourth edition (DSM-IV) criteria (26). PGC performed a mega-analysis, 
which required centralising the genotype data from all GWA samples prior to performing 
consistent QC, imputation and association analysis. Individual genotypes were all imputed up 
to the CEU and TSI (Toscani in Italy) HapMap3 reference panel. Association analysis was 
carried out using a logistic regression with an assumed additive SNP effect (allelic 
association). The final PGC MDD GWAS comprised results for 1235109 SNPs. 
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CONVERGE MDD 
The 2015 CONVERGE MDD GWAS sample (http://www.well.ox.ac.uk/converge) (412) 
recruited 10640 independent Han Chinese females (5303 MDD cases and 5337 health 
controls), who had been diagnosed with recurrent and severe MDD (two or more episodes) 
using the Composite International Diagnostic Interview (CIDI, Chinese version) according to 
the DSM-IV criteria. By using low coverage whole genome sequencing, genotypes were 
calibrated through a stringent quality control process according to 1000 Genomes Phase1 
East Asian reference panel. SNPs were then imputed via BEAGLE program (443) without 
using haplotypes reference panel and the biallelic SNPs with same genotype likelihoods had a 
second round of imputation. GWAS was performed using LMM in which a SNP is included 
as a fixed effect, and a genetic relationship matrix [GRM] is included as an additional random 
effect to model genetic correlation between individuals. The final CONVERGE MDD 
GWAS comprised association results for 6208598 SNPs. 
 
Statistical analyses 
Meta-analysis of PGC MDD and CONVERGE MDD 
Meta-analysis of PGC MDD and CONVERGE MDD was conducted using METAL (URL: 
http://genome.sph.umich.edu/wiki/METAL_Program) fixed-effect model (77) and 
METASOFT (URL: http://genetics.cs.ucla.edu/meta/) Han and Eskin’s random-effects model 
(78). Two types of fixed-effect models were built using METAL to evaluate their 
performance in the presence effect heterogeneity, for which there was increased potential due 
to analysing different studies and diseases. The first model calculates p-values via a signed Z-
score weighted by the sample size (N) for each study (i.e., sample size based fixed-effect 
model [SSB model]); and the second model calculates p-values via an effect size (β) 
weighted by its standard error (se) (i.e., inverse variance based fixed-effect model [IVB 
model]). In addition, to test the presence of effect heterogeneity across studies, the 
METASOFT Han and Eskin’s random-effects model (RE2 model) was also built based on β 
and its se, after adjusted by effect heterogeneity across studies. That is, assuming β of each 
study complies with a normal distribution with variance σ2, β would be weighted by its se and 
σ2. A total of 999976 SNPs with results in both the PGC and CONVERGE MDD GWAS 
were used in the MDD GWA meta-analysis. 
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Estimating SNP-based genetic architecture of migraine and MDD 
LD represents the phenomenon of non-random co-occurrence of two alleles at different loci 
on the same haplotype. LD score is a statistic quantified by an additive sum of LD 
measurements (r2) of one tagging allelic variant in LD with all other causal variants (114). 
Generally, for each SNP, a higher LD score corresponds to a higher GWAS test statistics 
(e.g., Z-score, β), and vice versa. According to this principle, we used LD score regression to 
compute SNP-based heritability of migraine and MDD, and their genetic correlation. The 
estimated slope of LD score regression corresponds to the SNP-based heritability for single-
trait and the genetic covariance for cross-traits. Also, the intercept of LD score regression is 
used to measure sample overlap between datasets. It is constrained at 1 for single-trait 
analysis (i.e., completed sample overlap). While for the cross-trait analysis, intercept will be 
constrained at 0 when there is certainty of no sample overlap; otherwise, intercept will not be 
constrained or constrained at a fixed value calculated from the overlapping sample size. 
LD score regression was performed using the LDSC software (https://github.com/bulik/ldsc) 
under Python distribution Anaconda (https://www.continuum.io). The CEU HapMap3 
reference panel was used for the IHGC migraine and PGC MDD analyses, while the EAS 
(East Asian) HapMap3 reference was used for CONVERGE MDD analysis. SNPs were 
removed if they were not present in relevant reference panel, had a rare frequency (minor 
allele frequency [MAF]<0.01), poorly imputed (INFO score<0.90) or strand-ambiguous. 
We first built a single-trait LD score regression to evaluate the h2SNP for IHGC migraine, 
PGC MDD and CONVERGE MDD, respectively; and then built a cross-trait LD score 
regression to estimate rG between each two samples. Because the ancestry of CONVERGE 
MDD is not matched with IHGC migraine and PGC MDD, we estimated rG between 
CONVERGE MDD and IHGC migraine and between CONVERGE MDD and PGC MDD by 
averaging over using either CEU HapMap3 or EAS HapMap3 as the reference panels. 
Furthermore, we also estimated h2SNP for MDD using the GWAS results generated by meta-
analysis of the PGC GWAS and CONVERGE GWAS, and its rG with IHGC migraine, PGC 
MDD, and CONVERGE MDD. 
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Results 
Meta-analysis of PGC MDD and CONVERGE MDD 
A total of 29399 participants (14543 cases and 14856 controls) were included in the meta-
analysis. According to the results of three models (see Appendix D, Table D-1), 64 SNPs 
showed association with MDD risk at suggestive significance level, but none reached 
genome-wide significance level. We then separated SNPs into groups based on their LD 
patterns (r2>0.8) and selected the top risk SNP in each group with the lowest p-value 
(summarised in Table 6-1). Two candidate SNPs almost reached genome-wide significance. 
One SNP in an intron of the Sirtuin 1 (SIRT1) gene (rs16924945, chromosome 10:67914590) 
produced the lowest p-value of 7.25×10-8 using the IVB model and p=8.49×10-8 using the 
RE2 model; while SNP rs7647854 (chromosome 3:185158995), located near the 
Chromosome 3 Open Reading Frame 70 (C3orf70) gene and Enoyl-CoA, Hydratase/3-
Hydroxyacyl CoA Dehydrogenase (EHHADHI) gene, produced the lowest p-value of 
8.43×10-8 using the SSB model. 
 
SNP-based heritability of migraine and MDD (single-trait analysis) 
The estimated h2SNP of IHGC migraine, PGC MDD and CONVERGE MDD are presented in 
Table 6-2. To estimate h2SNP on the liability scale, the population prevalence was set at 12% 
for migraine and 20% for MDD, and the sample prevalence was set at 20% for migraine and 
50% for MDD. The h2SNP was significantly estimated at 14% (95% confidence interval [CI]: 
12–16%) for IHGC migraine, 25% (20–30%) for PGC MDD and 47% (39–56%) for 
CONVERGE MDD. 
Using the same prevalence settings, we next estimated h2SNP of MDD using the GWAS 
results generated by meta-analysis of the PGC GWAS and CONVERGE GWAS 
(PGC+CONVERGE MDD). Using either the CEU or EAS HapMap3 reference panel, the 
h2SNP of MDD was consistently estimated at around 22–25%, with highest estimate of 
24.50% for the IVB model based on CEU HapMap3 and lowest estimate at 22.03% for the 
RE2 model based on EAS HapMap3, suggesting that the IVB model produced slightly more 
significant GWA meta-analysis results compared to the other two models. Therefore, we also 
calculated h2SNP of MDD under the IVB model after removing a small number of SNPs with a 
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significant p-value for SNP effect heterogeneity (based on Cochran’s Q statistics). As 
expected, the h2SNP slightly increased to 24.66% using CEU HapMap3 and 23.73% using 
EAS HapMap3. 
Table 6-1 Summary of selected risk SNPs* based on meta-analysis of PGC 
MDD and CONVERGE MDD 
Chromosome SNP SSB p-value IVB p-value RE2 p-value p-value (PGC) p-value (CON) 
1 rs2922240 –^ – 4.49×10-6 0.011 2.80×10-6 
rs3753555 – – 4.47×10-6 0.17 6.98×10-7 
rs931009 9.27×10-6 5.93×10-6 7.26×10-6 0.0026 0.0073 
rs4659657 6.66×10-6 1.74×10-6 2.12×10-6 6.09×10-6 0.14 
rs966365 8.91×10-6 2.45×10-6 3.00×10-6 7.80×10-5 0.15 
rs10802826 7.70×10-6 7.10×10-6 8.67×10-6 0.0010 0.0022 
2 rs16836496 6.72×10-7 4.27×10-7 5.16×10-7 0.00082 0.00014 
3 rs16839984 – 7.19×10-6 8.78×10-6 1.47×10-5 0.12 
rs9817813 – 9.42×10-6 – 1.74×10-5 0.14 
rs7626688 1.79×10-6 1.18×10-6 1.45×10-6 8.47×10-6 0.043 
rs6445194 1.10×10-6 8.05×10-7 9.83×10-7 6.04×10-6 0.037 
rs9830950 2.51×10-7 1.35×10-7 1.64×10-7 1.24×10-6 0.033 
rs9843007 3.62×10-6 9.05×10-6 – 9.68×10-5 0.012 
rs7637028 4.80×10-6 5.02×10-6 6.15×10-6 5.32×10-5 0.025 
rs9847523 7.56×10-6 8.20×10-6 – 0.00010 0.022 
rs7647854 8.43×10-8 2.26×10-7 2.42×10-7 6.51×10-7 0.022 
4 rs4862792 1.41×10-7 1.01×10-7 1.12×10-7 0.000021 0.0019 
5 rs2973765 – 5.69×10-6 6.96×10-6 0.0082 0.00038 
7 rs11764517 7.01×10-6 5.40×10-6 6.61×10-6 0.0046 0.00021 
8 rs12549100 3.80×10-7 2.50×10-7 1.56×10-7 0.0050 2.43×10-6 
rs11986046 2.45×10-6 2.56×10-6 3.15×10-6 0.0016 0.00028 
rs907586 1.37×10-6 1.36×10-6 1.66×10-6 0.0013 0.00017 
rs2942219 3.24×10-6 1.51×10-6 6.80×10-7 0.021 2.92×10-6 
10 rs10999064 6.60×10-6 5.71×10-6 6.98×10-6 0.00011 0.019 
rs16924945 – 7.25×10-8 8.49×10-8 0.50 3.03×10-8 
rs35841851 – 6.38×10-7 4.96×10-7 0.55 6.11×10-8 
12 rs11052463 3.32×10-6 4.53×10-6 5.55×10-6 0.0019 0.00032 
13 rs7985182 6.99×10-6 4.75×10-6 5.83×10-6 4.34×10-5 0.041 
14 rs10129827 – – 5.09×10-7 1.37×10-5 0.00016 
rs9323497 – – 1.24×10-7 1.57×10-6 0.00022 
18 rs10853287 – – 8.97×10-6 0.00081 8.94×10-5 
rs12457691 2.65×10-6 2.57×10-6 3.16×10-6 0.00086 0.00072 
rs1587989 5.10×10-6 6.13×10-6 7.51×10-6 0.00022 0.0074 
*risk SNPs were selected based on the LD threshold r2>0.8 and lowest p-values under all three models; ^p>1×10-
5. 
SSB: sample size based fixed-effect model; IVB: inverse variance based fixed-effect model; RE2: new random-
effects model; PGC: MDD GWAS performed by the Psychiatric Genomics Consortium; CON: MDD GWAS 
performed by the consortium of China Oxford and Virginia Commonwealth University Experimental Research 
on Genetic Epidemiology. 
 
SNP-based genetic correlation between traits (cross-trait analysis) 
With respect to analysing cross-trait genetic correlation, as summarised in Table 6-3, IHGC 
migraine was significantly correlated with PGC MDD with an rG of 0.18 (95% CI: 0.02–
0.34) but was not correlated with CONVERGE MDD. Not surprisingly, the rG between 
IHGC migraine and PGC+CONVERGE MDD had a substantial drop to 0.10–0.12 at nearly 
10% statistical significance level compared to PGC MDD. Similar to the single-trait analysis, 
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the IVB model also provided the highest rG at about 0.12 between PGC+CONVERGE MDD 
and IHGC migraine and this rG had a marginal increase after removing SNPs with 
heterogeneous effects. 
Meanwhile, a significant rG was observed between PGC MDD and CONVERGE MDD 
according to either CEU HapMap3 (rG=0.23, 95% CI: 0.10–0.35) or EAS HapMap3 
(rG=0.23, 95% CI: 0.11–0.36) reference panel, supporting our rationale of meta-analysing 
these two GWA studies. As expected, both PGC MDD and CONVERGE MDD showed 
significant high genetic correlation (rG=0.55–0.99) with PGC+CONVERGE MDD. 
Table 6-2 SNP-based univariate heritability of migraine and MDD 
Sample SNP reference panel Number of SNPs in analysis h2SNP (95% CI) 
IHGC migraine CEU HapMap3 834361 14.13% (12.17–16.09%) 
PGC MDD CEU HapMap3 877768 25.04% (20.14–29.94%) 
CONVERGE MDD EAS HapMap3 973144 47.38% (38.56–56.20%) 
METAL (SSB) CEU HapMap3 856124 23.09% (20.15–26.03%) 
EAS HapMap3 849586 22.18% (19.24–25.12%) 
METAL (IVB) CEU HapMap3 856124 24.50% (21.36–27.64%) 
EAS HapMap3 849586 23.51% (20.37–26.65%) 
METASOFT (RE2) CEU HapMap3 856124 23.18% (20.04–26.32%) 
EAS HapMap3 849586 22.03% (18.89–25.17%) 
METAL (new IVB)* CEU HapMap3 806233 24.66% (21.33–27.99%) 
EAS HapMap3 800100 23.73% (20.59–26.87%) 
h2SNP: SNP-based univariate heritability; CI: confidence interval; SSB: sample size based fixed-effect model; 
IVB: inverse variance based fixed-effect model; RE2: new random-effect model. *the inverse variance based 
fixed-effect model after excluding SNPs with significant p-value of heterogeneity. 
 
Discussion 
This study performed a meta-analysis of MDD by combining summary statistics from a large 
European GWAS and a large Han Chinese GWAS. The two fixed-effect models (METAL 
SSB and METAL IVB) produced very similar results, thus the IVB model was preferred due 
its generation of more easily interpreted results (i.e., the IVB model provides a pooled odds 
ratio and 95% confidence error for the effect size, whereas the SSB provides a pooled signed 
Z-statistic). While the random effects (METASOFT RE2) model did not detect any 
association signals that were not observed in the fixed-effect model, suggesting the MDD 
SNP effects were generally consistent across the two populations. 
The most significant risk locus based on the IVB model and the RE2 model was rs16924945 
(chromosome 10:69674347), located in an intron region of SIRT1 gene. As a protein-coding 
gene, polymorphisms of SIRT1 were well studied in a relationship with mood disorders such 
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as depression (444, 445) and anxiety (446). Polymorphisms of SIRT1 possibly induce MDD 
through abnormal mitochondrial biogenesis (336) and/or regulating activation of the 
monoamine oxidase A to decrease serotonin levels (337). It is worth noting that rs16924945 
is located at chromosome 10––same as the two identified genome-wide significant SNPs 
from CONVERGE MDD (rs12415800 near the SIRT1, chromosome 10:69624180, 
p=2.53×10-10; and rs35936514 mapped to an intron region of LHPP, chromosome 10: 
126244970, p=6.45×10-12)––and shows a mild LD (r2=0.35) with rs35936514. Therefore, this 
SNP may be influenced by the CONVERGE MDD and more likely to relate to MDD cases 
from Han Chinese populations, since the rs16924945 is not significant (p=0.50) in the PGC 
MDD but genome-wide significant (p=3.03×10-8) in the CONVERGE MDD. 
Table 6-3 SNP-based genetic correlation between migraine and MDD 
Phenotype 1 Phenotype 2 SNP reference panel rG (se) p-value 
IHGC migraine PGC MDD CEU HapMap3 0.18 (0.082) 0.028 
 
IHGC migraine 
 
CONVERGE MDD 
CEU HapMap3 -0.044 (0.040) 0.27 
EAS HapMap3 -0.041 (0.040) 0.31 
average -0.043 – 
 
PGC MDD 
 
CONVERGE MDD 
CEU HapMap3 0.23 (0.064) 0.0004 
EAS HapMap3 0.23 (0.063) 0.0002 
average 0.23 – 
METAL (SSB) IHGC migraine CEU HapMap3 0.10 (0.063) 0.10 
EAS HapMap3 0.088 (0.059) 0.13 
average 0.096 – 
METAL (IVB) IHGC migraine CEU HapMap3 0.11 (0.063) 0.064 
EAS HapMap3 0.081 (0.059) 0.17 
average 0.099 – 
METASOFT (RE2) IHGC migraine CEU HapMap3 0.10 (0.063) 0.098 
EAS HapMap3 0.082 (0.060) 0.17 
average 0.093 – 
METAL (new IVB)* IHGC migraine CEU HapMap3 0.12 (0.066) 0.07 
EAS HapMap3 0.085 (0.062) 0.17 
average 0.10 – 
METAL (SSB) PGC MDD CEU HapMap3 0.64 (0.10) 1.65×10-10 
METAL (IVB) PGC MDD CEU HapMap3 0.76 (0.025) 7.89×10-205 
METASOFT (RE2) PGC MDD CEU HapMap3 0.74 (0.11) 2.28×10-12 
METAL (new IVB)* PGC MDD CEU HapMap3 0.85 (0.014) 0 
METAL (SSB) CONVERGE MDD EAS HapMap3 0.55 (0.078) 1.48×10-12 
METAL (IVB) CONVERGE MDD EAS HapMap3 0.94 (0.078) 1.16×10-33 
METASOFT (RE2) CONVERGE MDD EAS HapMap3 0.82 (0.078) 3.43×10-26 
METAL (new IVB)* CONVERGE MDD EAS HapMap3 0.99 (0.026) 0 
rG: genetic correlation; se: standard error; SSB: sample size based fixed-effect model; IVB: inverse variance 
based fixed-effect model; RE2: new random-effect model. *the inverse variance based fixed-effect model after 
excluding SNPs with significant p-value of heterogeneity. 
 
The other risk locus, most strongly implicated by the SSB model, was rs7647854 
(chromosome 3:186359477), located close to C3orf70 and EHHADH gene. The p-value of 
rs7647854 calculated based on the IVB model (p=2.26×10-7) and the RE2 model (p=2.42×10-
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7) also reached suggestive significance level, strongly supporting the risk of rs7647854 in 
MDD liability. The C3orf70 gene is likely related to the encoded protein that involved in 
neurological pathways, and the EHHADH gene may increase depression risk via some 
metabolic pathways such as peroxisomal beta-oxidation (447). 
Recently, another meta-analysis (448) combined analysing the European-based PGC MDD 
and the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) 
depressive symptom study, and observed two novel genome-wide significant SNPs with a 
broader definition of depression: rs9825823 (chromosome 3: 61082153; p=8.2×10-9) in FHIT 
and rs9323497 (chromosome 14: 67873128; p=3.3×10-8) in PLEK2. Both of these SNPs 
produced suggestive evidence of association in our study (see Appendix D, Table D-1). 
Although our study identified rs7626688 (chromosome 3: 61081361) as the top risk SNP 
rather than rs9825823, rs7626688 shared strong LD with rs9825823 (r2=0.94) and had 
relatively more significant p-value than rs9825823 under all three models. 
We detected a mild h2SNP at approximately 14% of IHGC migraine, 25% of PGC MDD and 
47% of CONVERGE MDD. The heritability of migraine and MDD based on European 
population is lower than the estimated heritability from twin and family studies (7, 301). This 
so-called “missing heritability” is likely due to the combined effects of rare SNPs and SNPs 
with small effects that are difficult to identify using current GWAS sample sizes and analysis 
of common SNPs (449, 450). The h2SNP of CONVERGE MDD was significantly higher than 
that of PGC MDD, most likely due to the MDD cases involved in CONVERGE study were 
more severe (most cases [85%] met the DSM-IV based melancholia) and believed to be more 
heritable and more homogenous genotype data. The h2SNP of PGC+CONVERGE MDD was 
lower than the estimated heritability of either PGC MDD or CONVERGE MDD, which may 
be due to the analysis of fewer SNPs in addition to the differences in genotype and 
phenotype. 
Our study reported a moderate SNP-based rG between migraine and MDD at least for 
European populations (rG=0.18), although this rG was slightly lower compared to the 
estimates (rG=0.30–0.36) from twin and family studies (61, 62). In contrast, the rG was not 
significant between IHGC migraine and CONVERGE MDD, suggesting the contribution of 
shared genetic effects to migraine and depression may differ across these ancestral 
populations and co-occurring migraine and depression may have different genetic aetiologies 
in Caucasian and Chinese populations. Reassuringly, a significant rG between PGC MDD and 
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CONVERGE MDD was observed using either the CEU HapMap3 or EAS HapMap3 
reference, suggesting that despite differences in ancestry, ascertainment and phenotype 
definition, genetic risk factors for MDD are shared across these Caucasian and Chinese 
populations. 
Several limitations are worth noting in this study. First, our study utilised two multi-
continental MDD GWAS samples from European and Han Chinese populations, but LD 
score regression often estimates rG between GWAS data originated from a same ancestry. 
However, results from averaging over using either the CEU HapMap3 or EAS HapMap3 
reference showed minimal influence of the reference on the estimated rG. Secondly, we 
calculated h2SNP and rG without adjusting gender. Considering that the CONVERGE MDD 
study only recruited females, our results, especially for MDD, may be more generalisable to 
females than males. Another concern is the increased heterogeneity of MDD after combining 
two studies because MDD cases in CONVERGE appeared to be more severe than the cases 
in PGC study. However, given the PGC and CONVERGE MDD cases were all diagnosed 
according to the DSM-IV criteria and most PGC MDD cases were diagnosed via clinical 
interviews, differences in the MDD phenotype may have had a minimal impact on the results. 
Last but not least, LD score regression defaults with calculating heritability based on the 
observed scale. Although we converted the conditions onto the liability scale by setting a 
fixed prevalence of migraine and MDD for both population and sample, the estimates may 
still be underestimated due to the relatively high sample prevalence of MDD (around 50%). 
In summary, in line with previous studies in Caucasians, our study identified risk SNPs 
associated with MDD only at the genome-wide suggestive level. Two SNPs (rs16924945 and 
rs7647854) almost reached genome-wide significance, although appear predominately 
associated with MDD in the Han Chinese. We also report a significant SNP-based heritability 
of migraine and MDD, and a significant genetic correlation between the two disorders in the 
European populations. Our results provide further evidence for the shared genetically 
mechanisms underlying migraine and MDD at molecular genetic level. This genetic 
association was not significant across the Caucasian and Han Chinese samples, indicating 
comorbid migraine and depression may have different genetic aetiologies in Caucasian and 
Asian populations. 
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Chapter 7: Conclusion and discussion 
 
7.1 Concluding remarks 
Although a number of previous studies have improved our knowledge on the association 
between migraine and depression, questions remain regarding the relative contribution of 
genetic and environmental influences and whether a causal relationship exists between 
migraine and depression. This thesis makes important contributions to understanding the 
association between migraine and depression via the analysis of phenotypic and genetic data. 
In phenotypic studies, by analysing a large Australian population-based twin sample, strong 
familial aggregation was observed for both migraine and depression. Notably, a bidirectional 
association between the two diseases was confirmed, with a significantly increased risk for 
depression in co-twins of twin probands reporting migraine, and vice versa. This association 
was found to strengthen with increased severity (e.g., between IHS MO/MA and MDD). Of 
particular importance, the observed risk for migraine in co-twins of twin probands reporting 
depression was found to be considerably higher than the reverse. These results add further 
support to a previous study (64) suggesting that patients with comorbid migraine and 
depression appear more similar to patients with only depression than patients with only 
migraine. 
Significant genetic effects to migraine and depression liabilities were observed using twin 
modelling, with an estimated univariate heritability of 56% and 42% for broad definitions of 
migraine and depression, respectively. The two-threshold model (i.e., non-migraine, self-
report/ID migraine and IHS MO/MA; and non-depressed, MiDD and MDD) consistently 
produced higher heritability estimates for migraine and depression compared to the one-
threshold model (e.g., non-migraine and broad migraine; and non-depressed and broad 
depression), indicating that different migraine classifications (self-report, ID migraine and 
IHS MO/MA) and depression classifications (MiDD and MDD) can be conceptualised as 
different levels of severity on a single dimension of liability. Furthermore, analysing the strict 
clinically-accepted definitions of two diseases, the heritability estimates increased to 59% for 
IHS MO/MA and 49% for MDD, respectively. 
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The main achievement of this thesis is the characterisation of genetic and environmental 
components shared between migraine and depression. Results from bivariate Cholesky twin 
modelling indicated a significant additive bivariate heritability (h2=5.5%) and genetic 
correlation (rG=0.36) between broad migraine and broad depression. Additionally, analysis of 
the stricter IHS MO/MA and MDD definitions produced increased bivariate heritability 
(h2=13.3%) and genetic correlation (rG=0.51) estimates. Therefore, similar to the univariate 
heritability results, the shared genetic components between migraine and depression increase 
in line with their increased severity. Most importantly, our results indicate that for both broad 
and narrow definitions, the observed comorbidity between migraine and depression is best 
explained by a shared aetiology rather than a causal relationship due almost entirely to the 
shared underlying genetically determined disease mechanisms. 
In addition to the phenotypic and genetic twin model analyses, we analysed molecular genetic 
(SNP) data and found a significant SNP-based genetic correlation (rG=0.18) between 
migraine and MDD in Europeans. Compared with the results of twin modelling, the lower 
genetic correlation evaluated by LD score regression is likely due to the combined effects of 
rare SNPs and SNPs with small effects that are difficult to identify using current GWAS 
sample sizes and analysis of common SNPs. It is noteworthy that the SNP-based genetic 
correlation was not significant between European population-based migraine and Han 
Chinese population-based MDD, suggesting the comorbid migraine and depression may have 
a different genetic aetiology in Asian compared to Caucasian populations. Reassuringly, we 
showed that although MDD is a high heterogeneous disease, European and Han Chinese 
MDD cases share a similar genetic aetiology, with a significant genetic correlation (rG=0.23) 
estimated between two population-based MDD GWA studies. Thus supporting our rationale 
to perform a meta-analysis of the European and Han Chinese population-based MDD GWA 
studies to identify novel genetic risk variants associated with MDD. 
By comprehensively reviewing published genetic studies of migraine and depression, some 
common candidate genes were identified, including genes from the serotonergic system (e.g., 
the s allele of the 5-HTTLPR polymorphism in SLC6A4), dopaminergic system (e.g., the 48-
bp VNTR in DRD4, rs72393728 in DBH, rs40184 in DAT1), and the GABAergic systems 
(e.g., rs3810651 in GABRQ), together with the genetic variants in MTHFR (i.e., the C677T in 
MTHFR) and BDNF (i.e., rs2049046 in BDNF). However, no genome-wide significant SNP 
loci have been robustly associated with both migraine and depression susceptibility. 
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In summary, our studies provide strong evidence for a bidirectional association between 
migraine and depression, which can be explained almost entirely by shared underlying 
genetically determined disease mechanisms. 
 
7.2 General discussions and recommendations for 
future studies 
Although this thesis systematically investigated the association between migraine and 
depression, there are still some limitations worth noting. One important problem in 
phenotypic studies is the potential misclassification of migraine and depression status, 
because both migraine and depression status were diagnosed according to the self-report of 
symptoms as opposed to direct interview by a neurologist or psychologist. However, the 
consistency of findings across multiple definitions supports their reliability. Furthermore, the 
IHS MO/MA and MDD definitions fulfil the clinically accepted diagnostic criteria, and 
showed a consistent lifetime prevalence with published literature (5, 301, 427, 435). 
Moreover, on a more practical level, it is not feasible to collect large samples of clinic-based 
patients that would be required to provide sufficient power for such genetic studies. 
Another limitation relates to the episodic nature of migraine and depression. Furthermore, 
patients may develop migraine and depression over an extended period, during which time 
they gradually acquire and relinquish disease-related symptoms. Therefore, compared to 
analysing cross-sectional data, analysis of longitudinal data may provide additional 
information regarding the relationship between migraine and depression. 
Another issue concerns the diversiform subtypes of migraine and depression that may 
increase phenotypic heterogeneity and perhaps genetic heterogeneity. Particularly for 
migraine, several studies (194, 203, 205) suggested that MA may be a more severe phenotype 
with a stronger genetic basis compared to MO. In our phenotypic studies, we did not separate 
the diagnosis of IHS MO/MA into IHS MO and IHS MA, because only a small number of 
participants are diagnosed with certain MA status in our sample, as a consequence of the low 
response rate of aura-related questions. However, given previous studies (205, 451) indicated 
a strong familial aggregation and genetic overlap between MO and MA, combined MO and 
MA status provides the most effective use of the data and maximum statistical power. 
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However, further studies independently focussing on MO and MA with respect to co-
occurring depression may prove useful to better understand these primary migraine subtypes. 
Furthermore, this thesis provides strong evidence for the shared genetic factors across 
migraine and depression, but it is still not feasible to determine the presence of genetic 
pleiotropy, which represents the phenomenon that the same gene accounts for susceptibilities 
of multiple phenotypes. Systematic detection of pleiotropy is challenging but of great 
importance, due to its potential to expand our understanding of both biological mechanisms 
and gene functions and the potential to tailor drug development for multiple diseases (452). 
Further studies are recommended for exploring the presence of such pleiotropy (using 
Mendelian randomisation or advanced multivariate approaches) and investigating how 
pleiotropy influences the evolution of these diseases. 
The limited success from previous depression GWAS is most likely caused by the joint 
genetic contributions from multiple SNPs with small effects, which current GWAS have 
insufficient power. Hence, the most effective and direct solution of this limitation is the 
collection of larger samples. Meta-analysis of existing GWA studies can effectively improve 
such study power by combined data across studies. Although our meta-analysis of PGC and 
CONVERGE MDD GWAS failed to identify any new genetic variants at genome-wide 
significance level, the p-value of most SNPs became more significant and two candidate 
SNPs were observed approaching genome-wide significance. We therefore believe that the 
meta-analysis of future MDD GWA studies, regardless of ancestry, holds much promise to 
identify novel genetic risk factors for MDD. In addition, compared to studying individual 
SNPs, extending our studies from SNP-level to gene-level provides further information on 
the biological pathways underlying these diseases, and provides specific targets (genes) for 
follow-up studies. 
However, given we found a non-significant genetic correlation between migraine and MDD 
across the European and Han Chinese populations, comorbid migraine and MDD may have 
different shared underlying genetic mechanisms in different populations. These results may 
explain the wide variation in lifetime prevalence of migraine and depression across different 
populations. Thus, when analysing genetics of co-occurring migraine and depression, it 
would appear preferable to concentrate on utilising participants from one homogeneous 
population to prevent confounding due to population differences. 
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Lastly, for moderately heritable diseases such as migraine and depression, where genetic and 
environmental factors play equally important roles, the likelihood of gene-environment 
(G×E) interaction exists. G×E interaction refers to genetic differences in sensitivity to 
particular environmental effects (453, 454). Also, gene-environment correlation (rGE), which 
refers to genetic differences in exposure to particular environments (96), may play an 
important role in risk for migraine and depression. Therefore, future research examining the 
interplay between genetic risk factors and environmental trigger factors, such as stress and 
sleep, has potential to provide further insight into the mechanisms underlying these diseases. 
Overall, this Ph.D. thesis has presented a number of novel insights into the association 
between migraine and depression and their possible underlying mechanisms. Elucidating the 
genetics of migraine, depression and their co-occurrence is challenging. However, large 
genomic studies comparing cases with i) migraine, ii) depression, and iii) comorbid migraine 
and depression, to the health controls, are sure to provide novel insight into the biological 
mechanisms underlying their occurrence.  
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Appendix B: Supplement tables for Chapter 4 
Table B-1: Twin-pair migraine-migraine: cross-tabulations 
Zygosity group Proband Co-twin 
No migraine Self-report migraine ID migraine IHS MO/MA Any migraine 
Total sample No migraine 1882 356 321 179 856 
Self-report migraine 467 163 146 81 390 
ID migraine 466 159 198 105 462 
IHS MO/MA 251 102 116 327 545 
Any migraine 1184 424 460 513 1397 
MZ No migraine 905 159 162 63 384 
Self-report migraine 196 89 87 34 210 
ID migraine 186 88 138 58 284 
IHS MO/MA 67 34 49 141 224 
Any migraine 449 211 274 233 718 
DZ No migraine 977 197 159 116 472 
Self-report migraine 271 74 59 47 180 
ID migraine 280 71 60 47 178 
IHS MO/MA 184 68 67 186 321 
Any migraine 735 213 186 280 679 
Same-sex DZ No migraine 547 112 105 82 299 
Self-report migraine 134 48 50 40 138 
ID migraine 118 39 36 38 113 
IHS MO/MA 93 44 45 122 211 
Any migraine 345 131 131 200 462 
MZ F-F No migraine 476 107 120 35 262 
Self-report migraine 121 64 69 28 161 
ID migraine 134 64 113 53 230 
IHS MO/MA 50 24 41 124 189 
Any migraine 305 152 223 205 580 
MZ M-M No migraine 429 52 42 28 122 
Self-report migraine 75 25 18 6 49 
ID migraine 52 24 25 5 54 
IHS MO/MA 17 10 8 17 35 
Any migraine 144 59 51 28 138 
DZ F-F No migraine 268 62 69 61 192 
Self-report migraine 76 32 37 28 97 
ID migraine 81 31 33 29 93 
IHS MO/MA 72 34 42 109 185 
Any migraine 229 97 112 166 375 
DZ M-M No migraine 279 50 36 21 107 
Self-report migraine 58 16 13 12 41 
ID migraine 37 8 3 9 20 
IHS MO/MA 21 10 3 13 26 
Any migraine 116 34 19 34 87 
DZ F-M No migraine 430 85 54 34 173 
Self-report migraine 137 26 9 7 42 
ID migraine 162 32 24 9 65 
IHS MO/MA 91 24 22 64 110 
Any migraine 390 82 55 80 217 
DZ M-F No migraine 430 137 162 91 390 
Self-report migraine 85 26 32 24 82 
ID migraine 54 9 24 22 55 
IHS MO/MA 34 7 9 64 80 
Any migraine 173 42 65 110 217 
IHS: the International Headache Society; MZ: monozygotic twin pairs; DZ: dizygotic twin pairs; F: female; M: 
male. 
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Table B-2: Twin-pair depression-depression: cross-tabulations 
Zygosity group Proband Co-twin  
No depression MDD Any depression 
Total sample No depression 2017 804 1028 
MDD 857 856 997 
Any depression 1101 991 1173 
MZ No depression 1012 339 441 
MDD 306 439 496 
Any depression 427 497 576 
DZ No depression 1005 465 587 
MDD 551 417 501 
Any depression 674 494 597 
Same-sex DZ No depression 570 300 370 
MDD 282 262 308 
Any depression 344 313 369 
MZ F-F No depression 634 241 301 
MDD 192 334 371 
Any depression 270 372 418 
MZ M-M No depression 378 98 140 
MDD 114 105 125 
Any depression 157 125 158 
DZ F-F No depression 310 202 258 
MDD 199 191 218 
Any depression 240 224 256 
DZ M-M No depression 260 98 112 
MDD 83 71 90 
Any depression 104 89 113 
DZ F-M No depression 435 165 217 
MDD 269 155 193 
Any depression 330 181 228 
DZ M-F No depression 435 269 330 
MDD 165 155 181 
Any depression 217 193 228 
MDD: major depressive disorder. MZ: monozygotic twin pairs; DZ: dizygotic twin pairs; F: female; M: male. 
 
Table B-3: Twin-pair any migraine-any depression: cross-tabulations 
Zygosity group Proband Co-twin  
No any depression Any depression 
Total sample No any migraine 1669 1069 
any migraine 1449 1132 
MZ No any migraine 813 476 
any migraine 626 541 
DZ No any migraine 856 593 
any migraine 823 591 
Same-sex DZ No any migraine 479 367 
any migraine 435 372 
MZ F-F No any migraine 441 297 
any migraine 463 422 
MZ M-M No any migraine 372 179 
any migraine 163 119 
DZ F-F No any migraine 241 219 
any migraine 309 295 
DZ M-M No any migraine 238 148 
any migraine 126 77 
DZ F-M No any migraine 377 226 
any migraine 388 219 
DZ M-F No any migraine 444 376 
any migraine 208 182 
MZ: monozygotic twin pairs; DZ: dizygotic twin pairs; F: female; M: male. 
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Table B-4: Twin-pair any depression-any migraine: cross-tabulations 
Zygosity group Proband Co-twin 
No any migraine Any migraine 
Total sample No any depression 1848 1197 
any depression 1218 1056 
MZ No any depression 884 569 
any depression 470 533 
DZ No any depression 964 628 
any depression 748 523 
Same-sex DZ No any depression 520 420 
any depression 372 341 
MZ F-F No any depression 501 434 
any depression 280 408 
MZ M-M No any depression 383 135 
any depression 190 125 
DZ F-F No any depression 267 301 
any depression 230 266 
DZ M-M No any depression 253 119 
any depression 142 75 
DZ F-M No any depression 444 208 
any depression 376 182 
DZ M-F No any depression 377 388 
any depression 226 219 
The interpretation is same as the information in Table B-3. 
 
Table B-5: Twin-pair IHS MO/MA-MDD: cross-tabulations 
Zygosity group Proband Co-twin 
No MDD MDD 
Total sample No IHS MO/MA 1669 876 
IHS MO/MA 424 318 
MZ No IHS MO/MA 813 384 
IHS MO/MA 139 137 
DZ No IHS MO/MA 856 492 
IHS MO/MA 285 181 
Same-sex DZ No IHS MO/MA 479 308 
IHS MO/MA 167 114 
MZ F-F No IHS MO/MA 441 256 
IHS MO/MA 109 119 
MZ M-M No IHS MO/MA 372 128 
IHS MO/MA 30 18 
DZ F-F No IHS MO/MA 241 184 
IHS MO/MA 143 98 
DZ M-M No IHS MO/MA 238 124 
IHS MO/MA 24 16 
DZ F-M No IHS MO/MA 377 184 
IHS MO/MA 118 67 
DZ M-F No IHS MO/MA 444 313 
IHS MO/MA 52 53 
IHS: the International Headache Society; MDD: major depressive disorder; MZ: monozygotic twin pairs; DZ: 
dizygotic twin pairs; F: female; M: male. 
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Table B-6: Twin-pair MDD-IHS MO/MA: cross-tabulations 
Zygosity group Proband Co-twin 
No IHS MO/MA IHS MO/MA 
Total sample No MDD 1848 324 
MDD 959 319 
MZ No MDD 884 132 
MDD 348 142 
DZ No MDD 964 192 
MDD 611 177 
Same-sex DZ No MDD 520 140 
MDD 298 124 
MZ F-F No MDD 501 101 
MDD 210 122 
MZ M-M No MDD 383 31 
MDD 138 20 
DZ F-F No MDD 267 112 
MDD 189 100 
DZ M-M No MDD 253 28 
MDD 109 24 
DZ F-M No MDD 444 52 
MDD 313 53 
DZ M-F No MDD 377 118 
MDD 184 67 
The interpretation is same as the information in Table B-5. 
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Appendix C: Supplement tables for Chapter 5 
Table C-1 Summary of univariate analyses of broad migraine/depression 
Model A C (or D) E df AIC p-value 
Section 1: one-threshold model 
Univariate model for broad migraine (non-migraine vs broad migraine) [5319] 
ACE 0.48 (0.34–0.53) 0* (0–0.11) 0.52 (0.48–0.57) 10632 -6919.75 – 
AE# 0.48 (0.43–0.52) – 0.52 (0.48–0.57) 10633 -6921.75 1 
CE – 0.35 (0.31–0.39) 0.65 (0.61–0.70) 10633 -6881.87 2.7×10-10 
ADE 0.45 (0.21–0.52) 0.034 (0–0.28) 0.52 (0.47–0.57) 10632 -6919.83 – 
Univariate model for broad depression (non-depressed vs broad depression) [5319] 
ACE 0.40 (0.35–0.45) 0 (0–0) 0.60 (0.55–0.65) 10632 -6992.74 – 
AE 0.40 (0.35–0.45) – 0.60 (0.55–0.65) 10633 -6994.74 1 
CE – 0.28 (0.24–0.32) 0.72 (0.68–0.76) 10633 -6957.64 1.1×10-9 
ADE 0.22 (0–0.43) 0.20 (0–0.45) 0.58 (0.53–0.64) 10632 -6995.05 – 
Univariate sex-limitation model for broad migraine (non-migraine vs broad migraine) [5319] 
ACE  F 
M 
0.35 (0.033–0.50) 
0.34 (0.017–0.53) 
0.11 (0–0.39) 
0.093 (0–0.36) 
0.54 (0.48–0.62) 
0.57 (0.47–0.68) 
10629 -7277.71 – 
AE  
 
F 
M 
0.48 (0.41–0.54) 
0.44 (0.34–0.53) 
– 
– 
0.52 (0.46–0.59) 
0.56 (0.47–0.66) 
10631 -7278.18 0.17 
ADE  F 
M 
0.34 (0.22–0.55) 
0.44 (0.14–0.53) 
0.12 (0–0.26) 
0.0002 (0–0.33) 
0.53 (0.46–0.61) 
0.56 (0.47–0.65) 
10629 -7271.34 – 
Univariate sex-limitation model for broad depression (non-depressed vs broad depression) [5319] 
ACE  F 
M 
0.41 (0.31–0.47) 
0.094 (0–0.37) 
0.0015 (0–0.073) 
0.28 (0.045–0.42) 
0.59 (0.53–0.66) 
0.62 (0.53–0.71) 
10629 -7060.382 – 
AE  
 
F 
M 
0.41 (0.34–0.47) 
0.41 (0.32–0.50) 
– 
– 
0.59 (0.32–0.66) 
0.59 (0.50–0.68) 
10631 -7059.099 0.071 
ADE  F 
M 
0.10 (0–0.37) 
0.41 (0.19–0.50) 
0.33 (0.046–0.47) 
0.0035 (0–0.22) 
0.57 (0.50–0.64) 
0.59 (0.50–0.68) 
10629 -7059.996 – 
Section 2: two-threshold model 
Univariate model for broad migraine (non-migraine vs self-report migraine + ID migraine vs IHS 
MO/MA) [5319] 
ACE 0.47 (0.35–0.58) 0.080 (0–0.17) 0.45 (0.41–0.49) 10631 -1229.03 – 
AE 0.56 (0.52–0.60) – 0.44 (0.40–0.48) 10632 -1228.33 0.10 
CE – 0.41 (0.38–0.44) 0.59 (0.56–0.62) 10632 -1174.09 4.5×10-14 
ADE 0.56 (0.48–0.60) 0 (0–0.091) 0.44 (0.40–0.47) 10631 -1226.33 – 
Univariate model for broad depression (non-depressed vs MiDD vs MDD) [5319] 
ACE 0.42 (0.35–0.46) 0 (0–0.047) 0.58 (0.54–0.63) 10631 -2760.71 – 
AE 0.42 (0.37–0.46) – 0.58 (0.54–0.63) 10632 -2762.71 1 
CE – 0.29 (0.25–0.33) 0.71 (0.67–0.75) 10632 -2712.21 1.2×10-12 
ADE 0.19 (0–0.41) 0.25 (0.012–0.47) 0.56 (0.51–0.61) 10631 -2764.97 – 
Univariate sex-limitation model for broad migraine (non-migraine vs self-report migraine + ID migraine 
vs IHS MO/MA) [5319] 
ACE  F 
M 
0.35 (0.19–0.63) 
0.044 (0–0.20) 
0.22 (0–0.35) 
0.36 (0.25–0.45) 
0.43 (0.35–0.48) 
0.59 (0.51–0.67) 
10628 -1284.81 – 
AE  
 
F 
M 
0.60 (0.55–0.64) 
0.49 (0.40–0.55) 
– 
– 
0.40 (0.36–0.45) 
0.52 (0.45–0.60) 
10630 -1285.59 0.20 
ADE  F 
M 
0.60 (0.50–0.64) 
0.48 (0.29–0.55) 
0 (0–0.10) 
0 (0–0.20) 
0.40 (0.36–0.45) 
0.52 (0.45–0.60) 
10628 -1281.59 – 
Univariate sex-limitation model for broad depression (non-depressed vs MiDD vs MDD) [5319] 
ACE  F 
M 
0.44 (0.35–0.50) 
0.21 (0–0.46) 
0 (0–0) 
0.17 (0–0.36) 
0.56 (0.50–0.62) 
0.62 (0.53–0.71) 
10628 -2814.10 – 
AE  
 
F 
M 
0.44 (0.38–0.50) 
0.40 (0.32–0.48) 
– 
– 
0.56 (0.50–0.62) 
0.60 (0.52–0.68) 
10630 -2816.23 0.39 
ADE  F 
M 
0.12 (0–0.43) 
0.40 (0.14–0.48) 
0.34 (0.022–0.50) 
0.0026 (0–0.27) 
0.54 (0.48–0.60) 
0.60 (0.52–0.68) 
10628 -2816.60 – 
*All estimates would be recorded as 0 if < 1×10-5. #The model with best fit (in bold) was selected generally 
based on comparing the AIC values and p-value under the likelihood ratio (LR) test. Although some models 
provided non-zero estimations of C or D (e.g., the two-threshold univariate sex-limitation ACE model for broad 
migraine), other factors, such as model plausibility, were also taken into consideration.  For instance, the two-
threshold univariate sex-limitation ACE model for broad migraine fit worse than the two-threshold univariate 
sex-limitation AE model due to: i) lower AIC value; ii) non-significant p-value of LR test; and iii) the non-
significant heritability of broad migraine for males which in implausible/unrealistic. 
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Table C-2 Summary of univariate analyses of narrow migraine/depression 
Model A C (or D) E df AIC p-value 
Univariate model for IHS MO/MA (non-migraine vs IHS MO/MA) [2793] 
ACE# 0.59 (0.43–0.76) 0.25 (0.091–0.39) 0.16 (0.12–0.21) 5580 -5907.00 – 
AE 0.86 (0.81–0.89) – 0.14 (0.11–0.19) 5581 -5899.13 0.0017 
CE – 0.67 (0.63–0.72) 0.33 (0.28–0.37) 5581 -5863.67 1.7×10-11 
ADE 0.86 (0.76–0.89) 0 (0–0.093) 0.14 (0.11–0.19) 5580 -5897.13 – 
Univariate model for MDD (non-depressed vs MDD) [4534] 
ACE 0.49 (0.43–0.54) 0 (0–0) 0.51 (0.46–0.57) 9062 -6415.92 – 
AE 0.49 (0.43–0.54) – 0.51 (0.46–0.57) 9063 -6417.92 1 
CE – 0.34 (0.30–0.38) 0.66 (0.62–0.70) 9063 -6365.89 5.5×10-13 
ADE 0.22 (0–0.48) 0.29 (0.014–0.55) 0.49 (0.43–0.55) 9062 -6420.20 – 
Univariate sex-limitation model for IHS MO/MA (non-migraine vs IHS MO/MA) [2793] 
ACE F 
M 
0.65 (0.46–0.82) 
0.43 (0.083–0.75) 
0.19 (0.044–0.36) 
0.32 (0.051–0.62) 
0.16 (0.11–0.21) 
0.25 (0.15–0.39) 
5577 -6092.62 – 
AE F 
M 
0.86 (0.81–0.90) 
0.79 (0.67–0.87) 
– 
– 
0.14 (0.10–0.19) 
0.21 (0.13–0.33) 
5579 -6089.12 0.023 
ADE F 
M 
0.86 (0.71–0.90) 
0.79 (0.62–0.87) 
0 (0–0.15) 
0 (0–0.16) 
0.14 (0.10–0.19) 
0.21 (0.13–0.33) 
5577 -6085.12 – 
Univariate sex-limitation model for MDD (non-depressed vs MDD) [4534] 
ACE F
M 
0.51 (0.41–0.57) 
0.30 (0.012–0.55) 
0 (0–0.073) 
0.15 (0–0.40) 
0.49 (0.43–0.56) 
0.56 (0.45–0.66) 
9059 -6498.52 – 
AE F 
M 
0.51 (0.44–0.57) 
0.46 (0.36–0.56) 
– 
– 
0.49 (0.43–0.56) 
0.54 (0.44–0.64) 
9061 -6501.59 0.63 
ADE F 
M 
0.15 (0–0.49) 
0.46 (0.083–0.56) 
0.38 (0.024–0.57) 
0.0076 (0–0.40) 
0.47 (0.40–0.54) 
0.53 (0.44–0.64) 
9059 -6501.93 – 
*All estimates would be recorded as 0 if < 1×10-5. 
#Model selection processes followed the same principles as mentioned in supplement table C-1. 
 
 
 
Table C-3 Summary of bivariate analyses based on best fitting model 
selected from univariate analyses 
Model# A C (or D) E 
Section 1: one-threshold model for broad diagnoses 
Bivariate model for broad migraine and broad depression  
(non-migraine vs broad migraine & non-depressed vs broad depression) [5319] 
Broad migraine [AE] 0.48 (0.44–0.53) – 0.52 (0.47–0.57) 
Broad depression [AE] 0.40 (0.35–0.45) – 0.60 (0.55–0.65) 
Bivariate variance 0.052 (0.035–0.080) – 2.7×10-3 (2.0×10-3–0.011) 
correlation 0.36 (0.27–0.45) – 0.067 (-4.5×10-4–0.13) 
Bivariate sex-limitation model for broad migraine and broad depression  
(non-migraine vs broad migraine & non-depressed vs broad depression) [5319] 
Broad migraine [AE] 
 
F 
M 
0.49 (0.30–0.55) 
0.44 (0.31–0.70) 
– 
– 
0.51 (0.34–0.70) 
0.56 (0.30–0.88) 
Broad depression 
[AE] 
F 
M 
0.42 (0.35–0.59) 
0.41 (0.30–0.51) 
– 
– 
0.58 (0.51–0.65) 
0.59 (0.32–0.70) 
Bivariate variance 
 
F 
M 
0.032 (0.013–0.052) 
0.063 (0.013–0.13) 
– 
– 
1.5×10-3 (1.1×10-6–0.011) 
3.5×10-3 (8.0×10-5–0.12) 
Correlation 
 
F 
M 
0.27 (0.16–0.79) 
0.39 (0.18–0.58) 
– 
– 
0.050 (-0.063–0.29) 
0.077 (-0.056–0.20) 
Section 2: two-threshold model for broad status 
Bivariate model for broad migraine and broad depression 
(non-migraine vs self-report migraine + ID migraine vs IHS MO/MA & non-depressed vs MiDD vs MDD) 
[5319] 
Broad migraine [AE] 0.56 (0.53–0.60) – 0.44 (0.40–0.47) 
Broad depression [AE] 0.42 (0.37–0.47) – 0.58 (0.53–0.63) 
Bivariate variance 0.055 (0.036–0.078) – 1.5×10-3 (3.4×10-6, 7.2×10-3) 
correlation 0.36 (0.29–0.43) – 0.050 (-0.011–0.11) 
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Table C-3 Summary of bivariate analyses based on best fitting model 
selected from univariate analyses 
Model# A C (or D) E 
Bivariate sex-limitation model for broad migraine and broad depression 
(non-migraine vs self-report migraine + ID migraine vs IHS MO/MA & non-depressed vs MiDD vs MDD) 
[5319] 
Broad migraine [AE] 
 
F 
M 
0.60 (0.55–0.64) 
0.49 (0.41–0.56) 
– 
– 
0.40 (0.36–0.45) 
0.51 (0.44–0.59) 
Broad depression 
[AE] 
 
F 
M 
0.44 (0.38–0.50) 
0.40 (0.31–0.48) 
– 
– 
0.56 (0.50–0.62) 
0.60 (0.52–0.69) 
Bivariate variance 
 
F 
M 
0.047 (0.026–0.074) 
0.058 (0.024–0.11) 
– 
– 
4.1×10-6 (4.1×10-6–4.3×10-6) 
7.3×10-3 (2.1×10-5–0.028) 
Correlation 
 
F 
M 
0.33 (0.25–0.41) 
0.38 (0.25–0.52) 
– 
– 
2.7×10-3 (-0.075–0.080) 
0.11 (5.4×10-3–0.21) 
Section 3: one-threshold model for narrow diagnoses 
Bivariate model for IHS MO/MA and MDD 
(non-migraine vs IHS MO/MA & non-depressed vs MDD) [2406] 
IHS MO/MA [ACE] 0.53 (0.35–0.72) 0.29 (0.13–0.44) 0.18 (0.13–0.24) 
MDD [AE] 0.52 (0.44–0.59) – 0.48 (0.41–0.56) 
Bivariate variance 0.13 (0.070–0.24) – 2.0×10-4 (8.6×10-11–0.018) 
correlation 0.51 (0.37–0.69) – -0.020 (-0.19–0.15) 
Bivariate sex-limitation model for IHS MO/MA and MDD 
(non-migraine vs IHS MO/MA & non-depressed vs MDD) [2406] 
IHS MO/MA [ACE] F 
M 
0.60 (0.39–0.80) 
0.32 (0.040–0.70) 
0.23 (0.054–0.41) 
0.36 (0.056–0.62) 
0.16 (0.11–0.23) 
0.32 (0.19–0.48) 
MDD [AE] F 
M 
0.56 (0.46–0.65) 
0.42 (0.27–0.56) 
– 
– 
0.44 (0.35–0.50) 
0.58 (0.44–0.73) 
Bivariate variance F 
M 
0.094 (0.038–0.20) 
0.13 (0.020–0.52) 
– 
– 
0.016 (5.7×10-7–0.074) 
0.047 (1.6×10-6–0.18) 
correlation F 
M 
0.41 (0.26–0.60) 
0.56 (0.19–1) 
– 
– 
-0.19 (-0.41–0.036) 
0.29 (-8.5×10-4–0.56) 
Section 4: mix-threshold model for partly narrow migraine/depression status 
Bivariate model for broad migraine and MDD  
(non-migraine vs broad migraine &  non-depressed vs MDD) [4534] 
Broad migraine [AE] 0.48 (0.43–0.53) – 0.52 (0.47–0.57) 
MDD [AE] 0.49 (0.43–0.54) – 0.51 (0.46–0.57) 
Bivariate variance 0.073 (0.045–0.11) – 2.4×10-3 (8.1×10-10–8.8×10-3) 
correlation 0.39 (0.30–0.47) – 0.068 (-9.8×10-3–0.15) 
Bivariate model for IHS MO/MA and broad depression 
(non-migraine vs IHS MO/MA & non-depressed vs broad depression) [2793] 
IHS MO/MA [ACE] 0.56 (0.39–0.72) 0.28 (0.13–0.42) 0.17 (0.12–0.22) 
Broad depression [AE] 0.45 (0.38–0.52) – 0.55 (0.48–0.62) 
Bivariate variance 0.097 (0.050–0.17) – 3.4×10-5 (4.5×10-9–0.014) 
correlation 0.46 (0.33–0.62) – -7.8×10-3 (-0.17–0.15) 
#Generally, because the model selection results for bivariate analyses were quite similar as the univariate 
analyses, we describe these best fitting models as extensions to the best fitting models of univariate analyses of 
migraine and depression. 
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Appendix D: Supplement table for Chapter 6 
Table D-1 Summary of 64 suggestive significant SNPs based on Meta-
analysis 
Chromosome SNP p-value 
(SSB) 
p-value 
(IVB) 
p-value 
(RE2) 
p-value 
(PGC) 
p-value 
(CON) 
1 rs1025977 8.27×10-6 2.32×10-6 2.85×10-6 8.00×10-6 0.14 
1 rs10802533 –^ 3.01×10-6 3.69×10-6 1.02×10-6 0.15 
1 rs10802826 7.7×10-6 7.10×10-6 8.67×10-6 0.0010 0.0022 
1 rs11121733 – – 5.00×10-6 0.010 2.80×10-6 
1 rs1891230 – 8.65×10-6 – 0.0024 0.0011 
1 rs2272784 – – 9.31×10-6 0.17 1.53×10-6 
1 rs2922240 – – 4.49×10-6 0.011 2.80×10-6 
1 rs3099623 – – 7.36×10-6 0.0077 5.64×10-6 
1 rs3753555 – – 4.47×10-6 0.17 6.98×10-7 
1 rs3766685 – – 6.56×10-6 0.18 1.04×10-6 
1 rs4659657 6.66×10-6 1.74×10-6 2.12×10-6 6.09×10-6 0.14 
1 rs4659660 6.95×10-6 1.94×10-6 2.38×10-6 6.42×10-6 0.14 
1 rs4659664 – 5.80×10-6 7.09×10-6 2.39×10-5 0.14 
1 rs6673040 8.18×10-6 2.29×10-6 2.81×10-6 7.89×10-6 0.14 
1 rs931009 9.27×10-6 5.93×10-6 7.26×10-6 0.0027 0.00073 
1 rs966364 – 2.78×10-6 3.41×10-6 9.55×10-6 0.15 
1 rs966365 8.91×10-6 2.45×10-6 3.00×10-6 7.80×10-6 0.15 
2 rs16836496 6.72×10-7 4.27×10-7 5.16×10-7 0.00082 0.00014 
3 rs12714788 – 9.79×10-6 – 1.97×10-5 0.17 
3 rs16839984 – 7.19×10-6 8.78×10-6 1.48×10-5 0.12 
3 rs17678033 – 9.73×10-6 – 2.31×10-5 0.16 
3 rs6445194 1.10×10-6 8.05×10-7 9.83×10-7 6.04×10-6 0.037 
3 rs7626688 1.79×10-6 1.18×10-6 1.45×10-6 8.47×10-6 0.043 
3 rs7636123 – 9.72×10-6 – 1.96×10-5 0.13 
3 rs7637028 4.80×10-6 5.02×10-6 6.15×10-6 5.32×10-5 0.025 
3 rs7639455 5.29×10-6 5.65×10-6 6.91×10-6 6.34×10-5 0.024 
3 rs7647854 8.43×10-8 2.26×10-7 2.42×10-7 6.51×10-7 0.021 
3 rs9817813 – 9.42×10-6 – 1.74×10-5 0.14 
3 rs9825823 3.94×10-6 2.73×10-6 3.35×10-6 4.08×10-6 0.12 
3 rs9830950 2.51×10-7 1.35×10-7 1.64×10-7 1.24×10-6 0.033 
3 rs9843007 3.62×10-6 9.05×10-6 – 9.68×10-5 0.012 
3 rs9847523 7.56×10-6 8.20×10-6 – 0.00011 0.022 
3 rs9864890 – 9.16×10-6 – 1.99×10-5 0.13 
4 rs4862792 1.41×10-7 1.01×10-7 1.19×10-7 2.09×10-5 0.0019 
5 rs2973765 – 5.69×10-6 6.96×10-6 0.0082 0.00038 
7 rs11764517 7.01×10-6 5.40×10-6 6.61×10-6 0.0046 0.00021 
8 rs11135759 9.81×10-6 3.31×10-6 4.06×10-6 0.0012 0.0024 
8 rs11986046 2.45×10-6 2.56×10-6 3.15×10-6 0.0016 0.00028 
8 rs11995691 6.91×10-7 4.19×10-7 2.49×10-6 0.0068 3.16×10-6 
8 rs11995896 7.12×10-7 4.42×10-7 2.60×10-6 0.0067 3.50×10-6 
8 rs12549100 3.80×10-7 2.50×10-7 1.56×10-6 0.0050 2.43×10-6 
8 rs2942219 3.24×10-6 1.51×10-6 6.80×10-6 0.021 2.92×10-6 
8 rs4872167 5.91×10-6 3.59×10-6 3.45×10-6 0.0093 4.57×10-5 
8 rs6983724 5.99×10-7 4.19×10-7 2.49×10-7 0.0064 2.95×10-6 
8 rs7004793 8.64×10-6 2.84×10-6 3.47×10-6 0.0010 0.0024 
8 rs907586 1.37×10-6 1.36×10-6 1.66×10-6 0.0013 0.00017 
10 rs10999064 6.60×10-6 5.71×10-6 6.98×10-6 0.00011 0.019 
10 rs16924945 – 7.25×10-8 8.49×10-8 0.50 3.03×10-8 
10 rs35841851 – 6.38×10-7 4.96×10-7 0.55 6.11×10-8 
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Table D-1 Summary of 64 suggestive significant SNPs based on Meta-
analysis 
Chromosome SNP p-value 
(SSB) 
p-value 
(IVB) 
p-value 
(RE2) 
p-value 
(PGC) 
p-value 
(CON) 
12 rs10506104 5.29×10-6 8.92×10-6 – 0.0019 0.00056 
12 rs10772038 7.55×10-6 – – 0.0027 0.00055 
12 rs11052463 3.32×10-6 4.53×10-6 5.55×10-6 0.0019 0.00032 
12 rs11052483 9.69×10-6 – – 0.0032 0.00058 
12 rs1392331 7.74×10-6 – – 0.0022 0.00073 
12 rs7973393 7.13×10-6 – – 0.0025 0.00056 
13 rs6563407 9.53×10-6 6.98×10-6 8.53×10-6 6.19×10-5 0.041 
13 rs7985182 6.99×10-6 4.75×10-6 5.83×10-6 4.34×10-5 0.041 
14 rs10129827 – – 5.09×10-7 1.37×10-5 0.00016 
14 rs12587989 – – 5.71×10-7 0.000015 0.00016 
14 rs7142068 – – 2.05×10-6 6.94×10-5 0.00012 
14 rs9323497 – – 1.24×10-7 1.57×10-6 0.00022 
18 rs10853287 – – 8.97×10-6 0.00081 8.94×10-5 
18 rs12457691 2.65×10-6 2.57×10-6 3.16×10-6 0.00086 0.00072 
18 rs1587989 5.10×10-6 6.13×10-6 7.51×10-6 0.00022 0.0074 
^p>1×10-5; SSB: sample size based fixed-effect model; IVB: inverse variance based fixed-effect model; RE2: 
new random-effects model; PGC: MDD GWAS performed by the Psychiatric Genomics Consortium; CON: 
MDD GWAS performed by the consortium of China Oxford and Virginia Commonwealth University 
Experimental Research on Genetic Epidemiology. 
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